<SEC-DOCUMENT>0001104659-20-046445.txt : 20200414
<SEC-HEADER>0001104659-20-046445.hdr.sgml : 20200414
<ACCEPTANCE-DATETIME>20200414172205
ACCESSION NUMBER:		0001104659-20-046445
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20200414
DATE AS OF CHANGE:		20200414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-237180
		FILM NUMBER:		20791981

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>tm2012395-3_s1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<html>
  <head>
    <title>tm2012395-3_s1a - block - 5.3312594s</title>
  </head>
  <body style="width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">

          <div style="text-align:center; width:541.31pt; line-height:10pt;">As filed with the Securities and Exchange Commission on April&#160;14, 2020.<font style="font-weight:normal;"> </font></div>


          <div style="margin-top:-3pt; text-align:right; width:541.31pt; line-height:10pt;">Registration No. 333-237180&#8203;</div>

        <div style="margin-top:2.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541.31pt; line-height:12.5pt;font-size:12pt;">UNITED STATES <br >SECURITIES AND EXCHANGE COMMISSION <br ><font style="font-size:8pt;">WASHINGTON, D.C. 20549</font><font style="font-weight:normal;"> </font></div>

          <div style="margin-top:1pt; text-align:center; width:541.31pt; line-height:8pt;font-size:10pt;">Amendment No. 1<br >to <br ><font style="font-size:12pt;">FORM S-1</font> <br ><font style="font-size:8pt;">REGISTRATION STATEMENT </font><br ><font style="font-size:8pt;">UNDER </font><br ><font style="font-size:8pt;">THE SECURITIES ACT OF 1933 </font></div>

        <div style="margin-top:4pt; text-align:center; width:541.31pt; line-height:14pt;font-size:14pt;">CYCLACEL PHARMACEUTICALS, INC.<font style="font-weight:normal;font-size:8pt;">&#8203; </font></div>
        <div style="margin-top:-3pt; text-align:center; width:541.31pt; line-height:10pt;">(Exact name of registrant as specified in its charter)<font style="font-weight:normal;font-size:10pt;">&#8203; </font></div>

          <table style="width:541.31pt;height:25.5pt;margin-top:6pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
                <div style="text-align:center;">Delaware </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
                <div style="text-align:center;">3826 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
                <div style="text-align:center;">91-1707622 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:7pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 0.5pt 0pt; width:172.44pt;">
                <div style="text-align:center;">(State or Other Jurisdiction of<br >Incorporation or Organization)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 0.5pt 0pt; width:172.44pt;">
                <div style="text-align:center;">(Primary Standard Industrial<br >Classification Code Number)</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0.667pt 0pt 0.5pt 0pt; width:172.43pt;">
                <div style="text-align:center;">(I.R.S. Employer<br >Identification Number)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:-0.3pt; text-align:center; width:541.31pt; line-height:8pt;">Cyclacel Pharmaceuticals, Inc. <br >200 Connell Drive, Suite 1500<br >Berkeley Heights, NJ 07922<br >(908) 517-7330 <br ><font style="font-size:7pt;">(Address, including zip code, and telephone number, including area code of registrant&#8217;s principal executive offices)</font><font style="font-weight:normal;"> </font></div>
        <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:8pt;">Spiro Rombotis<br >Chief Executive Officer<br >Cyclacel Pharmaceuticals, Inc.<br >200 Connell Drive, Suite 1500<br >Berkeley Heights, NJ 07922<br >(908) 517-7330 <br ><font style="font-size:7pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-weight:normal;"> </font></div>

          <div style="margin-top:3pt; text-align:center; width:541.31pt; line-height:10pt;font-style:italic;">Copies to:<font style="font-style:normal;font-weight:normal;"> </font></div>


          <table style="width:541.31pt;margin-bottom:5pt;margin-top:2pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:172.44pt;">
                <div style="text-align:center;">Joel I. Papernik, Esq.<br >Mintz, Levin, Cohn, Ferris, Glovsky and <br >Popeo, P.C.<br >666 Third Avenue<br >New York, New York 10017<br >(212) 935-3000 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:172.44pt;">
                <div style="text-align:center;">Spiro Rombotis<br >Chief Executive Officer<br >Cyclacel Pharmaceuticals, Inc.<br >200 Connell Drive, Suite 1500<br >Berkeley Heights, NJ 07922<br >(908) 517-7330 </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:172.43pt;">
                <div style="text-align:center;">Robert F. Charron, Esq.<br >Charles E. Phillips, Esq.<br >Joseph A. Smith, Esq.<br >Ellenoff Grossman &amp; Schole LLP<br >1345 Avenue of the Americas<br >New York, New York 10105<br >(212) 370-1300</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:-0.3pt; text-align:center; width:541.31pt; line-height:10pt;font-weight:normal;">
          <font style="font-weight:bold;">Approximate date of commencement of proposed sale to the public:</font> As soon as practicable after the effective date of this registration statement. </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;font-weight:normal;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933 check the following box. &#9746; </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;font-weight:normal;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;font-weight:normal;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;font-weight:normal;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744; </div>
        <div style="text-indent:20pt; margin-top:1pt; width:541.31pt; line-height:8pt;font-weight:normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. </div>
        <table style="width:501.31pt;height:16.59pt;margin-left:20pt;margin-top:3pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:116.33pt;">Large accelerated filer&nbsp;&nbsp;&nbsp;&#9744; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:116.33pt;">Accelerated filer&nbsp;&nbsp;&nbsp;&#9744; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:116.33pt;">Non-accelerated filer&nbsp;&nbsp;&nbsp;&#9746; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:116.33pt;">Smaller reporting company&nbsp;&nbsp;&nbsp;&#9746; </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:116.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:116.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:116.33pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.003pt 0pt 0.5pt 0pt; width:116.33pt;">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:2.79pt; width:541.31pt; line-height:8.5pt;font-weight:normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. &#9744; </div>

          <table style="width:541.31pt;height:82pt;margin-top:4pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
              <td style="border-bottom:3px double #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="15">
                <div style="white-space:nowrap; text-align:center;">CALCULATION OF REGISTRATION FEE </div>
              </td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.417pt 0pt 0.833pt 0pt; width:409.4pt;">
                <div style="white-space:nowrap; text-align:center;">Title of each class of securities to be registered </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.417pt 0pt 0.833pt 0pt;" colspan="4">
                <div style="text-align:center;">Proposed Maximum<br >Aggregate Offering<br >Price<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font> </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.417pt 0pt 0.833pt 0pt;" colspan="4">
                <div style="text-align:center;">Amount of<br >Registration <br >Fee<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font> </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt; width:409.4pt;text-align:left;">Common Stock, par value $0.001 per share<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(2)(3)</font> </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">20,000,000</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt; width:409.4pt;text-align:left;">Pre-funded warrants to purchase shares of common stock and common stock issuable upon exercise thereof<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(2)(3)</font> </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">20,000,000</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt; width:409.4pt;text-align:left;">Warrants to purchase shares of common stock and common stock issuable upon exercise thereof<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(2)</font> </td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">20,000,000</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
              <td style="border-bottom:3px double #000000;padding:1.75pt 0pt 1pt 0pt; width:409.4pt;text-align:left;">Total </td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">40,000,000</td>
              <td style="padding:0pt;padding-left:13.63pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:5.75pt;">&#8203;</td>
              <td style="width:0pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:5.75pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">5,192<font style="position:absolute;"><font style=" position:relative; bottom:2.75pt;font-size:6pt;">(4)</font></font></td>
              <td style="padding:0pt;padding-left:9.195pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
              <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style=" float:left; line-height:10pt; margin-top:6.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;">(1)<br ></div>
        <div style=" margin-top:6.01pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-weight:normal;">Estimated solely for the purpose of calculating the registration fee in accordance with Rule&#160;457(o) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:1.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;">(2)<br ></div>
        <div style=" margin-top:1.3pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-weight:normal;">Pursuant to Rule&#160;416 under the Securities Act of 1933, as amended, the securities being registered hereunder include such indeterminate number of additional securities as may be issuable to prevent dilution resulting from stock splits, dividends or similar transactions. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; line-height:10pt; margin-top:1.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;">(3)<br ></div>
          <div style=" margin-top:1.3pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-weight:normal;">The proposed maximum aggregate offering price of the common stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the pre-funded warrants offered and sold in the offering (plus the aggregate exercise price of the common stock issuable upon exercise of the pre-funded warrants), and as such the proposed aggregate maximum offering price of the common stock and pre-funded warrants (including the common stock issuable upon exercise of the pre-funded warrants), if any, is $20,000,000. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:10pt; margin-top:-0.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;">(4)<br ></div>
          <div style=" margin-top:-0.2pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;font-weight:normal;">Of this amount, $2,596 was previously paid. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="text-indent:20pt; margin-top:1.81pt; width:541.31pt; line-height:8pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:3.3pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.8pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="position:relative;overflow-x:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:741.85pt;left:27pt;height:30pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any state where the offer or sale of these securities is not permitted.<font style="color:#000000;"> </font><br ></div>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:63pt;width:505.31pt;">

          <div style="text-align:center; width:505.31pt; line-height:12pt;font-weight:bold;color:#FC0014;font-size:10pt;">SUBJECT TO COMPLETION, DATED APRIL&#160;14, 2020<font style="font-weight:normal;color:#000000;"> </font></div>


          <div style="margin-top:3pt; width:505.31pt; line-height:12pt;font-weight:bold;color:#FC0014;font-size:10pt;">PRELIMINARY PROSPECTUS<font style="font-weight:normal;color:#000000;"> </font></div>

        <div style="position:relative;z-index:-1;margin-top:1.8pt; text-align:center; width:505.31pt;">
          <img src="lg_cyclacelreg-4c.jpg" alt="[MISSING IMAGE: lg_cyclacelreg-4c.jpg]" height="70" width="186" >
        </div>

          <div style="margin-top:6.1pt; text-align:center; width:505.31pt; line-height:13pt;font-weight:bold;font-size:12pt;">2,564,102 Shares of Common Stock </div>

        <div style="margin-top:3pt; text-align:center; width:505.31pt; line-height:13pt;font-weight:bold;font-size:12pt;">Pre-Funded Warrants to Purchase Shares of Common Stock </div>

          <div style="margin-top:3pt; text-align:center; width:505.31pt; line-height:12.5pt;font-weight:bold;font-size:12pt;">Warrants to Purchase up to 2,564,102 Shares of Common Stock<font style="font-weight:normal;"> </font></div>


          <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:8pt;">We are offering 2,564,102 shares of our common stock, par value $0.001 per share (the &#8220;common stock&#8221;) and common warrants to purchase an aggregate of 2,564,102 shares of our common stock (and the shares of common stock that are issuable from time to time upon exercise of the warrants). We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable for one share of our common stock. The purchase price of each pre-funded warrant and the accompanying common warrant will be equal to the price at which a share of common stock and accompanying common warrant are sold to the public in this offering, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001 per share. The pre-funded warrants will be immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. Each share of common stock and pre-funded warrant is being sold together with a common warrant to purchase one share of our common stock, at an exercise price of $7.80 per share. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. Because we will issue a common warrant for each share of our common stock and for each pre-funded warrant to purchase one share of our common stock sold in this offering, the number of common warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold. The common warrants will be exercisable immediately and will expire five years from the date of issuance. The shares of common stock and pre-funded warrants, and the accompanying common warrants, can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance. Our common stock is listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;CYCC.&#8221; The last reported sale price of our common stock on Nasdaq on April&#160;9, 2020 was $7.80 per share. On April&#160;14, 2020, we implemented a reverse stock split of 1:20, and all numbers in this prospectus have thus been adjusted to give effect to such reverse stock split. The public offering price per share of common stock and accompanying common warrant and any pre-funded warrant and accompanying common warrant, as the case may be, will be determined by us at the time of pricing, may be at a discount to the current market price, and the recent market price used throughout this prospectus may not be indicative of the final offering price. There is no established public trading market for the pre-funded warrants or common warrants, and we do not expect a market to develop. In addition, we do not intend to apply for a listing of the pre-funded warrants or common warrants on any national securities exchange. </div>

        <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:8pt;">You should read this prospectus and any prospectus supplement, together with additional information described under the headings &#8220;Incorporation of Certain Information by Reference&#8221; and &#8220;Where You Can Find More Information,&#8221; carefully before you invest in any of our securities. </div>
        <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:9pt;font-weight:bold;font-size:9pt;">Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">6</a> of this prospectus as well as in the documents incorporated by reference herein.<font style="font-weight:normal;"> </font></div>

          <table style="width:465.31pt;height:55.27pt;margin-left:20pt;margin-top:0.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:285.02pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Per Share and<br >Common Warrant</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
                <div style="text-align:center;">Per Pre-Funded<br >Warrant and<br >Common Warrant </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Total </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.97999999999996pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:1.263pt 0pt 0.5pt 0pt; width:285.02pt;text-align:left;">
                <div style="white-space:nowrap;">Public offering price  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.07pt;width:0pt;">&#8203;</td>
              <td style="padding:1.263pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.263pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199; </td>
              <td style="padding:0pt;padding-left:22.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.07pt;width:0pt;">&#8203;</td>
              <td style="padding:1.263pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.263pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199; </td>
              <td style="padding:0pt;padding-left:20.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.263pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.263pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.97999999999996pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:1.513pt 0pt 0.5pt 0pt; width:285.02pt;text-align:left;">
                <div style="white-space:nowrap;">Placement agent fees<font style=" position:relative; bottom:3.25pt;font-size:6pt;">(1)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.07pt;width:0pt;">&#8203;</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:22.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.07pt;width:0pt;">&#8203;</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:20.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:7.97999999999996pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:1.513pt 0pt 0.5pt 0pt; width:285.02pt;text-align:left;">
                <div style="white-space:nowrap;">Proceeds to us, before expenses  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:22.07pt;width:0pt;">&#8203;</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:22.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:20.07pt;width:0pt;">&#8203;</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;"> </td>
              <td style="padding:0pt;padding-left:20.07pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:3pt; text-align:right; ">$</td>
              <td style="padding:1.513pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:13.01pt; width:505.31pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>

          <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
          <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:10pt; text-align:left; margin-left:20pt;">We have also agreed to reimburse the lead placement agent for its legal fees and expenses incurred in connection with this offering in the amount of up to $75,000. See &#8220;Plan of Distribution&#8221; for additional information regarding placement agent compensation. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:8pt;">We have retained Roth Capital Partners, LLC as our lead placement agent and Ladenburg Thalmann &amp; Co. Inc. and Brookline Capital Markets, a division of Arcadia Securities, LLC as our co-placement agents to use their reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agents have no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. Because there is no minimum offering amount required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. </div>

        <div style="text-indent:20pt; margin-top:12pt; width:505.31pt; line-height:8pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.<font style="font-weight:normal;"> </font></div>
        <div style="margin-left:20pt; margin-top:12pt; width:485.31pt; line-height:8.5pt;">Delivery of the securities offered hereby is expected to be made on or about&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2020. </div>

          <div style="margin-top:4pt; text-align:center; width:505.31pt; line-height:8.5pt;font-style:italic;">Lead Placement Agent<font style="font-style:normal;"> </font></div>

        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">Roth Capital Partners<font style="font-weight:normal;"> </font></div>

          <div style="margin-top:4pt; text-align:center; width:505.31pt; line-height:8.5pt;font-style:italic;">Co-Placement Agents</div>


          <table style="width:505.31pt;margin-top:2.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:13pt;">
            <tr style="line-height:15pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:13pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:331.31pt;">Ladenburg Thalmann </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0.5pt 0.5pt 0pt; width:162pt;white-space:normal;text-align:right;">
                <div style="text-align:right;">Brookline&#160;Capital Markets,&#8203;</div>
                <div style="margin-top:2pt; text-align:center;font-size:10pt;">a division of </div>
                <div style="margin-top:-0.5pt; text-align:center;font-size:10pt;">Arcadia Securities, LLC</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:21.9pt; text-align:center; width:505.31pt; line-height:12pt;font-weight:bold;font-size:10pt;">The date of this prospectus is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2020</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-bottom:113pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">TABLE OF CONTENTS<font style="font-weight:normal;"> </font></div>

          <table style="width:456pt;height:250pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tPRSU">Prospectus Summary </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tPRSU">1 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tTHOF">The Offering </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tTHOF">4 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tRIFA">Risk Factors </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tRIFA">6 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tSNRF">Special Note Regarding Forward-Looking Statements </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tSNRF">9 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tUOP">Use Of Proceeds </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tUOP">11 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDIPO">Dividend Policy </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tDIPO">11 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDIL">Dilution </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tDIL">11 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tSFD">Selected Financial Data </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tSFD">13 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tPRST">Principal Stockholders </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tPRST">13 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDOCS">Description Of Capital Stock </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tDOCS">15 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDOSW">Description Of Securities We Are Offering </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tDOSW">26 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tPOD">Plan Of Distribution </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tPOD">28 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tLEMA">Legal Matters </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tLEMA">31 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tEXP">Experts </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tEXP">31 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tWYCF">Where You Can Find More Information </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tWYCF">32 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tIOCI">Incorporation Of Certain Information By Reference </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tIOCI">32 </a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <a href="#tDOCP">Disclosure Of Commission Position On Indemnification For Securities Act Liability </a>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">
                <a href="#tDOCP">33</a>
              </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under &#8220;Where You Can Find More Information.&#8221; You should carefully read this prospectus as well as additional information described under &#8220;Incorporation of Certain Information by Reference,&#8221; before deciding to invest in our common stock. </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Neither we nor the placement agents have authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the Securities and Exchange Commission. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The placement agents are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For investors outside the United States: We and the placement agents have not done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States.</div>

      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">i<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">PROSPECTUS SUMMARY<font style="font-weight:normal;"> </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">The following summary highlights information contained or incorporated by reference elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes and other documents incorporated by reference in this prospectus, as well as the information under the caption &#8220;Risk Factors&#8221; herein and under similar headings in the other documents that are incorporated by reference into this prospectus.<font style="font-style:normal;"> </font></div>

            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">A 1:20 reverse stock split of our common stock was effected on April&#160;14, 2020. All share amounts in this prospectus have been adjusted to give effect to this reverse stock split, except for the financial statements and notes thereto.</div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus to &#8220;Cyclacel,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Cyclacel Pharmaceuticals, Inc.<font style="font-style:normal;"> </font></div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Company Overview<font style="font-weight:normal;"> </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We are a clinical-stage biopharmaceutical company using our expertise in cell cycle, transcriptional regulation and DNA damage response (&#8220;DDR&#8221;) biology in cancer cells to develop innovative, targeted medicines for cancer and other serious diseases. We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. We have retained rights to commercialize our clinical development candidates and our business objective is to enter into selective partnership arrangements with these programs. Substantially all efforts of the Company since its founding in 1997 have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Loss of control of the cell cycle, the process by which cells grow and divide, lies at the heart of cancer. In normal cells, a complex set of interacting proteins tightly regulates progression through the phases of the cell cycle by which a cell grows, replicates its DNA and divides. This process also includes mechanisms known as cell cycle checkpoints, to ensure all necessary events of each cell cycle phase are completed before beginning the next phase. If the events are not completed correctly, the cells may commit suicide by a process of programmed cell death called apoptosis. Cyclin dependent kinases (&#8220;CDKs&#8221;) are key regulators among the numerous proteins involved in cell cycle control processes. CDKs connect with proteins called cyclins to regulate cell cycle checkpoints and control transcription, DNA repair and metastatic spread. The discovery of CDKs and cyclins and their regulation of cell cycle checkpoint control were cited in the 2001 Nobel Prize in Physiology or Medicine. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Using our core strength in cancer cell cycle biology, we are evaluating several families of anticancer drugs that impact the cell cycle. In our transcriptional regulation program CYC065, our cyclin dependent kinase, or CDK, inhibitor, is being evaluated as a single agent and in combination with venetoclax (an FDA-approved drug owned by others to which we have no rights) in Phase&#160;1 studies in patients with solid tumors and hematological malignancies. In our DDR program we are evaluating sapacitabine in combination with venetoclax in Phase&#160;1 studies in patients with hematological malignancies. In our anti-mitotic program, we are evaluating CYC140, a polo-like kinase (&#8220;PLK1&#8221;) inhibitor, in Phase&#160;1 studies in patients with hematological malignancies. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">In addition to our programs involving cell cycle control biology, we have generated several families of potential anticancer drugs that act on the cell cycle, including CDK inhibitors, nucleoside analogs and PLK1 inhibitors. In our development programs, we have used biomarker analysis to help evaluate whether our drug candidates are having their intended effect through their assumed mechanisms at different doses and schedules. Biomarkers are proteins or other biological substances, or analytes, whose presence in patient samples can serve as an indicator or marker of diseases, or may highlight patients more likely to respond to a particular treatment. Biomarker data from early clinical trials may also enable us to design subsequent trials more efficiently and to monitor patient compliance with trial protocols. For example, we have observed </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">1<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">evidence of durable target engagement by CYC065 with prolonged suppression of the myeloid cell leukemia1 (&#8220;MCL1&#8221;) protein biomarker in peripheral blood cells in patient samples from our Phase&#160;1 clinical study, and we reported that sapacitabine efficacy is enhanced in tumor cells that are defective in homologous recombination DNA repair and that sapacitabine treatment increased a DNA damage marker in patient samples. We believe that biomarkers may allow us to select patients who are more likely to respond to our drugs in clinical trials and to increase the benefit to such patients. Although a number of pharmaceutical and biotechnology companies are currently attempting to develop CDK inhibitors, nucleoside analogs and PLK inhibitors, we believe that our drug candidates are differentiated in that they are available intravenously and/or orally-available and demonstrate unique target profiles and mechanisms. </div>
          <div style="text-indent:20pt; margin-top:7.82pt; width:456pt; line-height:11.5pt;">We plan to continue to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates and utilizing our area of historical expertise in cancer cell cycle and mitosis biological mechanisms. </div>
          <div style="margin-top:10.92pt; width:456pt; line-height:12pt;font-weight:bold;">Research and Development Pipeline<font style="font-weight:normal;"> </font></div>
          <div style="margin-left:20pt; margin-top:7.12pt; width:436pt; line-height:12pt;">The following table summarizes our development pipeline: </div>

            <table style="width:456pt;height:359.5pt;margin-top:8pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:116pt;text-align:left;">
                  <div style="white-space:nowrap;">PROGRAM </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:116pt;">
                  <div style="white-space:nowrap; text-align:center;">INDICATION </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:116pt;">
                  <div style="text-align:center;">DEVELOPMENT<br >STATUS </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
                <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:72pt;">
                  <div style="text-align:center;">RETAINED<br >COMMERCIAL<br >RIGHTS </div>
                </td>
                <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:3.25pt 0pt 1.5pt 0pt; width:116pt;text-align:left;">
                  <div style="white-space:nowrap;">Transcriptional Regulation</div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;text-align:left;">CYC065 CDK inhibitor (i.v.) </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Solid Tumors incl. MCL1, MYC family, Cyclin E amplification </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;white-space:nowrap;">
                  <div style="text-align:center;">Phase&#160;1 part 2 (ongoing) </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;white-space:nowrap;">
                  <div style="text-align:center;">Worldwide </div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;text-align:left;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;white-space:normal;">
                  <div style="text-align:center;">CLL combination with venetoclax, BCL2 inhibitor</div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Phase&#160;1 (ongoing)</div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;">
                  <div style="text-align:center;">Worldwide </div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;text-align:left;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;white-space:normal;">
                  <div style="text-align:center;">AML/MDS combination with venetoclax, BCL2 inhibitor </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Phase&#160;1 (ongoing) </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;">
                  <div style="text-align:center;">Worldwide </div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;white-space:normal;text-align:left;">CYC065 CDK inhibitor (oral) </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Solid tumors </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Phase&#160;1 part 3 (ongoing) </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;">
                  <div style="text-align:center;">Worldwide </div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:9.5pt 0pt 1.5pt 0pt; width:116pt;text-align:left;">DNA Damage Response</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;text-align:left;">Sapacitabine (oral)</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;white-space:normal;">
                  <div style="text-align:center;">AML/MDS combination with venetoclax, BCL2 inhibitor</div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Phase 1/2 (ongoing)</div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;white-space:normal;">
                  <div style="text-align:center;">Worldwide (except Japan)</div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;text-align:left;">Sapacitabine (oral) and olaparib PARP inhibitor </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">BRCA mutation positive breast cancer </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Phase&#160;1 (ongoing investigator-sponsored study) </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;">
                  <div style="text-align:center;">Worldwide (except Japan) </div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;text-align:left;">Sapacitabine (oral) in AML Phase&#160;3 SEAMLESS study </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">AML &ge;70&#160;years unfit for or refused intensive chemotherapy </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:116pt;">
                  <div style="text-align:center;">Phase&#160;3 failed (subgroup effectiveness analysis ongoing) </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 0.833pt 0pt; width:72pt;">
                  <div style="text-align:center;">Worldwide (except Japan) </div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:9.5pt 0pt 1.5pt 0pt; width:116pt;text-align:left;">Mitosis Regulation</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:116pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt 0pt 0.5pt 0pt; width:72pt;">&#8203;</td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
              <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
                <td style="padding:2.167pt 0pt 1.5pt 0pt; width:116pt;white-space:normal;text-align:left;">CYC140 PLK inhibitor (i.v.) </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 1.5pt 0pt; width:116pt;">
                  <div style="text-align:center;">Advanced leukemias </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 1.5pt 0pt; width:116pt;">
                  <div style="text-align:center;">Phase&#160;1 (ongoing) </div>
                </td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:0pt; width:6pt;">&#8203;</td>
                <td style="padding:2.167pt 0pt 1.5pt 0pt; width:72pt;">
                  <div style="text-align:center;">Worldwide</div>
                </td>
                <td style="padding:0pt; width:0pt;">&#8203;</td>
              </tr>
            </table>

          <div style="margin-top:8.91pt; width:456pt; line-height:12pt;font-weight:bold;">Risks Associated with Our Business<font style="font-weight:normal;"> </font></div>
          <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">Our business and ability to execute our business strategy are subject to a number of risks of which you should be aware before you decide to buy our common stock. In particular, you should consider the following risks, which are discussed more fully in the section entitled &#8220;Risk Factors&#8221; in this prospectus, as well as the other risks described in &#8220;Risk Factors.&#8221; </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:4.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">We are substantially dependent on the success of our lead product candidates, the clinical and commercial successes of which will depend on a number of factors, including proof of effectiveness, many of which are beyond our control. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">2<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">We expect to continue to incur substantial operating losses and may be unable to obtain additional financing, causing our independent registered public accounting firm to express substantial doubt about our ability to continue as a going concern. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">We will need additional funding, and we cannot guarantee that we will find adequate sources of capital in the future. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">Funding constraints may negatively impact our research and development, forcing us to delay our efforts to develop certain product candidates in favor of developing others, which may prevent us from commercializing our product candidates as quickly as possible. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">We depend on key personnel, the loss of which could impact the ability to manage our business. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">We may be subject to future litigation, which could result in substantial liabilities that may exceed our insurance coverage. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">Confidentiality agreements with employees, treating physicians and others may not adequately prevent disclosure of trade secrets and other proprietary information. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">We may be subject to regulatory, enforcement and investigative proceedings, which could adversely affect our financial condition or operations. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">We may not fully comply with complex and increasing regulation by state and federal authorities, which could negatively impact our business operations. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">Our share price is volatile and may be influenced by numerous factors, some of which are beyond our control. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">If we are unable to obtain, maintain or protect intellectual property rights related to our product candidates, or if the scope of such intellectual property protection is not sufficiently broad, we may not be able to compete effectively in our markets. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">Our product candidates may cause or have attributed to them undesirable side effects or have the properties that delay or prevent their regulatory approval or limit their commercial potential. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">If we fail to comply with the continued listing requirements of Nasdaq, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Corporate Information<font style="font-weight:normal;"> </font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We were incorporated in Delaware in August&#160;1997. Our corporate headquarters are located at 200&#160;Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922, and our telephone number is 908-517-7330. This is also where our medical and regulatory functions are located. Our research facility is located in Dundee, Scotland, which is also the center of our translational work and development programs. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We are a &#8220;smaller reporting company&#8221; as defined in Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies. As a result, the information that we provide may be different than you might receive from other public reporting companies in which you hold equity interests. </div>

            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Our corporate website address is www.cyclacel.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections&#160;13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission. The Securities and Exchange Commission maintains an internet site that contains our public filings with the Securities and Exchange Commission and other information regarding our company, at www.sec.gov. These reports and other information concerning our company may also be accessed at the Securities and Exchange Commission&#8217;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the Securities and Exchange Commission at 1-800-SEC-0330. The contents of these websites are not incorporated into this prospectus. Further, our references to the URLs for these websites are intended to be inactive textual reference only. </div>

        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">3<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Information contained in, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus. Our design logo, &#8220;Cyclacel,&#8221; and our other registered and common law trade names, trademarks, and service marks are the property of Cyclacel Pharmaceuticals, Inc. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The trademarks, trade names, and service marks appearing in this prospectus are the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks, trade names, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies or products. </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">THE OFFERING<font style="font-weight:normal;"> </font></div>

            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">Common stock to be offered<font style="font-weight:normal;"> </font></div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">2,564,102 shares, assuming the sale of our common stock at an assumed public offering price of $7.80 per share, which is the last reported sale price of our common stock on April&#160;9, 2020, and no sale of any pre-funded warrants. </div>


            <div style="width:144pt;">
              <div style="margin-top:6pt; line-height:11pt;font-weight:bold;font-size:9.3pt;">
                <font style="letter-spacing:-0.35pt;font-size:10pt;">Pre-funded warrants offered by us</font>
              </div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if such purchasers so choose, pre-funded warrants, in lieu of shares of common stock that would otherwise result in any such purchaser&#8217;s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable for one share of our common stock. The purchase price of each pre-funded warrant and accompanying common warrant will equal the price at which the share of common stock and the accompanying common warrant are being sold to the public in this offering, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001 per share. The pre-funded warrants will be exercisable immediately and may be exercised at any time until all of the pre-funded warrants are exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any pre-funded warrants sold in this offering. For each pre-funded warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. Because we will issue a common warrant for each share of our common stock and for each pre-funded warrant to purchase one share of our common stock sold in this offering, the number of common warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and pre-funded warrants sold. </div>


            <div style="width:144pt;">
              <div style="margin-top:6pt; line-height:11.5pt;font-weight:bold;font-size:9.5pt;">
                <font style="letter-spacing:-0.25pt;font-size:10pt;">Common warrants offered by us</font><font style="font-weight:normal;font-size:10pt;">&#8203; </font>
              </div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">Common warrants to purchase an aggregate of 2,564,102 shares of our common stock. Each share of our common stock and each pre-funded warrant to purchase one share of our common stock is being sold together with a common warrant to purchase one share of our common stock. Each common warrant will have an exercise price of $7.80 per share, will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The shares of common stock and pre-funded warrants, and the accompanying common warrants, as the case may be, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. This prospectus also </div>

        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">4<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:36pt; margin-left:12pt;width:456pt;">

            <div style="margin-left:168pt; width:288pt; line-height:12pt;">relates to the offering of the shares of common stock issuable upon exercise of the common warrants. </div>


            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">Common stock to be outstanding after this offering<font style="font-weight:normal;"> </font> </div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">3,424,100 shares (assuming none of the warrants issued in this offering are exercised and assuming the sale of our common stock at an assumed public offering price of $7.80 per share, which is the last reported sale price of our common stock on April 9, 2020, and no sale of any pre-funded warrants). </div>


            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">Use of proceeds<font style="font-weight:normal;"> </font></div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">We estimate that the net proceeds from this offering will be approximately $18.4 million based on an assumed offering price of $7.80 per share, which was the last reported sales price of our common stock on The Nasdaq Capital Market on April 9, 2020, and assuming no sale of any pre-funded warrants, after deducting estimated placement agent fees and estimated offering expenses payable by us.</div>


            <div style="margin-left:168pt; margin-top:6pt; width:288pt; line-height:12pt;">We intend to use the net proceeds from this offering primarily for general corporate purposes, including working capital, general and administrative matters and capital expenditures. These expectations are subject to change. See &#8220;Use of Proceeds&#8221; for additional information. </div>


            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">Risk factors<font style="font-weight:normal;"> </font></div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">An investment in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; and the other information included in this prospectus and incorporated by reference herein for a discussion of factors you should carefully consider before deciding to invest in our securities stock. </div>


            <div style="width:144pt;">
              <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">National Securities Exchange Listing<font style="font-weight:normal;"> </font> </div>
            </div>


            <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;CYCC.&#8221; We do not intend to list the pre-funded warrants or common warrants on any securities exchange or nationally recognized trading system.</div>


            <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The number of shares of our common stock that will be outstanding after this offering is based on 859,998 shares of common stock outstanding as of December&#160;31, 2019, assumes the effectiveness of a 1:20 reverse stock split of our common stock that was effected on April&#160;14, 2020, and assumes the sale and issuance by us of 2,564,102 shares of common stock (and no sale of any pre-funded warrants) in this offering and excludes: </div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">100,278 shares of common stock issuable upon the exercise of options outstanding as of December&#160;31, 2019 at a weighted average exercise price of&#8201; $54.40 per share; </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">14,000 shares of common stock issuable upon vesting of restricted stock&#160;units outstanding as of December&#160;31, 2019 at a weighted average exercise price of&#8201; $10.60 per share </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">10,439 shares of common stock reserved for future issuance under our equity incentive plan as of December&#160;31, 2019; </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">374,525 shares of common stock issuable upon the exercise of warrants outstanding as of December&#160;31, 2019 at a weighted-average exercise price of&#8201; $40.00 per share; and </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


            <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
            <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">shares of common stock issuable upon the exercise of the common warrants issued in this offering. </div>
            <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Unless otherwise indicated, this prospectus reflects and assumes no issuances or exercises of any other outstanding options or warrants after December&#160;31, 2019.</div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">5<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">RISK FACTORS<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">Investing in our common stock involves a high degree of risk. You should consider carefully the following risks and uncertainties as well as the risks and uncertainties described in the section entitled &#8220;Risk Factors&#8221; contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, as filed with the Securities and Exchange Commission, or SEC, on March&#160;5, 2020, as well as in our subsequent Quarterly and Annual Reports filed with the SEC, which descriptions are incorporated in this prospectus by reference in their entirety, as well as in any prospectus supplement hereto. These risks and uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not currently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected. In that case, the trading price of our common stock could decline and you might lose all or part of your investment. You should carefully consider the following information about risks, together with the other information contained in this prospectus, before making an investment in our common stock.<font style="font-style:normal;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans.<font style="font-style:normal;font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We have retained Roth Capital Partners, LLC to act as our lead placement agent and Ladenburg Thalmann &amp; Co. Inc. and Brookline Capital Markets, a division of Arcadia Securities, LLC to act as our co-placement agents in connection with this offering. The placement agents have agreed to use their reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agents have no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business plans outlined in this prospectus. Thus, we may not raise the amount of capital we believe is required for our business and may need to raise additional funds, which may not be available or available on terms acceptable to us. Despite this, any proceeds from the sale of securities offered by us will be available for our immediate use, and because there is no escrow account and no minimum offering amount in this offering, investors could be in a position where they have invested in us, but we are unable to accomplish our objectives due to a lack of interest in this offering. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our business may be adversely affected by the recent coronavirus outbreak.<font style="font-style:normal;font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China. In January 2020, COVID-19 spread to other parts of the world, including the United States and Europe, and efforts to contain its spread have intensified. </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The global outbreak of COVID-19 continues to rapidly evolve. As a result, businesses have closed and limits have been placed on travel. The extent to which COVID-19 may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">These and similar, and perhaps more severe, disruptions could negatively impact our business, operating results and financial condition. In addition, quarantines, stay-at-home, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">6<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">difficult to assess or predict, it has significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The ultimate impact of the COVID-19 outbreak or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, the effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">If you purchase shares of common stock in this offering, you will experience immediate and substantial dilution in your investment. You will experience further dilution if we issue additional equity or equity-linked securities in the future.<font style="font-style:normal;font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Since the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common stock, you will suffer immediate and substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on the combined assumed public offering price of $7.80 per share of common stock and accompanying warrants being sold in this offering, which is the last reported sale price of our common stock on Nasdaq on April&#160;9, 2020, assuming no sale of any pre-funded warrants and after deducting discounts and commissions and estimated offering expenses payable by us, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $4.81 per share with respect to the net tangible book value of the common stock. See the section entitled &#8220;Dilution&#8221; for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we issue additional shares of common stock, or securities convertible into or exchangeable or exercisable for shares of common stock, our stockholders, including investors who purchase shares of common stock and accompanying warrants in this offering, will experience additional dilution, and any such issuances may result in downward pressure on the price of our common stock. We also cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Future sales of substantial amounts of our common stock, or the possibility that such sales could occur, could adversely affect the market price of our common stock.<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Future sales in the public market of shares of our common stock, including shares referred to in the foregoing risk factor or shares issued upon exercise of our outstanding stock options, or the perception by the market that these sales could occur, could lower the market price of our common stock or make it difficult for us to raise additional capital. </div>

          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">There is no public market for the pre-funded warrants or common warrants being offered in this offering.<font style="font-style:normal;font-weight:normal;"> </font></div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">There is no established public trading market for the pre-funded warrants or common warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the pre-funded warrants or common warrants on any securities exchange or nationally recognized trading system, including The Nasdaq Capital Market. Without an active market, the liquidity of the pre-funded warrants or common warrants will be limited. </div>


          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Holders of pre-funded warrants or common warrants purchased in this offering will have no rights as common stockholders until such holders exercise such warrants and acquire our common stock.<font style="font-style:normal;font-weight:normal;"> </font></div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Until holders of pre-funded warrants or common warrants acquire shares of our common stock upon exercise of such warrants, holders of pre-funded warrants or common warrants will have no rights with respect to the shares of our common stock underlying such warrants. Upon exercise of the pre-funded warrants or common warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">7<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">We will have broad discretion in the use of our existing cash and cash equivalents, including the proceeds from this offering, and may invest or spend our cash in ways with which you do not agree and in ways that may not increase the value of your investment.<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We will have broad discretion over the use of our cash and cash equivalents, including the proceeds from this offering. You may not agree with our decisions, and our use of cash may not yield any return on your investment. We intend to use the net proceeds from this offering to fund our ongoing research and development activities, and for general corporate purposes, including working capital, operating expenses and capital expenditures. Our failure to apply the net proceeds from this offering effectively could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. You will not have the opportunity to influence our decisions on how to use our net proceeds from this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Our common stock may have a volatile public trading price.<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">An active public market for our common stock has not developed. Our stock can trade in small volumes which may make the price of our stock highly volatile. The last reported price of our stock may not represent the price at which you would be able to buy or sell the stock. The market prices for securities of companies comparable to us have been highly volatile. Often, these stocks have experienced significant price and volume fluctuations for reasons that are both related and unrelated to the operating performance of the individual companies. In addition, the stock market as a whole and biotechnology and other life science stocks in particular have experienced significant recent volatility. Like our common stock, these stocks have experienced significant price and volume fluctuations for reasons unrelated to the operating performance of the individual companies. Factors giving rise to this volatility may include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">disclosure of actual or potential clinical results with respect to product candidates we are developing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">regulatory developments in both the United States and abroad; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">developments concerning proprietary rights, including patents and litigation matters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">public concern about the safety or efficacy of our product candidates or technology, or related technology, or new technologies generally; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">concern about the safety or efficacy of our product candidates or technology, or related technology, or new technologies generally; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">public announcements by our competitors or others; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">general market conditions and comments by securities analysts and investors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">If we fail to comply with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Our common stock is currently listed for trading on The Nasdaq Capital Market. We must satisfy Nasdaq&#8217;s continued listing requirements, including, among other things, a minimum stockholders&#8217; equity of&#8201;$2.5&#160;million and a minimum bid price for our common stock of&#8201;$1.00 per share, or risk delisting, which would have a material adverse effect on our business. A delisting of our common stock from The Nasdaq Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">On January&#160;11, 2019, we received a letter from the Listing Qualifications Staff&#8201; (the &#8220;Staff&#8221;) of The Nasdaq Stock Market LLC indicating that the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule&#160;5450(a)(1) (the &#8220;Bid Price Rule&#8221;). Pursuant to The Nasdaq Listing Rule&#160;5810(c)(3)(A), the Company was granted a 180-calendar day compliance period, or until July&#160;7, 2019, to regain compliance with the minimum bid price requirement. During the initial compliance period, the Company&#8217;s shares of </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">8<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">common stock continued to be listed and traded on the Nasdaq Capital Market. To regain compliance, the closing bid price of the Company&#8217;s shares of common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180-day grace period, which was not satisfied during the initial compliance period. Thereafter, the Company had been afforded a second 180-calendar day compliance period, or until January&#160;6, 2020, to regain compliance with the Bid Price Rule since the Company notified Nasdaq of its intent to cure the deficiency by effecting a reverse stock split in order to regain compliance therewith. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The Company was unable to regain compliance with the Bid Price Rule by January&#160;6, 2020. Accordingly, on January&#160;7, 2020, the Company received a letter from the Staff notifying it that its Common Stock would be subject to delisting from Nasdaq unless the Company timely appealed Nasdaq&#8217;s determination to a Nasdaq Listing Qualifications Panel (the &#8220;Panel&#8221;). </div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The Company timely appealed Nasdaq&#8217;s determination to the Panel to request a hearing On March&#160;23, 2020, the Company received written notification that the Panel granted the Company an extension for continued listing through June&#160;12, 2020. If the Company does not regain compliance with the Bid Price Rule by June&#160;12, 2020, the Company&#8217;s Common Stock and preferred stock would be subject to delisting from Nasdaq. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">On October&#160;28, 2019 the Company&#8217;s stockholders adopted and approved an amendment to our Amended and Restated Certificate of Incorporation that effects a reverse stock split at a ratio of not less than 1-for-5 and not greater than 1-for-20, with the exact ratio and effective time of the reverse stock split to be determined by the Company&#8217;s board of directors at any time within one year of the date of the Special Meeting. On March 26, 2020, the Company&#8217;s board of directors adopted and approved an amendment to our Amended and Restated Certificate of Incorporation that effects a reverse stock split at a ratio of 1-for-20. On April&#160;14, 2020, the Company effected such reverse stock split to cure the deficiency at a split ratio of 1-for-20 in order to regain compliance with the minimum closing bid price requirement. While the reverse stock split has been effected, there can be no assurance that the Company will regain compliance with the minimum closing bid price requirement. </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">If our shares of common stock lose their status on The Nasdaq Capital Market, we believe that our shares of common stock would likely be eligible to be quoted on the inter-dealer electronic quotation and trading system operated by Pink OTC Markets Inc., commonly referred to as the Pink Sheets and now known as the OTCQB market. Our shares of common stock may also be quoted on the Over-the-Counter Bulletin Board, an electronic quotation service maintained by the Financial Industry Regulatory Authority. These markets are generally not considered to be as efficient as, and not as broad as, The Nasdaq Capital Market. Selling our shares of common stock on these markets could be more difficult because smaller quantities of shares would likely be bought and sold, and transactions could be delayed. In addition, in the event our shares of common stock are delisted, broker-dealers have certain regulatory burdens imposed upon them, which may discourage broker-dealers from effecting transactions in our common stock, further limiting the liquidity of our common stock. These factors could result in lower prices and larger spreads in the bid and ask prices for our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Fluctuations in our operating losses could adversely affect the price of our common stock.<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Our operating losses may fluctuate significantly on a quarterly basis. Some of the factors that may cause our operating losses to fluctuate on a period-to-period basis include the status of our preclinical and clinical development programs, level of expenses incurred in connection with our preclinical and clinical development programs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring revenue or expenses under any such agreement, and compliance with regulatory requirements. Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Our fluctuating losses may fail to meet the expectations of securities analysts or investors. Our failure to meet these expectations may cause the price of our common stock to decline. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">This prospectus and the documents incorporated by reference herein contain forward-looking statements that reflect our management&#8217;s beliefs and views with respect to future events and are subject to substantial </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">9<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">risks and uncertainties within the meaning of Section&#160;27A of the Securities Act, Section&#160;21E of the Securities Exchange Act of 1934, as amended and the safe harbor provisions for the U.S. Private Securities Litigation Reform Act of 1955. All statements, other than statements of historical fact, contained in this prospectus and the documents incorporated by reference herein, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;pro&#160;forma,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or other similar words or expressions (including their use in the negative), or by discussions of future matters such as the development of products, technology enhancements, possible changes in legislation, and other statements that are not historical. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in &#8220;Risk Factors&#8221; and elsewhere in this prospectus and the documents incorporated by reference herein, regarding, among other things: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the outcome of clinical trials to prove our three lead products are safe and effective; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the size and growth potential of the markets for our products, and our ability to serve those markets; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the rate and degree of market acceptance of our products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">ability to expand our sales organization to address effectively existing and new markets that we intend to target; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">ability to compete effectively in a competitive industry; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the success of competing technologies that are or may become available; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the performance of our third-party contract sales organizations, suppliers and manufacturers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">our ability to attract and retain key scientific or management personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">our ability to obtain funding for our operations; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">our ability to attract collaborators and strategic partnerships. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. We operate in a very competitive and rapidly changing environment. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make, and accordingly you should not place undue reliance on our forward-looking statements. We have included important factors in the cautionary statements included in this prospectus, particularly in the &#8220;Risk Factors&#8221; section in this prospectus and the documents incorporated by reference herein, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">You should read this prospectus, the documents incorporated by reference herein and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this prospectus and the documents incorporated by reference </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">10<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a><a name="tDIPO">&#8203;</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">herein by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">USE OF PROCEEDS<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We estimate that we will receive net proceeds of approximately $18.4 million from the sale of the securities offered by us in this offering, assuming a public offering price of $7.80 per share and accompanying common warrants, which was the last reported sale price of our common stock on The Nasdaq Capital Market on April&#160;9, 2020, and after deducting estimated placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the common warrants issued in this offering. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A $0.50 increase or decrease in the assumed combined public offering price of $7.80 per share and accompanying common warrant would increase or decrease the expected net proceeds of the offering to us by approximately $1.3 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated placement agent fees and estimated offering expenses payable by us. An increase or decrease of 1.0&#160;million shares from the assumed number of shares sold in this offering would increase or decrease the expected net proceeds of the offering to us by approximately $6.5 million, assuming the combined public offering price of&#8201;$7.80 per share and accompanying common warrant remains the same, and after deducting the estimated placement agent fees and estimated offering expenses payable by us. </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The principal purposes of this offering are to obtain additional capital to support our operations. As of the date of this prospectus, we have no specific plan for the net proceeds from this offering, or any significant portion thereof. However, we intend to use the net proceeds from this offering primarily for general corporate purposes, including working capital, general and administrative matters and capital expenditures. We may also use a portion of our net proceeds to co-develop, acquire or invest in products, technologies or businesses that are complementary to our business. However, we currently have no agreements or commitments to complete any such transaction. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The foregoing discussion assumes no sale of pre-funded warrants, which if sold, would reduce the number of shares of common stock that we are offering on a one-for-one basis. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our management will have broad discretion in the application of the net proceeds from this offering, and investors will be relying on the judgment of our management regarding the application of those net proceeds. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business. Pending the uses described above, we plan to invest these net proceeds in short-term, interest bearing investments, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the United States. We also may use a portion of the net proceeds from the offering to fund acquisitions or other business development opportunities. However, we have no current commitments or obligations with respect to any such acquisitions or business development opportunities at this time. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">DIVIDEND POLICY<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have never declared any cash dividends with respect to our common stock. Future payment of dividends is within the discretion of our board of directors and will depend on our earnings, capital requirements, financial condition and other relevant factors. Although there are no material restrictions limiting, or that are likely to limit, our ability to pay dividends on our common stock, we presently intend to retain future earnings, if any, for use in our business and have no present intention to pay cash dividends on our common stock. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">DILUTION<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If you invest in our securities, your ownership interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after the closing of this offering. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">11<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">Our historical net tangible book value as of December&#160;31, 2019 was $11.7 million, or $13.60 per share of common stock. Our historical net tangible book value is the amount of our total tangible assets less our liabilities. Historical net tangible book value per common share is our historical net tangible book value divided by the number of shares of common stock outstanding as of December&#160;31, 2019. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">After giving effect to the sale of shares of common stock and accompanying common warrants in this offering at an assumed combined public offering price of $7.80 per share and accompanying common warrant, which was the last reported sale price of our common stock on The Nasdaq Capital Market on April&#160;9, 2020, and after deducting estimated placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the common warrants issued in this offering, our as adjusted net tangible book value as of December&#160;31, 2019 would be $30.1 million, or $8.79 per share of common stock. This amount represents an immediate decrease in as adjusted net tangible book value of $4.81 per share to our existing stockholders and an immediate accretion of&#8201; $0.99 per share to investors participating in this offering. We determine dilution per share to investors participating in this offering by subtracting as adjusted net tangible book value per share after this offering from the assumed public offering price per share paid by investors participating in this offering. </div>

        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The following table illustrates this dilution on a per share basis to new investors: </div>

          <table style="width:456pt;height:70.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; width:416.29pt;text-align:left;">
                <div style="white-space:nowrap;">Assumed public offering price per share and accompanying common warrant  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:0pt 0pt 1pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">7.80</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416.29pt;text-align:left;">
                <div style="white-space:nowrap;">Historical net tangible book value per share as of December 31, 2019  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">13.60</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416.29pt;text-align:left;">
                <div style="white-space:nowrap;">Decrease in as adjusted net tangible book value per share attributable to this offering  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">4.81</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:416.29pt;text-align:left;">
                <div style="white-space:nowrap;">As adjusted net tangible book value per share after giving effect to this offering  </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;"> 8.79</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:416.29pt;text-align:left;">
                <div style="white-space:nowrap;">Accretion per share to new investors in this offering  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">0.99</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="text-indent:20pt; margin-top:12.9pt; width:456pt; line-height:11.5pt;">The as-adjusted dilution information discussed above is illustrative only and will change based on the actual public offering price. Each $1.00 increase (decrease) in the assumed combined public offering price of $7.80 per share and accompanying common warrant, which was the last reported sale price of our common stock on The Nasdaq Capital Market on April&#160;9, 2020, would increase (decrease) the as-adjusted net tangible book value per share by $0.75 per share and the dilution per share to investors participating in this offering by $0.25 per share, assuming that the number of shares and accompanying common warrants offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the common warrants issued in this offering. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We may also increase or decrease the number of shares we are offering. A 200,000 share increase in the number of shares and accompanying common warrants offered by us, as set forth on the cover page of this prospectus, would decrease the as adjusted net tangible book value per share by $0.05 and decrease the accretion per share to new investors participating in this offering by $0.05, assuming the assumed combined public offering price of $7.80 per share and accompanying common warrant, which was the last reported sale price of our common stock on The Nasdaq Capital Market on April 9, 2020, remains the same and after deducting estimated placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the common warrants issued in this offering. A 200,000 share decrease in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase the as adjusted net tangible book value per share after this offering by $0.06 and increase the accretion per share to new investors participating in this offering by $0.06, assuming the assumed combined public offering price of $7.80 per share and accompanying common warrant, which was the last reported sale price of our common stock on The Nasdaq Capital Market on April&#160; 9, 2020, remains the same and after deducting estimated placement agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the common warrants issued in this offering. The information discussed above, which takes into account a 1-for-20 reverse stock split of our common stock, is illustrative only and will adjust based on the actual public offering price, the actual number of shares and common warrants that we offer in this offering, and other terms of this offering determined at pricing. The discussion and table above assume (i)&#160;no sale of pre-funded warrants, which, if sold, would reduce the number of shares of common stock that we are offering on a one-for-one basis and (ii)&#160;no exercise of common warrants accompanying the shares of common stock sold in this offering. </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">12<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSFD">&#8203;</a><a name="tPRST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">SELECTED FINANCIAL DATA<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The selected statements of operations data for the&#160;years ended December&#160;31, 2018 and 2019 and the balance sheet data as of December&#160;31, 2018 and 2019 are derived from our audited financial statements appearing in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, which is incorporated by reference herein. Our historical results are not necessarily indicative of our results in any future period and results from our interim period may not necessarily be indicative of the results of the entire year. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">You should read the following selected financial data together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section and our financial statements and the related notes in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, which is incorporated by reference herein. The selected financial data in this section are not intended to replace our financial statements and the related notes and are qualified in their entirety by the financial statements and related notes included elsewhere in this prospectus. </div>

          <table style="width:416pt;height:229pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:329.93pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="text-align:center;">Year ended<br >December&#160;31, </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:329.93pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2018 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2019 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="white-space:nowrap;">Total revenue  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">150 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">Operating expenses </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="margin-left:10pt;">Cost of revenue </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="margin-left:10pt;">Research and development  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,327 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,658 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="margin-left:10pt;">Selling, general and administrative  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5,371 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">5,024 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="margin-left:10pt;">Impairment of property and equipment  </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="margin-left:20pt;">Total operating expenses  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">9,698 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">9,682 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="white-space:nowrap;">Interest income (expense)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">331 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">224 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="white-space:nowrap;">Other income (expense)  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">592 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">332 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="white-space:nowrap;">Provision for income taxes  </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,337 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,296 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:329.93pt;text-align:left;">
                <div style="white-space:nowrap;">Net loss  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,288<font style="position:absolute;">) </font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,830<font style="position:absolute;">) </font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">Net loss per share:<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font> </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.93pt;text-align:left;">
                <div style="white-space:nowrap;">Basic and diluted  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.62<font style="position:absolute;">) </font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(0.49<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <table style="width:416pt;height:172pt;margin-left:20pt;margin-top:13pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.93pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2018 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2019 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">Balance Sheet Data:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Cash and cash equivalents  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">17,504 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,885 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Working capital  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">15,336 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,597 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Total assets  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19,823 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">15,308 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Convertible note  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Long-term debt  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Total liabilities  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,551 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,611 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Convertible preferred stock  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212; </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Accumulated deficit  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(349,797<font style="position:absolute;">) </font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(357,627<font style="position:absolute;">) </font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
                <div style="white-space:nowrap;">Total stockholders&#8217; equity  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">15,272 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">11,697</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:11.5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">PRINCIPAL STOCKHOLDERS<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following table sets forth information regarding beneficial ownership of our capital stock as of February&#160;20, 2020 by: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">13<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">each of our directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">each of our named executive officers; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">all of our current executive officers and directors as a group. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The&#160;percentage ownership information shown in the column titled &#8220;Before Offering&#8221; in the table is based on 859,998 shares of common stock outstanding as of February&#160;20, 2020. The&#160;percentage ownership information shown in the column titled &#8220;After Offering&#8221; in the table is based upon 3,424,100 shares, assuming the sale of 2,564,102 shares of our common stock and accompanying common warrants by us in this offering. </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants that are exercisable as of April&#160;20, 2020, which is 60&#160;days after February&#160;20, 2020. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the&#160;percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the&#160;percentage ownership of any other person. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G, if any, filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o&#160;Cyclacel Pharmaceuticals, Inc., 200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922. </div>

          <table style="width:456pt;height:310pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:297.45pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">Percentage of Shares<br >Beneficially Owned </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Name of Beneficial Owner </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">Number of Shares<br >Beneficially Owned </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">Before<br >Offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">After<br >Offering </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">Greater than 5% Stockholders</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Eastern Capital Limited<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">108,363</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">12.6<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.16<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Portfolio Services Ltd.<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">108,363</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">12.6<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.16<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Kenneth B. Dart<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(6)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">108,363</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">12.6<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.16<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Hudson Bay Capital Management LP<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(7)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">62,500</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.27<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.83<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Sander Gerber<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(7)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">62,500</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.27<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.83<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;">Directors and Named Executive Officers</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Sir John Banham  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">778</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Dr. Samuel L. Barker  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">704</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Dr. Judy Chiao<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">9,671</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.12<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Dr. Christopher Henney  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">810</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Paul McBarron<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(3)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,061</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.17<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Spiro Rombotis<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(4)</font>  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">17,222</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">2<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Dr. David U&#8217;Prichard  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">825</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Lloyd Sems  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">859</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Gregory T. Hradsky  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">721</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;">Dr. Robert Spiegel  </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">428</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">* </td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">* </td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:297.45pt;text-align:left;">
                <div style="white-space:nowrap;font-weight:bold;">All directors and executive officers as a group (10 persons)<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(5)</font> </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">42,079 </td>
              <td style="padding:0pt;padding-left:15.86pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.89<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.23<font style="position:absolute;">%</font></td>
              <td style="padding:0pt;padding-left:5.675pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="margin-top:12.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" margin-top:7.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Represents beneficial ownership of less than 1%. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">14<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Beneficial ownership also includes shares of common stock subject to options and warrants currently exercisable or convertible, or exercisable or convertible within 60&#160;days of February&#160;20, 2020. Except as indicated by footnote, to our knowledge, all persons named in the table above have sole voting and investment power with respect to all shares of common stock shown as beneficially owned. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Includes options to purchase 790 shares of common stock that are exercisable within 60&#160;days of February&#160;20, 2020. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Includes options to purchase 750 shares of common stock that are exercisable within 60&#160;days of February&#160;20, 2020. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
          <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Excludes 1,600 shares of the Company&#8217;s preferred stock. Includes options to purchase 1,411 shares of common stock that are exercisable within 60&#160;days of February&#160;20, 2020. Of the shares of common stock reported, 1 share is held indirectly by Mr.&#160;Rombotis through his IRA account. Does not include 613 shares of common stock beneficially owned by Kalliopi Rombotis, Mr.&#160;Rombotis&#8217; mother. Mr.&#160;Rombotis disclaims beneficial ownership of the foregoing shares. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">See footnotes 2 through and including 7. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Based solely on a Schedule&#160;13G/A filed by Eastern Capital Limited, or Eastern with the SEC on August&#160;25, 2017. Kenneth B. Dart is the beneficial owner of all of the outstanding shares of Portfolio Services Ltd., which, in turn, owns all of the outstanding shares of Eastern. The principal business address of each beneficial owner is 10 Market Street, #773, Camana Bay, Grand Cayman, KY1-9006, Cayman Islands. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Based solely on a Schedule&#160;13G filed by Hudson Bay Capital Management LP, or Hudson Bay on February&#160;2, 2018. Hudson Bay, which serves as the investment manager to Hudson Bay Master Fund&#160;Ltd., in whose name the securities reported are held, may be deemed to be the beneficial owner of all shares of Common Stock underlying the securities held by Hudson Bay Master Fund&#160;Ltd. Mr.&#160;Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay. The principal business address of each beneficial owner is 777 Third Avenue, 30 Floor, New York, NY 10017. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following description of our capital stock, certain provisions of our certificate of incorporation and bylaws, and certain provisions of Delaware law are summaries. The following description is not complete and is subject to and qualified in its entirety by our certificate of incorporation and bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">As of the date of this prospectus, our certificate of incorporation authorized us to issue 100,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Common Stock<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Dividends, Voting Rights and Liquidation<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, and do not have cumulative voting rights. Our amended and restated certificate of incorporation and amended and restated bylaws provide that our board of directors is divided into three classes, each serving staggered three-year terms ending at the annual meeting of our stockholders. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of funds legally available for dividend payments. All outstanding shares of common stock are fully paid and non-assessable, and the shares of common stock to be issued upon completion of this offering will be fully paid and non-assessable. The holders of common stock have no preferences or rights of conversion, exchange, pre-emption or other subscription rights. There are no </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">15<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">redemption or sinking fund provisions applicable to the common stock. In the event of any liquidation, dissolution or winding-up of our affairs, holders of common stock will be entitled to share ratably in our assets that are remaining after payment or provision for payment of all of our debts and obligations and after liquidation payments to holders of outstanding shares of preferred stock, if any. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Fully Paid and Non-Assessable<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Preferred Stock<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We have the authority to issue up to 5,000,000 shares of preferred stock. As of December&#160;31, 2019, 335,273 shares of our preferred stock were outstanding as 6% Convertible Exchangeable Preferred Stock (see &#8220;6% Convertible Exchangeable Preferred Stock&#8221; below) and 264 shares of our preferred stock were outstanding as Series&#160;A Convertible Preferred Stock (see &#8220;Series&#160;A Convertible Preferred Stock&#8221; below). The description of preferred stock provisions set forth below is not complete and is subject to and qualified in its entirety by reference to our certificate of incorporation and the certificate of designations relating to each series of preferred stock. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The board of directors has the right, without the consent of holders of common stock, to designate and issue one or more series of preferred stock, which may be convertible into common stock at a ratio determined by the board of directors. A series of preferred stock may bear rights superior to common stock as to voting, dividends, redemption, distributions in liquidation, dissolution, or winding up, and other relative rights and preferences. The board may set the following terms of any series of preferred stock: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the number of shares constituting the series and the distinctive designation of the series; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">dividend rates, whether dividends are cumulative, and, if so, from what date; and the relative rights of priority of payment of dividends; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">voting rights and the terms of the voting rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">conversion privileges and the terms and conditions of conversion, including provision for adjustment of the conversion rate; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">redemption rights and the terms and conditions of redemption, including the date or dates upon or after which shares may be redeemable, and the amount per share payable in case of redemption, which may vary under different conditions and at different redemption dates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">sinking fund provisions for the redemption or purchase of shares; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">rights in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights of priority of payment; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">any other relative powers, preferences, rights, privileges, qualifications, limitations and restrictions of the series. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Dividends on outstanding shares of preferred stock will be paid or declared and set apart for payment before any dividends may be paid or declared and set apart for payment on the common stock with respect to the same dividend period. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">If, upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the assets available for distribution to holders of preferred stock are insufficient to pay the full preferential amount to which the holders are entitled, then the available assets will be distributed ratably among the shares of all series of preferred stock in accordance with the respective preferential amounts (including unpaid cumulative dividends, if any) payable with respect to each series. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Holders of preferred stock will not be entitled to preemptive rights to purchase or subscribe for any shares of any class of capital stock of the corporation. The preferred stock will, when issued, be fully paid and non-assessable. The rights of the holders of preferred stock will be subordinate to those of our general creditors. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">16<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">We have previously issued shares of preferred stock in two series, designated as 6% Convertible Exchangeable Preferred Stock, of which 335,273 are currently outstanding and as Series&#160;A Convertible Preferred Stock, of which 264 are currently outstanding, and are quoted on The Nasdaq Capital Market under the symbol &#8220;CYCCP.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">6% Convertible Exchangeable Preferred Stock<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">General<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Our board of directors designated 2,046,813 shares of the preferred stock that were issued as convertible preferred stock on November&#160;3, 2004, of which 335,273 shares are currently outstanding. The shares of convertible preferred stock are duly and validly issued, fully paid and non-assessable. These shares will not have any preemptive rights if we issue other series of preferred stock. The convertible preferred stock is not subject to any sinking fund. We have no obligation to retire the convertible preferred stock. The convertible preferred stock has a perpetual maturity and may remain outstanding indefinitely, subject to the holder&#8217;s right to convert the convertible preferred stock and our right to cause the conversion of the convertible preferred stock and exchange or redeem the convertible preferred stock at our option. Any convertible preferred stock converted, exchanged or redeemed or acquired by us will, upon cancellation, have the status of authorized but unissued shares of convertible preferred stock. We will be able to reissue these cancelled shares of convertible preferred stock. This description does not give effect to the 1-for-20 reverse stock split of our common stock, which took effect on April&#160;14, 2020.</div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Dividends<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">When and if declared by our board of directors out of the legally available funds, holders of the convertible preferred stock are entitled to receive cash dividends at an annual rate of 6% of the liquidation preference of the convertible preferred stock. Dividends are payable quarterly on the first day of February, May, August and November. If any dividends are not declared, they will accrue and be paid at such later date, if any, as determined by our board of directors. Dividends on the convertible preferred stock will be cumulative from the issue date. Dividends will be payable to holders of record as they appear on our stock books not more than 60&#160;days nor less than 10&#160;days preceding the payment dates, as fixed by our board of directors. If the convertible preferred stock is called for redemption on a redemption date between the dividend record date and the dividend payment date and the holder does not convert the convertible preferred stock (as described below), the holder shall receive the dividend payment together with all other accrued and unpaid dividends on the redemption date instead of receiving the dividend on the dividend date. Dividends payable on the convertible preferred stock for any period greater or less than a full dividend period will be computed on the basis of a 360-day year consisting of twelve 30-day&#160;months. Accrued but unpaid dividends will not bear interest. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">If we do not pay or set aside cumulative dividends in full on the convertible preferred stock and any other preferred stock ranking on the same basis as to dividends, all dividends declared upon shares of the convertible preferred stock and any other preferred stock ranking on the same basis as to dividends will be declared on a pro&#160;rata basis until all accrued dividends are paid in full. For these purposes, &#8220;pro&#160;rata&#8221; means that the amount of dividends declared per share on the convertible preferred stock and any other preferred stock ranking on the same basis as to dividends bear to each other will be the same ratio that accrued and unpaid dividends per share on the shares of the convertible preferred stock and such other preferred stock bear to each other. We will not be able to redeem, purchase or otherwise acquire any of our stock ranking on the same basis as the convertible preferred stock as to dividends or liquidation preferences unless we have paid or set aside full cumulative dividends, if any, accrued on all outstanding shares of convertible preferred stock. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Unless we have paid or set aside cumulative dividends in full on the convertible preferred stock and any other of the convertible preferred stock ranking on the same basis as to dividends: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">we may not declare or pay or set aside dividends on common stock or any other stock ranking junior to the convertible preferred stock as to dividends or liquidation preferences, excluding dividends or distributions of shares, options, warrants or rights to purchase common stock or other stock ranking junior to the convertible preferred stock as to dividends; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">17<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">we will not be able to redeem, purchase or otherwise acquire any of our other stock ranking junior to the convertible preferred stock as to dividends or liquidation preferences, except in very limited circumstances. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Under Delaware law, we may only make dividends or distributions to our stockholders from: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">our surplus; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the net profits for the current fiscal year before which the dividend or distribution is declared under certain circumstances. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For the year ended December&#160;31, 2019, the company declared dividends of&#8201; $0.15 per share quarterly. These dividends were paid on May&#160;1, August&#160;1 and November&#160;1, 2019, and February&#160;1, 2020, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Conversion<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Conversion Rights<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Holders of our convertible preferred stock may convert the convertible preferred stock at any time into a number of shares of common stock determined by dividing the $10.00 liquidation preference by the conversion price of&#8201; $1,974.00. This conversion price is equivalent to a conversion rate of approximately 0.00507 shares of common stock for each share of convertible preferred stock. We will not make any adjustment to the conversion price for accrued or unpaid dividends upon conversion. We will not issue fractional shares of common stock upon conversion. However, we will instead pay cash for each fractional share based upon the market price of the common stock on the last business day prior to the conversion date. If we call the convertible preferred stock for redemption, the holder&#8217;s right to convert the convertible preferred stock will expire at the close of business on the business day immediately preceding the date fixed for redemption, unless we fail to pay the redemption price. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Automatic Conversion<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Unless we redeem or exchange the convertible preferred stock, we may elect to convert some or all of the convertible preferred stock into shares of our common stock if the closing price of our common stock has exceeded 150% of the conversion price for at least 20 out of 30 consecutive trading days ending within five trading days prior to the notice of automatic conversion. If we elect to convert less than all of the shares of convertible preferred stock, we shall select the shares to be converted by lot or pro&#160;rata or in some other equitable manner in our discretion. On or after November&#160;3, 2007, we may not elect to automatically convert the convertible preferred stock if full cumulative dividends on the convertible preferred stock for all past dividend periods have not been paid or set aside for payment. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Conversion Price Adjustment&#8201;&#8212;&#8201;General<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The conversion price of&#8201;$1,974.00 will be adjusted if: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we dividend or distribute common stock in shares of our common stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we subdivide or combine our common stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we issue to all holders of common stock certain rights or warrants to purchase our common stock at less than the current market price; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we dividend or distribute to all holders of our common stock shares of our capital stock or evidences of indebtedness or assets, excluding: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">those rights, warrants, dividends or distributions referred to in (1)&#160;or (3), or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">dividends and distributions paid in cash; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we made a dividend or distribution consisting of cash to all holders of common stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we purchase common stock pursuant to a tender offer made by us or any of our subsidiaries; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">18<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">a person other than us or any of our subsidiaries makes any payment on a tender offer or exchange offer and, as of the closing of the offer, the board of directors is not recommending rejection of the offer. We will only make this adjustment if the tender or exchange offer increases a person&#8217;s ownership to more than 25% of our outstanding common stock, and only if the payment per share of common stock exceeds the current market price of our common stock. We will not make this adjustment if the offering documents disclose our plan to engage in any consolidation, merger, or transfer of all or substantially all of our properties and if specified conditions are met. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we implement a stockholder rights plan, this new rights plan must provide that, upon conversion of the existing convertible preferred stock the holders will receive, in addition to the common stock issuable upon such conversion, the rights under such rights plan regardless of whether the rights have separated from the common stock before the time of conversion. The distribution of rights or warrants pursuant to a stockholder rights plan will not result in an adjustment to the conversion price of the convertible preferred stock until a specified triggering event occurs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The occurrence and magnitude of certain of the adjustments described above is dependent upon the current market price of our common stock. For these purposes, &#8220;current market price&#8221; generally means the lesser of: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the closing sale price on certain specified dates, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the average of the closing prices of the common stock for the ten trading day period immediately prior to certain specified dates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may make a temporary reduction in the conversion price of the convertible preferred stock if our board of directors determines that this decrease would be in our best interest. We may, at our option, reduce the conversion price if our board of directors deems it advisable to avoid or diminish any income tax to holders of common stock resulting from any dividend or distribution of stock or rights to acquire stock or from any event treated as such for income tax purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Conversion Price Adjustment&#8201;&#8212;&#8201;Merger, Consolidation or Sale of Assets<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we are involved in a transaction in which shares of our common stock are converted into the right to receive other securities, cash or other property, or a sale or transfer of all or substantially all of our assets under which the holders of our common stock shall be entitled to receive other securities, cash or other property, then appropriate provision shall be made so that the shares of convertible preferred stock will convert into: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the transaction is a common stock fundamental change, as defined below, common stock of the kind received by holders of common stock as a result of common stock fundamental change in accordance with paragraph (1)&#160;below under the subsection entitled &#8220;&#8212; Fundamental Change Conversion Price Adjustments,&#8221; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">if the transaction is not a common stock fundamental change, and subject to funds being legally available at conversion, the kind and amount of the securities, cash or other property that would have been receivable upon the recapitalization, reclassification, consolidation, merger, sale, transfer or share exchange by a holder of the number of shares of common stock issuable upon conversion of the convertible preferred stock immediately prior to the recapitalization, reclassification, consolidation, merger, sale, transfer or share exchange, after giving effect to any adjustment in the conversion price in accordance with paragraph (2)&#160;below under the subsection entitled &#8220;&#8212; Fundamental Change Conversion Price Adjustments.&#8221; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The company formed by the consolidation, merger, asset acquisition or share acquisition shall provide for this right in its organizational document. This organizational document shall also provide for adjustments so that the organizational document shall be as nearly practicably equivalent to adjustments in this section for events occurring after the effective date of the organizational document. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">19<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">The following types of transactions, among others, would be covered by this adjustment: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we recapitalize or reclassify our common stock, except for: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">a change in par value, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">a change from par value to no par value, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">a change from no par value to par value, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">a subdivision or combination of our common stock. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we consolidate or merge into any other person, or any merger of another person into us, except for a merger that does not result in a reclassification, conversion, exchange or cancellation of common stock, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.91pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:7.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we sell, transfer or lease all or substantially all of our assets and holders of our common stock become entitled to receive other securities, cash or other property, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">we undertake any compulsory share exchange. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Fundamental Change Conversion Price Adjustments<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">If a fundamental change occurs, the conversion price will be adjusted as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the case of a common stock fundamental change, the conversion price shall be the conversion price after giving effect to any other prior adjustments effected pursuant to the preceding paragraphs, multiplied by a fraction, the numerator of which is the purchaser stock price, as defined below, and the denominator of which is the applicable price, as defined below. However, in the event of a common stock fundamental change in which: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">100% of the value of the consideration received by a holder of our common stock is common stock of the successor, acquirer or other third party, and cash, if any, paid with respect to any fractional interests in such common stock resulting from such common stock fundamental change, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">All of our common stock shall have been exchanged for, converted into or acquired for, common stock of the successor, acquirer or other third party, and any cash with respect to fractional interests, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">the conversion price shall be the conversion price in effect immediately prior to such common stock fundamental change multiplied by a fraction, the numerator of which is one (1)&#160;and the denominator of which is the number of shares of common stock of the successor, acquirer or other third party received by a holder of one share of our common stock as a result of the common stock fundamental change; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">in the case of a non-stock fundamental change, the conversion price shall be the lower of: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">the conversion price after giving effect to any other prior adjustments effected pursuant to the preceding paragraph and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:50pt;">the product of </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">A.<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">the applicable price, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:60pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">B.<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:80pt;">a fraction, the numerator of which is $10 and the denominator of which is (x)&#160;the amount of the redemption price for one share of convertible preferred stock if the redemption date were the date of the non-stock fundamental change (or if the date of such non-stock fundamental change falls within the period beginning on the first issue date of the convertible preferred stock through October&#160;31, 2005, the twelve-month period commencing November&#160;1, 2005 and the twelve-month period commencing November&#160;1, 2006, the product of 106.0%, 105.4% or 104.8%, respectively, and $10) plus (y)&#160;any then-accrued and unpaid distributions on one share of convertible preferred stock. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">20<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Holders of convertible preferred stock may receive significantly different consideration upon conversion depending upon whether a fundamental change is a non-stock fundamental change or a common stock fundamental change. In the event of a non-stock fundamental change, the shares of convertible preferred stock will convert into stock and other securities or property or assets, including cash, determined by the number of shares of common stock receivable upon conversion at the conversion price as adjusted in accordance with (2)&#160;above. In the event of a common stock fundamental change, under certain circumstances, the holder of convertible preferred stock will receive different consideration depending on whether the holder converts his or her shares of convertible preferred stock on or after the common stock fundamental change. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Definitions for the Fundamental Change Adjustment Provision<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-weight:bold;">&#8220;applicable price&#8221;</font> means: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">in a non-stock fundamental change in which the holders of common stock receive only cash, the amount of cash received by a holder of one share of common stock, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">in the event of any other fundamental change, the average of the daily closing price for one share of common stock during the 10 trading days immediately prior to the record date for the determination of the holders of common stock entitled to receive cash, securities, property or other assets in connection with the fundamental change or, if there is no such record date, prior to the date upon which the holders of common stock shall have the right to receive such cash, securities, property or other assets. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">&#8220;common stock fundamental change&#8221;</font> means any fundamental change in which more than 50% of the value, as determined in good faith by our board of directors, of the consideration received by holders of our common stock consists of common stock that, for the 10 trading days immediately prior to such fundamental change, has been admitted for listing or admitted for listing subject to notice of issuance on a national securities exchange or quoted on The Nasdaq National Market, except that a fundamental change shall not be a common stock fundamental change unless either: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">we continue to exist after the occurrence of the fundamental change and the outstanding convertible preferred stock continues to exist as outstanding convertible preferred stock, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">not later than the occurrence of the fundamental change, the outstanding convertible preferred stock is converted into or exchanged for shares of preferred stock, which preferred stock has rights, preferences and limitations substantially similar, but no less favorable, to those of the convertible preferred stock. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">&#8220;fundamental change&#8221;</font> means the occurrence of any transaction or event or series of transactions or events pursuant to which all or substantially all of our common stock shall be exchanged for, converted into, acquired for or shall constitute solely the right to receive cash, securities, property or other assets, whether by means of an exchange offer, liquidation, tender offer, consolidation, merger, combination, reclassification, recapitalization or otherwise. However, for purposes of adjustment of the conversion price, in the case of any series of transactions or events, the fundamental change shall be deemed to have occurred when substantially all of the common stock shall have been exchanged for, converted into or acquired for, or shall constitute solely the right to receive, such cash, securities, property or other assets, but the adjustment shall be based upon the consideration that the holders of our common stock received in the transaction or event as a result of which more than 50% of our common stock shall have been exchanged for, converted into or acquired for, or shall constitute solely the right to receive, such cash, securities, property or other assets. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">&#8220;non-stock fundamental change&#8221;</font> means any fundamental change other than a common stock fundamental change. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;">&#8220;purchaser stock price&#8221;</font> means the average of the daily closing price for one share of the common stock received by holders of the common stock in the common stock fundamental change during the 10 trading days immediately prior to the date fixed for the determination of the holders of the common stock entitled to receive such common stock or, if there is no such date, prior to the date upon which the holders of the common stock shall have the right to receive such common stock. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">21<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Liquidation Rights<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">In the event of our voluntary or involuntary dissolution, liquidation, or winding up, the holders of the convertible preferred stock shall receive a liquidation preference of&#8201;$10 per share and all accrued and unpaid dividends through the distribution date. Holders of any class or series of preferred stock ranking on the same basis as the convertible preferred stock as to liquidation shall also be entitled to receive the full respective liquidation preferences and any accrued and unpaid dividends through the distribution date. Only after the preferred stock holders have received their liquidation preference and any accrued and unpaid dividends will we distribute assets to common stock holders or any of our other stock ranking junior to the shares of convertible preferred stock upon liquidation. If upon such dissolution, liquidation or winding up, we do not have enough assets to pay in full the amounts due on the convertible preferred stock and any other preferred stock ranking on the same basis with the convertible preferred stock as to liquidation, the holders of the convertible preferred stock and such other preferred stock will share ratably in any such distributions of our assets: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">first in proportion to the liquidation preferences until the preferences are paid in full, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">then in proportion to the amounts of accrued but unpaid dividends. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">After we pay any liquidation preference and accrued dividends, holders of the convertible preferred stock will not be entitled to participate any further in the distribution of our assets. The following events will not be deemed to be a dissolution, liquidation or winding up of Cyclacel: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">the sale of all or substantially all of the assets; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">our merger or consolidation into or with any other corporation; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">our liquidation, dissolution, winding up or reorganization immediately followed by a reincorporation as another corporation. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Optional Redemption<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption price of&#8201; $10.00 per share: </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Exchange Provisions<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may exchange the convertible preferred stock in whole, but not in part, for debentures on any dividend payment date on or after November&#160;1, 2005 at the rate of&#8201; $10 principal amount of debentures for each outstanding share of convertible preferred stock. Debentures will be issuable in denominations of&#8201; $1,000 and integral multiples of&#8201;&#8201;$1,000. If the exchange results in an amount of debentures that is not an integral multiple of&#8201;&#8201;$1,000, we will pay in cash an amount in excess of the closest integral multiple of&#8201;&#8201;$1,000. We will mail written notice of our intention to exchange the convertible preferred stock to each record holder not less than 30 nor more than 60&#160;days prior to the exchange date. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We refer to the date fixed for exchange of the convertible preferred stock for debentures as the &#8220;exchange date.&#8221; On the exchange date, the holder&#8217;s rights as a stockholder of Cyclacel shall cease, the shares of convertible preferred stock will no longer be outstanding, and will only represent the right to receive the debentures and any accrued and unpaid dividends, without interest. We may not exercise our option to exchange the convertible preferred stock for the debentures if: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">full cumulative dividends on the convertible preferred stock to the exchange date have not been paid or set aside for payment, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">an event of default under the indenture would occur on conversion, or has occurred and is continuing. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Voting Rights<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Holders of our convertible preferred stock have no voting rights except as described below or as required by law. Shares of our convertible preferred stock held by us or any entity controlled by us will not have any voting rights. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">22<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Company&#8217;s Board of Directors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Without the vote or consent of the holders of at least a majority of the shares of convertible preferred stock, we may not: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">adversely change the rights, preferences and limitations of the convertible preferred stock by modifying our certificate of incorporation or bylaws, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">authorize, issue, reclassify any of our authorized stock into, increase the authorized amount of, or authorize or issue any convertible obligation or security or right to purchase, any class of stock that ranks senior to the convertible preferred stock as to dividends or distributions of assets upon liquidation, dissolution or winding up of the stock. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">No class vote on the part of convertible preferred stock shall be required (except as otherwise required by law or resolution of our board of directors) in connection with the authorization, issuance or increase in the authorized amount of any shares of capital stock ranking junior to or on parity with the convertible preferred stock both as to the payment of dividends and as to distribution of assets upon our liquidation, dissolution or winding up, whether voluntary or involuntary, including our common stock and the convertible preferred stock. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, without the vote or consent of the holders of at least a majority of the shares of convertible preferred stock we may not: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">enter into a share exchange that affects the convertible preferred stock, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">consolidate with or merge into another entity, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">permit another entity to consolidate with or merge into us, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">unless the convertible preferred stock remains outstanding and its rights, privileges and preferences are unaffected or it is converted into or exchanged for convertible preferred stock of the surviving entity having rights, preferences and limitations substantially similar, but no less favorable, to the convertible preferred stock. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In determining a majority under these voting provisions, holders of convertible preferred stock will vote together with holders of any other preferred stock that rank on parity as to dividends and that have like voting rights. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Series&#160;A Preferred Stock<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">8,872 shares of the Company&#8217;s Series&#160;A Preferred Stock were issued in a underwritten public offering on July&#160;21, 2017 (the &#8220;July&#160;2017 Underwritten Public Offering&#8221;). Each share of Series&#160;A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing $1,000 by the initial conversion price of&#8201;$2.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series&#160;A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations. This description does not give effect to the 1-for-20 reverse stock split of our common stock, which took effect on April 14, 2020.</div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">During the year ended December&#160;31, 2017, 8,608 shares of the Series&#160;A Preferred Stock were converted into 4,304,000 shares of common stock. As of December&#160;31, 2019, 264 shares of the Series&#160;A Preferred Stock remain issued and outstanding. The 264 shares of Series&#160;A Preferred Stock issued and outstanding at December&#160;31, 2019, are convertible into 132,000 shares of common stock. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the event of a liquidation, the holders of Series&#160;A Preferred Shares are entitled to participate on an as-converted-to-common stock basis with holders of the common stock in any distribution of assets of the Company to the holders of the common stock. The Series&#160;A Certificate of Designation provides, among other things, that we shall not pay any dividends on shares of common stock (other than dividends in the form </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">23<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">of common stock) unless and until such time as we pay dividends on each Series&#160;A Preferred Share on an as-converted basis. Other than as set forth in the previous sentence, the Series&#160;A Certificate of Designation provides that no other dividends shall be paid on Series&#160;A Preferred Shares and that we shall pay no dividends (other than dividends in the form of common stock) on shares of common stock unless we simultaneously comply with the previous sentence. The Series&#160;A Certificate of Designation does not provide for any restriction on the repurchase of Series&#160;A Preferred Shares by us while there is any arrearage in the payment of dividends on the Series&#160;A Preferred Shares. There are no sinking fund provisions applicable to the Series&#160;A Preferred Shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">With certain exceptions, as described in the Series&#160;A Certificate of Designation, the Series&#160;A Preferred Stock has no voting rights. However, as long as any shares of Series&#160;A Preferred Stock remain outstanding, the Series&#160;A Certificate of Designation provides that we shall not, without the affirmative vote of holders of a majority of the then-outstanding Series&#160;A Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;A Preferred Stock or alter or amend the Series&#160;A Certificate of Designation, (b)&#160;increase the number of authorized shares of Series&#160;A Preferred Stock or (c)&#160;effect a stock split or reverse stock split of the Series&#160;A Preferred Stock or any like event. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each share of Series&#160;A Preferred Stock is convertible at any time at the holder&#8217;s option into a number of shares of common stock equal to $1,000 divided by the Series&#160;A Conversion Price. The &#8220;Series&#160;A Conversion Price&#8221; was initially $2.00 and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations. Notwithstanding the foregoing, the Series&#160;A Certificate of Designation further provides that we shall not effect any conversion of Series&#160;A Preferred Stock, with certain exceptions, to the extent that, after giving effect to an attempted conversion, the holder of Series&#160;A Preferred Shares (together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the holder, 9.99%) of the shares of our common stock then outstanding after giving effect to such exercise (the &#8220;Preferred Stock Beneficial Ownership Limitation&#8221;); provided, however, that upon notice to the Company, the holder may increase or decrease the Preferred Stock Beneficial Ownership Limitation, provided that in no event shall the Preferred Stock Beneficial Ownership Limitation exceed 9.99% and any increase in the Preferred Stock Beneficial Ownership Limitation will not be effective until 61&#160;days following notice of such increase from the holder to us. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to certain conditions, at any time following the issuance of the Series&#160;A Preferred Stock, we will have the right to cause each holder of the Series&#160;A Preferred Stock to convert all or part of such holder&#8217;s Series&#160;A Preferred Stock in the event that (i)&#160;the volume weighted average price of our common stock for 30 consecutive trading days (the &#8220;Measurement Period&#8221;) exceeds 300% of the initial conversion price of the Series&#160;A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii)&#160;the daily trading volume on each Trading Day during such Measurement Period exceeds $500,000 per trading day and (iii)&#160;the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. Our right to cause each holder of the Series&#160;A Preferred Stock to convert all or part of such holder&#8217;s Series&#160;A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Series&#160;A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series&#160;A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Warrants<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of December&#160;31, 2019, there were warrants to purchase 374,525 shares of common stock outstanding, each with an exercise price of&#8201; $2.00. All such warrants were issued in connection with the July&#160;2017 Underwritten Public Offering and are immediately exercisable. The Warrants expire in 2024. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">24<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">or any of such holder&#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our common stock then outstanding after giving effect to such exercise. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such warrant holders are utilizing the cashless exercise provision of the warrants. On the expiration date, unexercised warrants will automatically be exercised via the &#8220;cashless&#8221; exercise provision. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Prior to the exercise of any warrants to purchase common stock, holders of the warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as set forth therein. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">There were no warrants exercised during each of the&#160;years ended December&#160;31, 2019. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Anti-Takeover Provisions<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The provisions of Delaware law, our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws, certain provisions of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of our company. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws to be in Effect upon the Closing of this Offering<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of common stock may be able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide for stockholder actions at a duly called meeting of stockholders or, before the date on which all shares of common stock convert into a single class, by written consent. A special meeting of stockholders may be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer. Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. Our board of directors is divided into three classes with staggered three-year terms. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The foregoing provisions make it difficult for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three&#160;years after the date that such stockholder became an interested stockholder, subject to certain exceptions. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">25<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOSW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">DESCRIPTION OF SECURITIES WE ARE OFFERING<font style="font-weight:normal;"> </font></div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">We are offering (i) 2,564,102 shares of our common stock or pre-funded warrants to purchase shares of our common stock, assuming the sale of our common stock at an assumed offering price of $7.80 per share and (ii) common warrants to purchase up to an aggregate of 2,564,102 shares of our common stock. Each share of common stock or pre-funded warrant is being sold together with a common warrant to purchase one share of common stock. The shares of common stock or pre-funded warrants and accompanying common warrants will be issued separately. We are also registering the shares of common stock issuable from time to time upon exercise of the pre-funded warrants and common warrants offered hereby. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Common Stock<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;">The material terms and provisions of our common stock and each other class of our securities which qualifies or limits our common stock are described under the caption &#8220;Description of Capital Stock&#8221; in this prospectus. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Pre-Funded Warrants<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;font-style:italic;">The following summary of certain terms and provisions of pre-funded warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the pre-funded warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of pre-funded warrant for a complete description of the terms and conditions of the pre-funded warrants.<font style="font-style:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Duration and Exercise Price.</font>&nbsp;&nbsp;&nbsp;Each pre-funded warrant offered hereby will have an initial exercise price per share equal to $0.001. The pre-funded warrants will be immediately exercisable and may be exercised at any time until the pre-funded warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The pre-funded warrants will be issued separately from the accompanying common warrants, and may be transferred separately immediately thereafter. </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Exercisability.</font>&nbsp;&nbsp;&nbsp;The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). Purchasers of the pre-funded warrants in this offering may elect to deliver their exercise notice following the pricing of the offering and prior to the issuance of the pre-funded warrants at closing to have their pre-funded warrants exercised immediately upon issuance and receive shares of common stock underlying the pre-funded warrants upon closing of this offering. A holder (together with its affiliates) may not exercise any portion of the pre-funded warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61&#160;days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s pre-funded warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such&#160;percentage ownership is determined in accordance with the terms of the pre-funded warrants. Purchasers of pre-funded warrants in this offering may also elect prior to the issuance of the pre-funded warrants to have the initial exercise limitation set at 9.99% of our outstanding common stock. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. In lieu of fractional shares, we will round down to the next whole share. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Cashless Exercise.</font>&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its pre-funded warrants, a registration statement registering the issuance of the shares of common stock underlying the pre-funded warrants under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the pre-funded warrants. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Transferability.</font>&nbsp;&nbsp;&nbsp;Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer. </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">26<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;">Exchange Listing.</font>&nbsp;&nbsp;&nbsp;There is no trading market available for the pre-funded warrants on any securities exchange or nationally recognized trading system. We do not intend to list the pre-funded warrants on any securities exchange or nationally recognized trading system. </div>

          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Common Warrants</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">The following summary of certain terms and provisions of common warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the common warrants, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of common warrants for a complete description of the terms and conditions of the common warrants.</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Duration and Exercise Price.</font>&nbsp;&nbsp;&nbsp;Each common warrant offered hereby will have an initial exercise price per share equal to $7.80. The common warrants will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The common warrants will be issued separately from the common stock, and may be transferred separately immediately thereafter. A common warrant to purchase one share of our common stock will be issued for every one share of common stock purchased in this offering.</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Exercisability.</font>&nbsp;&nbsp;&nbsp;The common warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the common warrant to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s common warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the common warrants. No fractional shares of common stock will be issued in connection with the exercise of a common warrant. In lieu of fractional shares, we will round down to the next whole share.</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Cashless Exercise.</font>&nbsp;&nbsp;&nbsp;If, at the time a holder exercises its common warrants, a registration statement registering the issuance of the shares of common stock underlying the common warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the common warrants.</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Transferability.</font>&nbsp;&nbsp;&nbsp;Subject to applicable laws, a common warrant in book entry form may be transferred at the option of the holder through the facilities of the Depository Trust Company and common warrants in physical form may be transferred upon surrender of the common warrant to the warrant agent together with the appropriate instruments of transfer.</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Exchange Listing.</font>&nbsp;&nbsp;&nbsp;There is no established public trading market for the common warrants, and we do not expect a market to develop. In addition, we do not intend to list the common warrants on any securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the common warrants will be limited.</div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Right as a Stockholder</font>.&nbsp;&nbsp;&nbsp;Except as otherwise provided in the common warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holders of the common warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their common warrants. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="font-style:italic;">Fundamental Transaction.</font>&nbsp;&nbsp;&nbsp;In the event of a fundamental transaction, as described in the form of common warrant, and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">27<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the common warrants will be entitled to receive upon exercise of the common warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the common warrants immediately prior to such fundamental transaction. </div>

        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">PLAN OF DISTRIBUTION<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Roth Capital Partners, LLC, which we refer to as &#8220;Roth Capital Partners&#8221;, is acting as the lead placement agent, and Ladenburg Thalmann &amp; Co. Inc., which we refer to as &#8220;Ladenburg Thalmann&#8221;, and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents in connection with this offering, subject to the terms and conditions of a co-placement agency agreement dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. The placement agents are not purchasing or selling any of the securities offered by this prospectus, nor are the placement agents required to arrange the purchase or sale of any specific number or dollar amount of securities. The placement agents have agreed to use reasonable best efforts to arrange for the sale of all of the securities offered hereby. Therefore, we may not sell the entire amount of securities offered pursuant to this prospectus. The placement agents may engage one or more sub-agents or selected dealers in connection with this offering. </div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We will enter into a securities purchase agreement directly with the institutional investors, at the investor&#8217;s option, who purchase our securities in this offering. This agreement includes representations and warranties by us and the purchaser. This agreement also includes a covenant that in no event shall the total number of shares of common stock owned by a purchaser, or a group of which such purchaser is a part, exceed 19.9% of the number of shares of common stock outstanding prior to the offering, unless stockholder approval is obtained for such excess holding. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Only certain institutional investors purchasing the securities offered hereby will execute, at such investors&#8217; option, a securities purchase agreement with us, providing such investors with certain representations, warranties and covenants from us, which representations, warranties and covenants will not be available to other investors who will not execute a securities purchase agreement in connection with the purchase of the securities offered pursuant to this prospectus. Therefore, those investors shall rely solely on this prospectus in connection with the purchase of securities in the offering. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We will deliver the securities being issued to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver the securities being offered pursuant to this prospectus on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Commissions and Expenses<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have agreed to pay the placement agents an aggregate cash placement fee equal to 7.0% of the gross proceeds received at the closing from the sale of the securities with respect to the base offering amount, which is the amount of gross proceeds from the sale of securities to investors. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following table shows the per share, per pre-funded warrant and total cash placement agent fees we will pay to the placement agents in connection with the sale of the securities offered pursuant to this prospectus. </div>


          <table style="width:416pt;height:65.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:266.36pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:65.49pt;">
                <div style="text-align:center;">Per Share of <br >Common Stock and <br >Common Warant </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:60.14pt;">
                <div style="text-align:center;">Per <br >Pre-funded <br >Warrant and<br >Common Warrant </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:266.36pt;text-align:left;">
                <div style="white-space:nowrap;">Placement Agent Fees </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:65.49pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60.14pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:266.36pt;text-align:left;">
                <div style="margin-left:10pt;">Total</div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:65.49pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:60.14pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Because there is no minimum offering amount required as a condition to closing in this offering, the actual aggregate cash placement fee, if any, is not presently determinable and may be substantially less than the maximum amount set forth above. In addition, subject to FINRA Rule&#160;5110(f)(2)(d)(i), we have </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">28<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <div style="width:456pt; line-height:12pt;">agreed to reimburse the lead placement agent for reasonable out-of-pocket expenses up to a maximum of $75,000. We estimate that the total expenses of the offering payable by us, excluding the placement agent fees, will be approximately $210,000. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Determination of Offering Price<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The public offering price of the securities we are offering was negotiated between us and the investors, in consultation with the placement agents based on the trading of our common stock prior to the offering, among other things. Other factors considered in determining the public offering price of the securities we are offering include the history and prospects of the Company, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.</div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Indemnification<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have agreed to indemnify the placement agents against liabilities under the Securities Act. We have also agreed to contribute to payments the placement agents may be required to make in respect of such liabilities. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Electronic Distribution<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus may be made available in electronic format on websites or through other online services maintained by the placement agents, or by an affiliate. Other than this prospectus in electronic format, the information on the placement agents&#8217; website(s) and any information contained in any other website maintained by the placement agents or by an affiliate is not part of this prospectus or the registration statement of which this prospectus is a part, has not been approved and/or endorsed by us or the placement agents, and should not be relied upon by investors. </div>


          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The foregoing does not purport to be a complete statement of the terms and conditions of the co-placement agency agreement or the securities purchase agreement, copies of which are incorporated by reference into the registration statement of which this prospectus is a part. See &#8220;Where You Can Find More Information.&#8221; </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Regulation&#160;M Restrictions<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each placement agent may be deemed to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agents would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule&#160;415(a)(4) under the Securities Act and Rule&#160;10b-5 and Regulation&#160;M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of securities by the placement agents acting as principal. Under these rules and regulations, the placement agents may not engage in any stabilization activity in connection with our securities; and may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Passive Market Making<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In connection with this offering, the placement agents may engage in passive market making transactions in our Common Stock on the Nasdaq Capital Market in accordance with Rule&#160;103 of Regulation&#160;M promulgated under the Exchange Act during a period before the commencement of offers or sales of the securities and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. If all independent bids are lowered below the passive market maker&#8217;s bid, however, that bid must then be lowered when specified purchase limits are exceeded. </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">29<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">Lock-Up Agreements<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We and each of our officers and directors have agreed not to offer, pledge, sell, contract to sell, grant any option or contract to purchase, purchase any option or contract to sell, or otherwise dispose of, directly or indirectly, any common stock or any securities convertible into, exercisable for, or exchangeable for common stock, or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock for a period of 90&#160;days after the effective date of the registration statement of which this prospectus is a part without the prior written consent of Roth Capital Partners, except for sales of shares to satisfy tax withholding obligations upon settlement of restricted stock&#160;units outstanding as of the date of the lock-up agreement. This consent may be given at any time without public notice. Each officer and director shall be immediately and automatically released from all restrictions and obligations under the lock up agreement in the event that he or she ceases to be a director or officer of our company and has no further reporting obligations under Section&#160;16 of the Exchange Act. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Right of First Refusal<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we decide to make a public or private offering of our equity, equity-linked or debt securities, subject to certain exclusions, we have granted Roth Capital Partners the right to act as the exclusive placement agent or lead underwriter, for such offering until the date that is 90&#160;days following the closing of this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Other<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">From time to time, the placement agents and their affiliates may in the future provide various investment banking, financial advisory and other services to us and our affiliates for which services they may receive customary fees, but we have no present arrangements to do so. Subject to Regulation&#160;M and other applicable statutes and regulations, in the course of its businesses, the placement agents and their affiliates may actively trade our securities or loans for their own account or for the accounts of customers, and, accordingly, the placement agents may at any time hold long or short positions in such securities or loans. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Listing<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;CYCC.&#8221; There is no established trading market for the pre-funded warrants or common warrants offered by this prospectus, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the pre-funded warrants or common warrants, offered by this prospectus on any securities exchange or recognized trading system. </div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Selling Restrictions<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">European Economic Area<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus does not constitute an approved prospectus under Directive 2003/71/EC and no such prospectus is intended to be prepared and approved in connection with this offering. Accordingly, in relation to each Member State of the European Economic Area which has implemented Directive 2003/71/EC (each, a &#8220;Relevant Member State&#8221;) an offer to the public of any shares of common stock, which are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State except that an offer to the public in that Relevant Member State of any shares of common stock may be made at any time under the following exemptions under the Prospectus Directive, if and to the extent that they have been implemented in that Relevant Member State: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
          <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the representatives of the underwriter for any such offer; or </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">30<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">(c)<br ></div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">in any other circumstances which do not require any person to publish a prospectus pursuant to Article&#160;3 of the Prospectus Directive. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to any shares of common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase any shares of common stock, as the expression may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC (and any amendments thereto including the 2010 PD Amending Directive to the extent implemented in each Relevant Member State) and includes any relevant implementing measure in each Relevant Member State and the expression &#8220;2010 PD Amending Directive&#8221; means Directive 2010/73/EU. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">United Kingdom<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus is not an approved prospectus for purposes of the UK Prospectus Rules, as implemented under the EU Prospectus Directive (2003/71/EC), and have not been approved under section 21 of the Financial Services and Markets Act 2000 (as amended) (the &#8220;FSMA&#8221;) by a person authorized under FSMA. The financial promotions contained in this prospectus is directed at, and this prospectus is only being distributed to (1)&#160;persons who receive this prospectus outside of the United Kingdom, and (2)&#160;persons in the United Kingdom who fall within the exemptions under articles 19 (investment professionals) and 49(2)(a) to (d)&#160;(high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons together being referred to as &#8220;Relevant Persons&#8221;). This prospectus must not be acted upon or relied upon by any person who is not a Relevant Person. Any investment or investment activity to which this prospectus relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person that is not a Relevant Person. </div>

          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The placement agents have represented, warranted and agreed that: </div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">they have only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA in connection with the issue or sale of any of the shares of common stock in circumstances in which section 21(1) of the FSMA does not apply to the issuer; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">they have complied with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of common stock in, from or otherwise involving the United Kingdom.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">LEGAL MATTERS<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York, which has acted as our counsel in connection with this offering, will pass on certain legal matters with respect to U.S. federal law in connection with this offering. Ellenoff Grossman &amp; Schole LLP, New York, New York has acted as counsel to the lead placement agent in connection with this offering. </div>

        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">EXPERTS<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The consolidated financial statements incorporated in this prospectus by reference from the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference (which report expresses an unqualified opinion on the consolidated financial statements and includes an explanatory paragraph referring to the Company&#8217;s ability to continue as a going concern). Such consolidated financial statements have been so incorporated by reference in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </div>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">31<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a><a name="tIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">WHERE YOU CAN FIND MORE INFORMATION<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the securities being offered by this prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus, we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are subject to the information and periodic reporting requirements of the Exchange Act, and we file periodic reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC&#8217;s website at www.sec.gov. You may also request a copy of these filings, at no cost, by writing us at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922. We also maintain a website at www.cyclacel.com, at which you may access these materials free of charge after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We incorporate by reference into this prospectus and the registration statement of which this prospectus form a part the information or documents listed below that we have filed with the SEC, and any future filings we will make with the SEC under Sections&#160;13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, and until the termination of the offering of the shares covered by this prospectus (other than information furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K): </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000155837020002077/cycc-20191231x10k.htm">our Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC on March&#160;5, 2020;</a> </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">our Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920001633/tm201328d1_8k.htm">January&#160;7, 2020</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920003040/0001104659-20-003040-index.htm">January 10, 2020</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920035359/0001104659-20-035359-index.htm">March 18, 2020</a>, <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920039601/0001104659-20-039601-index.htm">March 27, 2020</a> and <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/0001104659-20-046360-index.htm">April&#160;14, 2020</a>; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">The description of our common stock contained in our Registration Statement on Form 8-A, filed on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504035678/d8a12g.htm">March&#160;8, 2004 (File No. 000-50626)</a>, which incorporates by reference the description of the shares of our common stock contained in our Registration Statement on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312503060474/ds1.htm">Form S-1 (File No. 333-109653) filed on October&#160;10, 2003</a> and declared effective by the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504043602/d424b4.htm">March&#160;17, 2004</a>, and any amendment or reports filed with the SEC for purposes of updating such description; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">The description of our preferred stock contained in our Registration Statement on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504179308/d8a12g.htm">Form 8-A, filed on October&#160;27, 2004 (File No. 000-50626)</a>, which incorporates by reference the description of the shares of our preferred stock contained in our Registration Statement on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504168220/ds1.htm">Form S-1 (File No. 333-119585)</a> filed on October&#160;7, 2004 and declared effective by the SEC on <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504182138/d424b3.htm">November&#160;1, 2004</a>, and any amendment or reports filed with the SEC for purposes of updating such description. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statements so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">32<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-bottom:456pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">requests for documents to Cyclacel Pharmaceuticals, Inc., 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922; telephone: (908) 517-7330. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">You also may access these filings on our website at www.cyclacel.com. We do not incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus). </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">33<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:13pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.9pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;z-index:-1;margin-top:10.4pt; text-align:center; width:456pt;">
          <img src="lg_cyclacelreg-4c.jpg" alt="[MISSING IMAGE: lg_cyclacelreg-4c.jpg]" height="79" width="211" >
        </div>

          <div style="margin-top:40.8pt; text-align:center; width:456pt; line-height:15.5pt;font-size:14pt;">2,564,102 Shares of Common Stock <br >Pre-Funded Warrants to Purchase Shares of Common Stock <br >Warrants to Purchase up to 2,564,102 Shares of Common Stock<font style="font-weight:normal;"> </font></div>

        <div style="margin-top:132pt; text-align:center; width:456pt; line-height:14pt;font-size:12pt;">PROSPECTUS</div>

          <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:normal;font-size:10pt;">Lead Placement Agent<font style="font-style:normal;"> </font></div>

        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:18pt;font-size:16pt;">Roth Capital Partners<font style="font-weight:normal;"> </font></div>

          <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:normal;font-size:10pt;">Co-Placement Agents<font style="font-style:normal;"> </font></div>


          <table style="width:456pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:13pt;">
            <tr style="line-height:15pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:13pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; width:282pt;">Ladenburg Thalmann </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt 0.5pt 0.5pt 0pt; width:162pt;white-space:normal;text-align:right;">
                <div style="text-align:right;">Brookline&#160;Capital&#160;Markets,&#8203;</div>
                <div style="margin-top:2pt; text-align:center; line-height:13.5pt;font-size:10pt;">a division of <br >Arcadia Securities, LLC</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

        <div style="text-indent:20pt; margin-top:72pt; width:456pt; line-height:12pt;font-size:10pt;">You should rely only on the information contained in this prospectus. No dealer, salesperson or other person is authorized to give information that is not contained in this prospectus. This prospectus is not an offer to sell nor is it seeking an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is correct only as of the date of this prospectus, regardless of the time of the delivery of this prospectus or any sale of these securities.<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">The date of this prospectus is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2020</div>
        <div style="margin-top:10.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">PART II<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Item&#160;13.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution<font style="font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following table sets forth the expenses to be incurred in connection with the offering described in this registration statement, all of which will be paid by the registrant. All amounts are estimates except the SEC registration fee. </div>

          <table style="width:456pt;height:83.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:406.29pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Amount </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
                <div style="white-space:nowrap;">SEC registration fee </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,192 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
                <div style="white-space:nowrap;">FINRA filing fee </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">3,500 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
                <div style="white-space:nowrap;">Legal fees and expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">175,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:406.29pt;text-align:left;">
                <div style="white-space:nowrap;">Accounting fees and expenses </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">25,000 </td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.5pt 0pt 3.25pt 0pt; width:406.29pt;text-align:left;">
                <div style="white-space:nowrap;">Total </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">208,692</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>


          <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">Item&#160;14.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers<font style="font-weight:normal;"> </font></div>

        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Our amended and restated certificate of incorporation, as amended, and amended and restated bylaws, as amended, provide that each person who was or is made a party or is threatened to be made a party to or is otherwise involved (including, without limitation, as a witness) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she is or was a director or an officer of Cyclacel Pharmaceuticals, Inc. or is or was serving at our request as a director, officer, or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan, whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee or in any other capacity while serving as a director, officer or trustee, shall be indemnified and held harmless by us to the fullest extent authorized by the Delaware General Corporation Law against all expense, liability and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement) reasonably incurred or suffered by such. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Section&#160;145 of the Delaware General Corporation Law permits a corporation to indemnify any director or officer of the corporation against expenses (including attorney&#8217;s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason of the fact that such person is or was a director or officer of the corporation, if such person acted in good faith and in a manner that he reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful. In a derivative action, (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably incurred by any director or officer in connection with the defense or settlement of such an action or suit if such person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought shall determine that the defendant is fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Pursuant to Section&#160;102(b)(7) of the Delaware General Corporation Law, our amended and restated certificate of incorporation eliminates the liability of a director to us or our stockholders for monetary damages for such a breach of fiduciary duty as a director, except for liabilities arising: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">from any breach of the director&#8217;s duty of loyalty to us or our stockholders; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">from acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">under Section&#160;174 of the Delaware General Corporation Law; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">from any transaction from which the director derived an improper personal benefit. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">II-1<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-bottom:120pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We carry insurance policies insuring our directors and officers against certain liabilities that they may incur in their capacity as directors and officers. In addition, we expect to enter into indemnification agreements with each of our directors and executive officers prior to completion of the offering. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company has entered into indemnification agreements with each of its directors and executive officers. Pursuant to the indemnification agreements, the Company agrees to hold harmless and indemnify its directors and executive officers to the fullest extent authorized or permitted by the provisions of the Company&#8217;s amended and restated certificate of incorporation, amended and restated by-laws and the DGCL, including for any amounts that such director or officer becomes obligated to pay because of any claim to which such director or officer is made or threatened to be made a party, witness or participant, by reason of such director&#8217;s or officer&#8217;s service as a director, officer, employee or other agent of the Company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">There are certain exceptions from the Company&#8217;s obligation to indemnify its directors and executive officers pursuant to the indemnification agreements, including for &#8220;short-swing&#8221; profit claims under Section&#160;16(b) of the Securities Exchange Act of 1934, as amended, losses that are as a result of conduct that is established by a final judgment as knowingly fraudulent or deliberately dishonest or that constituted willful misconduct, or that constituted a breach of the duty of loyalty to the Company or resulted in any improper personal profit or advantage, where payment is actually made to a director or officer under an insurance policy, indemnity clause, bylaw or agreement, except in respect of any excess beyond payment under such insurance, clause, bylaw or agreement, for indemnification which is not lawful, or in connection with any proceeding initiated by such director or officer, or any proceeding against the Company or its directors, officers, employees or other agents, unless (i)&#160;such indemnification is expressly required to be made by law, (ii)&#160;the proceeding was authorized by the board of directors of the Company, (iii)&#160;such indemnification is provided by the Company, in its sole discretion, pursuant to the powers vested in the Company under the DGCL, or (iv)&#160;the proceeding is initiated to enforce a claim for indemnification pursuant to the indemnification agreement. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">All agreements and obligations of the Company contained in the indemnification agreements shall continue during the period when the director or officer who is a party to an indemnification agreement is a director, officer, employee or other agent of the Company (or is or is serving at the request of the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise) and shall continue thereafter so long as such director or officer shall be subject to any possible claim or threatened, pending or completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative. In addition, the indemnification agreements provide for partial indemnification and advance of expenses. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended, may be permitted to our directors, officers or controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission this indemnification is against public policy as expressed in the Securities Act of 1933, as amended, and is, therefore, unenforceable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Item&#160;15.&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities<font style="font-weight:normal;"> </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">There have been no recent sales of unregistered securities. </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">II-2<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules<font style="font-weight:normal;"> </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">(a) Exhibits<font style="font-style:normal;font-weight:normal;"> </font></div>

          <table style="width:456pt;height:607.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:36pt;">Exhibit&#160;<br >Number </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:408pt;text-align:center;">
                <div style="white-space:nowrap; text-align:center;">Description </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.75pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex1-1.htm">1.1* </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex1-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex1-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.75pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex1-1.htm">Form of Co-Placement Agency Agreement. </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex1-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">3.1 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on April&#160;1, 2013, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">3.2 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May&#160;27, 2016, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">3.3 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">Amended and Restated Bylaws of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit&#160;3.2 to the Registrant&#8217;s Annual Report on Form 10-K, File No. 000-50626, originally filed with the SEC on March&#160;31, 2011 and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">3.4 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">Certificate of Designation of 6% Convertible Exchangeable Preferred Stock (previously filed as Exhibit&#160;3.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on November&#160;5, 2004, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">3.5 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">Certificate of Designation of Series&#160;A Preferred Stock (previously filed as Exhibit&#160;3.5 to the Registrant&#8217;s Registration Statement on Form S-1 (No. 333-218305), originally filed with the SEC on July&#160;17, 2017, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm">3.6</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on April&#160;14, 2020, and incorporated herein by reference).</a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920046360/tm2015825d1_ex3-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">4.1 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">Specimen of Common Stock Certificate (previously filed as Exhibit&#160;4.1 to Registrant&#8217;s Registration Statement on Form S-1, File No. 333-109653, originally filed with the SEC on February&#160;17, 2004, as subsequently amended, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">4.2 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">Specimen of Preferred Stock Certificate of Designation (previously filed as Exhibit&#160;3.2 to Registrant&#8217;s Registration Statement on Form S-1, File No. 333-119585, originally filed with the SEC on October&#160;21, 2004, as subsequently amended, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">4.3 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals, Inc. Common Stock (previously filed as Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on July&#160;1, 2011, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">4.4 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">Registration Rights Agreement, dated as of December&#160;14, 2012, by and between the Company and Aspire Capital Fund, LLC (previously filed as Exhibit&#160;4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;17, 2012, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">4.5 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">Registration Rights Agreement, dated November&#160;14, 2013, by and between the Company and Aspire Capital Fund, LLC (previously filed as Exhibit&#160;4.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, originally filed with the SEC on November&#160;14, 2013, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">4.6 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 0.5pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals, Inc.&#8217;s Common Stock (previously filed as Exhibit&#160;4.3 to the Registrant&#8217;s Registration Statement on Form S-1 (No.&#160;333-218305), originally filed with the SEC on July&#160;17, 2017, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-7.htm">4.7* </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-7.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-7.htm">&#8203;</a>
              </td>
              <td style="padding:4pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-7.htm">Form of Pre-Funded Warrant </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-7.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-8.htm">4.8* </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-8.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-8.htm">&#8203;</a>
              </td>
              <td style="padding:4pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-8.htm">Form of Warrant. </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex4-8.htm">&#8203;</a>
              </td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">II-3<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:36pt;">Exhibit&#160;<br >Number </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:408pt;text-align:center;">
                <div style="white-space:nowrap; text-align:center;">Description </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:3.75pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">5.1* </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:3.75pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">10.1&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">Amended and Restated 2006 Equity Incentive Plan (previously filed as Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May&#160;24, 2012, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">10.2&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">2015 Equity Incentive Plan (previously filed as Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May&#160;22, 2015, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418032151/tv495639_ex10-1.htm">10.3&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418032151/tv495639_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418032151/tv495639_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418032151/tv495639_ex10-1.htm">2018 Equity Incentive Plan (previously filed as Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form 8-K originally filed with the SEC on June&#160;1, 2018). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418032151/tv495639_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">10.4&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">Employment Agreement by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of January&#160;1, 2014 (previously filed as Exhibit&#160;10.4 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;26, 2014, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">10.5&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">Employment Agreement by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of January&#160;1, 2014 (previously filed as Exhibit&#160;10.5 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;26, 2014, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">10.6 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">Form of Change in Control Agreement by and between Cyclacel Pharmaceuticals, Inc. and Dr.&#160;Judy Chiao, dated as of December&#160;10, 2010 (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;14, 2010, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">10.7# </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">License Agreement by and between Sankyo Co., Ltd. and Cyclacel Limited, dated September&#160;10, 2003, and letter amendments dated April&#160;1, 2004 and April&#160;28, 2004 (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, for the quarterly period ended June&#160;30, 2011, originally filed with the SEC on August&#160;12, 2011, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">10.8# </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">Amendment No. 4 to License Agreement between Daiichi Sankyo Company, Limited and Cyclacel Limited, dated July&#160;11, 2011 (previously filed as Exhibit&#160;10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, for the quarterly period ended June&#160;30, 2011, originally filed with the SEC on August&#160;12, 2011, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">10.9&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of December&#160;22, 2016 (previously filed as Exhibit&#160;10.14 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;31, 2017, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">10.10&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of December&#160;22, 2016 (previously filed as Exhibit&#160;10.15 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;31, 2017, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">10.11&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of June&#160;27, 2017 (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on June&#160;27, 2017, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">10.12&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of June&#160;27, 2017 (previously filed as Exhibit&#160;10.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on June&#160;27, 2017, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">10.13&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of January&#160;1, 2017 (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;12, 2017, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">II-4<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">

          <table style="width:456pt;height:307.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:36pt;">Exhibit&#160;<br >Number </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.667pt 0pt; width:408pt;text-align:center;">
                <div style="white-space:nowrap; text-align:center;">Description </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.417pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">10.14&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.417pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of January&#160;1, 2017 (previously filed as Exhibit&#160;10.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;12, 2017, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm">10.15&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm">Clinical Collaboration Agreement by and between Cyclacel Pharmaceuticals, Inc. and the University of Texas M.D. Anderson Cancer Center dated as of August&#160;21, 2018 (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September&#160;30, 2018). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420418059346/tv506501_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-1.htm">10.16&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-1.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-1.htm">Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of January&#160;1, 2019 (previously filed as Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on January&#160;7, 2019, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-2.htm">10.17&#8224; </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-2.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-2.htm">Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of January&#160;1, 2019 (previously filed as Exhibit&#160;10.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on January&#160;7, 2019, and incorporated by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420419000763/tv510375_ex10-2.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex10-18.htm">10.18* </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex10-18.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex10-18.htm">&#8203;</a>
              </td>
              <td style="padding:4pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex10-18.htm">Form of Securities Purchase Agreement </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex10-18.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">21.1 </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">&#8203;</a>
              </td>
              <td style="padding:2.667pt 0pt 1.333pt 0pt; width:408pt;white-space:normal;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">Subsidiaries of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit&#160;21 to the Registrant&#8217;s Annual Report on Form 10 K, originally filed with the SEC on March&#160;26, 2014, and incorporated herein by reference). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex23-1.htm">23.1* </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex23-1.htm">&#8203;</a>
              </td>
              <td style="padding:4pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex23-1.htm">Consent of RSM US LLP, independent registered public accounting firm. </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d3_ex23-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">23.2* </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">&#8203;</a>
              </td>
              <td style="padding:4pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit&#160;5.1). </a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="tm2012395d4_ex5-1.htm">&#8203;</a>
              </td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:4pt 0pt 2pt 0pt; width:36pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920033221/tm2012395-1_s1.htm#tPOA">24.1## </a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920033221/tm2012395-1_s1.htm#tPOA">&#8203;</a>
              </td>
              <td style="padding:0pt; width:6pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920033221/tm2012395-1_s1.htm#tPOA">&#8203;</a>
              </td>
              <td style="padding:4pt 0pt 2pt 0pt; width:408pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920033221/tm2012395-1_s1.htm#tPOA">Power of Attorney (included on signature pages hereto).</a>
              </td>
              <td style="padding:0pt; width:0pt;">
                <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465920033221/tm2012395-1_s1.htm#tPOA">&#8203;</a>
              </td>
            </tr>
          </table>

        <div style="margin-top:12.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8224;<br ></div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Indicates management compensatory plan, contract or arrangement. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">#<br ></div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Confidential treatment has been granted with respect to certain portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission as part of an application for confidential treatment pursuant to the Securities and Exchange Act of 1934, as amended. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">##<br ></div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Previously filed. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>


          <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
          <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">Filed herewith. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">(b) Financial Statement Schedules<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or related notes, which are incorporated herein by reference. </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings<font style="font-weight:normal;"> </font></div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The undersigned registrant hereby undertakes: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">to include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">II-5<br ></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-bottom:36pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:60pt; width:396pt; line-height:12pt;">change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

          <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
          <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>

        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iii)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(iv)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:60pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(5)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(6)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(7)<br ></div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">II-6<br ></div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPOA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:6pt;margin-bottom:35.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">SIGNATURES<font style="font-weight:normal;"> </font></div>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Berkeley Heights, State of New Jersey, on April&#160;14, 2020. </div>

        <table style="width:456pt;margin-bottom:5pt;margin-top:14pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt; width:222pt;">CYCLACEL PHARMACEUTICALS, INC. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:15.167pt 0pt 1pt 0pt; width:222pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; text-align:left; width:20pt;white-space:nowrap;">By:<br ></div>
              <div style=" line-height:10pt; text-align:left; margin-left:20pt;">/s/ Paul McBarron </div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style="margin-left:20pt; margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 202pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-left:20pt; margin-top:2pt;">Paul McBarron <br >Chief Operating Officer, Chief Financial Officer, and Executive Vice President, Finance</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>

          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, this Amendment No.&#160;1 to the Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated. </div>


          <table style="width:456pt;height:389.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.833pt 0pt; width:132pt;">
                <div style="white-space:nowrap; text-align:center;">Signature </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.833pt 0pt; width:204pt;">
                <div style="white-space:nowrap; text-align:center;">Title </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.833pt 0pt; width:96pt;">
                <div style="white-space:nowrap; text-align:center;">Date </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:13.917pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Spiro Rombotis</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Spiro Rombotis </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:13.917pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">President &amp; Chief Executive Officer <br >(Principal Executive Officer) and Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:13.917pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 0.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Paul McBarron</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Paul McBarron </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 0.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Chief Operating Officer, Chief Financial<br >Officer, and Executive Vice President, Finance <br >(Principal Financial and Accounting Officer) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 0.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Dr.&#160;David U&#8217;Prichard*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Dr.&#160;David U&#8217;Prichard </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Chairman </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Dr.&#160;Christopher Henney*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Dr.&#160;Christopher Henney </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Vice Chairman </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Sir John Banham*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Sir John Banham </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Samuel L. Barker*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Samuel L. Barker </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Gregory Hradsky*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Gregory Hradsky </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Lloyd Sems*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Lloyd Sems </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020 </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
              <td style="padding:0pt; width:0pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:132pt;white-space:normal;">
                <div style="text-align:center;">/s/ Robert Spiegel*</div>
                <div style="margin-top:2.5pt; text-align:justify;">
                  <div style="margin-left: 0pt; width: 132pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
                </div>
                <div style="margin-top:2pt; text-align:center;">Robert Spiegel </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:204pt;">
                <div style="text-align:center;">Director </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:14.167pt 0pt 2.833pt 0pt; width:96pt;">
                <div style="text-align:center;">April&#160;14, 2020</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>

      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">&#160;<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">II-7<br ></div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2012395d3_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CO-PLACEMENT AGENCY
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 4.5in">________, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 4.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Roth Capital Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">888 San Clemente Drive, Suite 400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Newport Beach, CA 92660</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Brookline Capital Markets, a division of Arcadia Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">600 Lexington Avenue, 33<sup>rd</sup> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladenburg Thalmann &amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">277 Park Avenue, 26<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, NY 10172</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Introduction</B>.
Subject to the terms and conditions herein (this &ldquo;<U>Agreement</U>&rdquo;), Cyclacel Pharmaceuticals, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), hereby agrees to sell up to an aggregate of $__________ of registered
securities of the Company, including, but not limited to, shares (the &ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s
common stock, $0.001 par value per share (the &quot;<U>Common Stock</U>&rdquo;), pre-funded Common Stock purchase warrants
to purchase up to an aggregate of _______ shares of Common Stock (the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;), and common
stock purchase warrants to purchase up to an aggregate of ________ shares of Common Stock (the &ldquo;<U>Warrants</U>&rdquo;
and the shares of Common Stock underlying the Pre-Funded Warrants and the Warrants, the &ldquo;<U>Warrant Shares</U>&rdquo;
and, the Shares, the Pre-Funded Warrants, the Warrants and the Warrant Shares, the &ldquo;<U>Securities</U>&rdquo;), directly
to various investors (each, an &ldquo;<U>Investor</U>&rdquo; and, collectively, the &ldquo;<U>Investors</U>&rdquo;) through
Roth Capital Partners, LLC (&ldquo;<U>Roth</U>&rdquo; or the &ldquo;<U>Lead Placement Agent</U>&rdquo;), Brookline Capital Markets, a
division of Arcadia Securities,
LLC (&ldquo;<U>Arcadia</U>&rdquo;), and Ladenburg Thalmann &amp; Co. Inc. (&ldquo;<U>Ladenburg</U>&rdquo; and,
collectively with Roth and Arcadia the &ldquo;<U>Co-Placement Agents</U>&rdquo;) as co-placement agents. The documents
executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including,
without limitation, a securities purchase agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), shall be collectively
referred to herein as the &ldquo;<U>Transaction Documents</U>.&rdquo; The purchase price to the Investors for each Share is
$___, the purchase price for each Pre-Funded Warrant is $___, the exercise price to the Investors for each share of Common
Stock issuable upon exercise of the Pre-Funded Warrants is $__, and the exercise price to the Investors for each share of
Common Stock issuable upon exercise of the Warrants is $___. The Co-Placement Agents may retain other brokers or dealers to
act as sub-agents or selected-dealers on its behalf in connection with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby
confirms its agreement with the Co-Placement Agents as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 1.&#9;Agreement
to Act as Co-Placement Agents</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms and
conditions of this Agreement, the Co-Placement Agents shall be the exclusive placement agents in connection with the offering
and sale by the Company of the Securities pursuant to the Company's registration statement on Form S-1 (File No. 333-237180)
(the &ldquo;<U>Registration Statement</U>&rdquo;), with the terms of such offering (the &ldquo;<U>Offering</U>&rdquo;) to be
subject to market conditions and negotiations between the Company, the Co-Placement Agents and the prospective Investors. The
Co-Placement Agents will act on a reasonable best efforts basis and the Company agrees and acknowledges that there is no
guarantee of the successful placement of the Securities, or any portion thereof, in the prospective Offering. Under no
circumstances will the Co-Placement Agents or any of their &ldquo;<U>Affiliates</U>&rdquo; (as defined below) be obligated to
underwrite or purchase any of the Securities for their own account or otherwise provide any financing. The Co-Placement
Agents shall each act solely as the Company&rsquo;s agent and not as a principal. The Co-Placement Agents shall have no
authority to bind the Company with respect to any prospective offer to purchase Securities and the Company shall have the
sole right to accept offers to purchase Securities and may reject any such offer, in whole or in part. Subject to the terms
and conditions hereof, payment of the purchase price for, and delivery of, the Securities shall be made at one or more
closings (each a &ldquo;<U>Closing</U>&rdquo; and the date on which each Closing occurs, a &ldquo;<U>Closing
Date</U>&rdquo;). As compensation for services rendered, on each Closing Date, the Company shall pay to the Co-Placement
Agents the fees and expenses set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the Securities at the closing of the
Offering (the &ldquo;<U>Closing</U>&rdquo;). The Lead Placement Agent shall receive
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]% of the cash fee, Arcadia shall received [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]% of the cash fee, and Ladenburg shall receive [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]% of the cash fee. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company also agrees to reimburse the Lead Placement Agent&rsquo;s expenses (with supporting invoices/receipts) of $75,000
payable immediately upon the Closing of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of the Co-Placement Agents&rsquo; exclusive engagement will be until the completion of the Offering (the
 &ldquo;<U>Exclusive Term</U>&rdquo;); <U>provided</U>, <U>however</U>, that a party hereto may terminate the engagement with
respect to itself at any time upon 10 days written notice to the other parties. Notwithstanding anything to the contrary
contained herein, the provisions concerning confidentiality, indemnification and contribution contained herein and the
Company&rsquo;s obligations contained in the indemnification provisions will survive any expiration or termination of this
Agreement, and the Company&rsquo;s obligation to pay fees actually earned and payable and to reimburse expenses actually
incurred and reimbursable pursuant to Section 1 hereof and which are permitted to be reimbursed under FINRA Rule
5110(f)(2)(D), will survive any expiration or termination of this Agreement. Nothing in this Agreement shall be construed to
limit the ability of the Co-Placement Agents or their Affiliates to pursue, investigate, analyze, invest in, or engage in
investment banking, financial advisory or any other business relationship with Persons (as defined below) other than the
Company. As used herein (i) &ldquo;Persons&rdquo; means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind and (ii) &ldquo;Affiliate&rdquo; means any Person that, directly or
indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such
terms are used in and construed under Rule 405 under the Securities Act of 1933, as amended (the &ldquo;<U>Securities
Act</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 2.&#9;Representations,
Warranties and Covenants of the Company</B>. The Company hereby represents, warrants and covenants to the Co-Placement Agents as of
the date hereof, and as of each Closing Date, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Law Filings</U>. The Company has filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) the Registration
Statement under the Securities Act, which was declared effective on ______, 2020, for the registration of the Securities under
the Securities Act. Following the determination of pricing among the Company and the prospective Investors introduced to the Company
by Co-Placement Agents, the Company will file with the Commission pursuant to Rules 430A and 424(b) under the Securities Act, and the
rules and regulations (the &ldquo;<U>Rules and Regulations</U>&rdquo;) of the Commission promulgated thereunder, a final prospectus
relating to the placement of the Securities, their respective pricings and the plan of distribution thereof and will advise the
Co-Placement Agents of all further information (financial and other) with respect to the Company required to be set forth therein.
Such registration statement, at any given time, including the exhibits thereto filed at such time, as amended at such time, is
hereinafter called the &ldquo;<U>Registration Statement</U>&rdquo;; such prospectus in the form in which it appears in the Registration
Statement at the time of effectiveness, together with any preliminary prospectus relating to the Offering, is hereinafter called
the &ldquo;<U>Base Prospectus</U>&rdquo;; the preliminary prospectus in the form in which it was filed with the Commission pursuant
to Rule 424(b) is hereinafter called the &ldquo;<U>Preliminary Prospectus</U>&rdquo;; and the final prospectus, in the form in
which it will be filed with the Commission pursuant to Rule 424(b) (including the Base Prospectus as it may be amended or supplemented)
is hereinafter called the &ldquo;<U>Final Prospectus</U>.&rdquo; The Registration Statement at the time it originally became effective
is hereinafter called the &ldquo;<U>Original Registration Statement</U>.&rdquo; Any reference in this Agreement to the Registration
Statement, the Original Registration Statement, the Base Prospectus, the Preliminary Prospectus or the Final Prospectus shall be
deemed to refer to and include the documents incorporated by reference therein (the &ldquo;<U>Incorporated Documents</U>&rdquo;),
if any, which were or are filed under the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;),
at any given time, as the case may be; and any reference in this Agreement to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to the Registration Statement, the Original Registration Statement, the Base Prospectus,
the Preliminary Prospectus or the Final Prospectus shall be deemed to refer to and include the filing of any document under the
Exchange Act after the date of this Agreement, or the issue date of the Base Prospectus, the Preliminary Prospectus or the Final
Prospectus, as the case may be, deemed to be incorporated therein by reference. All references in this Agreement to financial statements
and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included,&rdquo; &ldquo;described,&rdquo; &ldquo;referenced,&rdquo;
 &ldquo;set forth&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Base Prospectus, the Preliminary Prospectus
or the Final Prospectus (and all other references of like import) shall be deemed to mean and include all such financial statements
and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Base
Prospectus, the Preliminary Prospectus or the Final Prospectus, as the case may be. As used in this paragraph and elsewhere in
this Agreement, &ldquo;<U>Time of Sale Disclosure Package</U>&rdquo; means the Base Prospectus, any preliminary prospectus, any
subscription agreement between the Company and the Investors, and any issuer free writing prospectus as defined in Rule 433 of
the Act (each, an &ldquo;<U>Issuer Free Writing Prospectus</U>&rdquo;), if any, that the parties hereto shall hereafter expressly
agree in writing to treat as part of the Time of Sale Disclosure Package. The term &ldquo;<U>any Prospectus</U>&rdquo; shall mean,
as the context requires, the Base Prospectus, the Final Prospectus, and any supplement to either thereof. The Company has not received
any notice that the Commission has issued or intends to issue a stop order suspending the effectiveness of the Registration Statement
or the use of the Base Prospectus or any prospectus or intends to commence a proceeding for any such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assurances</U>.
The Original Registration Statement, as amended, contains all exhibits and schedules as required by the Securities Act. Each of
the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material
respects with the Securities Act and the applicable Rules and Regulations and did not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.
The Base Prospectus, and the Final Prospectus, each as of its respective date, comply or will comply in all material respects with
the Securities Act and the applicable Rules and Regulations. Each of the Base Prospectus and the Final Prospectus, as amended or
supplemented, did not and will not contain as of the date thereof any untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
The Incorporated Documents, when they were filed with the Commission, conformed in all material respects to the requirements of
the Exchange Act and the applicable Rules and Regulations promulgated thereunder, and none of such documents, when they were filed
with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make the
statements therein (with respect to Incorporated Documents incorporated by reference in the Base Prospectus or Final Prospectus),
in light of the circumstances under which they were made, not misleading. No post-effective amendment to the Registration Statement
reflecting any facts or events arising after the date thereof which represent, individually or in the aggregate, a fundamental
change in the information set forth therein is required to be filed with the Commission. Except for this Agreement, there are no
documents required to be filed with the Commission in connection with the transaction contemplated hereby that (x) have not been
filed as required pursuant to the Securities Act or (y) will not be filed within the requisite time period. Except for this Agreement,
there are no contracts or other documents required to be described in the Base Prospectus or Final Prospectus, or to be filed as
exhibits or schedules to the Registration Statement, which have not been described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Offering
Materials</U>. Neither the Company nor any of its directors and officers has distributed and none of them will distribute, prior
to each Closing Date, any offering material in connection with the offering and sale of the Securities other than the Time of Sale
Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and the Time of Sale Disclosure Package and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of each of this Agreement by the Company and the consummation by it of the transactions contemplated
hereby and thereby and under the Base Prospectus have been duly authorized by all necessary action on the part of the Company and
no further action is required by the Company, the Company&rsquo;s Board of Directors (the &ldquo;<U>Board of Directors</U>&rdquo;)
or the Company&rsquo;s stockholders in connection therewith other than in connection with the Required Approvals (as defined below).
This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the
valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the transactions contemplated pursuant
to the Time of Sale Disclosure Package, the issuance and sale of the Securities and the consummation by it of the transactions
contemplated hereby and thereby to which it is a party do not and will not (i) conflict with or violate any provision of the Company&rsquo;s
or any Subsidiary&rsquo;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii)
conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights
of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit
facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company
or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)
subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction,
decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal
and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected;
except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material
adverse effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificates</U>.
Any certificate signed by an officer of the Company and delivered to the&nbsp;Co-Placement Agents or to counsel for the&nbsp;Co-Placement Agents shall be deemed to be a representation and warranty by the Company to&nbsp;the Co-Placement Agents as to the matters set forth
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&#9;<U>Reliance</U>.
The Company acknowledges that the&nbsp;Co-Placement Agents will rely upon the accuracy and truthfulness of the foregoing representations
and warranties and hereby consents to such reliance.<B>&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Forward-Looking
Statements</U>. No forward-looking statements (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange
Act) contained in the Time of Sale Disclosure Package has been made or reaffirmed without a reasonable basis or has been disclosed
other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Statistical
or Market-Related Data</U>. Any statistical, industry-related and market-related data included or incorporated by reference in
the Time of Sale Disclosure Package, are based on or derived from sources that the Company reasonably and in good faith believes
to be reliable and accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>FINRA
Affiliations</U>. There are no affiliations with any FINRA member firm that is participating in the Offering among the Company&rsquo;s
officers directors or, to the knowledge of the Company, any five percent (5%) or greater stockholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties Incorporated by Reference</U>. Each of the representations and warranties (together with any related disclosure
schedules thereto) made to the Investors in the Purchase Agreement is hereby incorporated herein by reference (as though fully
restated herein) and is hereby made to, and in favor of, the Co-Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
3.&#9;Delivery and Payment</B>. Each Closing shall occur at the offices of the Ellenoff Grossman &amp; Schole LLP, 1345
Avenue of the Americas, New York, New York 10105 (&ldquo;<U>Lead Placement Agent Counsel</U>&rdquo;) (or at such other place
as shall be agreed upon by the Lead Placement Agent and the Company). Subject to the terms and conditions hereof, at each
Closing, payment of the purchase price for the Securities sold on such Closing Date shall be made by Federal Funds wire
transfer, against delivery of such Securities, and such Securities shall be registered in such name or names and shall be in
such denominations, as the Co-Placement Agents may request at least one business day before the time of purchase (as defined
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deliveries of the
documents with respect to the purchase of the Securities, if any, shall be made at the offices of Lead Placement Agent
Counsel. All actions taken at a Closing shall be deemed to have occurred simultaneously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 4.&#9;Covenants
and Agreements of the Company</B>. The Company further covenants and agrees with the Co-Placement Agents as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Statement Matters</U>. The Company will advise the Co-Placement Agents promptly after it receives notice thereof of the time when any
amendment to the Registration Statement has been filed or becomes effective or any supplement to the Base Prospectus or the Final
Prospectus has been filed and will furnish the Co-Placement Agents with copies thereof. The Company will file promptly all reports
and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section
13(a), 14 or 15(d) of the Exchange Act subsequent to the date of any Prospectus and for so long as the delivery of a prospectus
is required in connection with the Offering. The Company will advise the Co-Placement Agents, promptly after it receives notice thereof,
(i) of any request by the Commission to amend the Registration Statement or to amend or supplement any Prospectus or for additional
information, and (ii) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement
or any post-effective amendment thereto or any order directed at any Incorporated Document, if any, or any amendment or supplement
thereto or any order preventing or suspending the use of the Base Prospectus or the Final Prospectus or any prospectus or any amendment
or supplement thereto or any post-effective amendment to the Registration Statement, of the suspension of the qualification of
the Securities for offering or sale in any jurisdiction, of the institution or threatened institution of any proceeding for any
such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or a Prospectus
or for additional information. The Company shall use its reasonable best efforts to prevent the issuance of any such stop order
or prevention or suspension of such use.&nbsp; If the Commission shall enter any such stop order or order or notice of prevention
or suspension at any time, the Company will use its reasonable best efforts to obtain the lifting of such order at the earliest
possible moment, or will file a new registration statement and use its reasonable best efforts to have such new registration statement
declared effective as soon as practicable.&nbsp; Additionally, the Company agrees that it shall comply with the provisions of Rules&nbsp;424(b),
430A, 430B and 430C, as applicable, under the Securities Act, including with respect to the timely filing of documents thereunder,
and will use its reasonable efforts to confirm that any filings made by the Company under such Rule&nbsp;424(b)&nbsp;are received
in a timely manner by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Blue
Sky Compliance</U>. The Company will cooperate with the Co-Placement Agents and the Investors in endeavoring to qualify the Securities
for sale under the securities laws of such jurisdictions (United States and foreign) as the Co-Placement Agents and the Investors may
reasonably request and will make such applications, file such documents, and furnish such information as may be reasonably required
for that purpose, provided the Company shall not be required to qualify as a foreign corporation or to file a general consent to
service of process in any jurisdiction where it is not now so qualified or required to file such a consent, and provided further
that the Company shall not be required to produce any new disclosure document. The Company will, from time to time, prepare and
file such statements, reports and other documents as are or may be required to continue such qualifications in effect for so long
a period as the Co-Placement Agents may reasonably request for distribution of the Securities. The Company will advise the Co-Placement Agents promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for
offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event
of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its reasonable best
efforts to obtain the withdrawal thereof at the earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
and Supplements to a Prospectus and Other Matters</U>. The Company will comply with the Securities Act and the Exchange Act, and
the rules and regulations of the Commission thereunder, so as to permit the completion of the distribution of the Securities as
contemplated in this Agreement, the Incorporated Documents and any Prospectus. If during the period in which a prospectus is required
by law to be delivered in connection with the distribution of Securities contemplated by the Incorporated Documents or any Prospectus
(the &ldquo;<U>Prospectus Delivery Period</U>&rdquo;), any event shall occur as a result of which, in the judgment of the Company
or in the opinion of the Co-Placement Agents or counsel for the Co-Placement Agents, it becomes necessary to amend or supplement the Incorporated
Documents or any Prospectus in order to make the statements therein, in the light of the circumstances under which they were made,
as the case may be, not misleading, or if it is necessary at any time to amend or supplement the Incorporated Documents or any
Prospectus or to file under the Exchange Act any Incorporated Document to comply with any law, the Company will promptly prepare
and file with the Commission, and furnish at its own expense to the Co-Placement Agents and to dealers, an appropriate amendment to
the Registration Statement or supplement to the Registration Statement, the Incorporated Documents or any Prospectus that is necessary
in order to make the statements in the Incorporated Documents and any Prospectus as so amended or supplemented, in the light of
the circumstances under which they were made, as the case may be, not misleading, or so that the Registration Statement, the Incorporated
Documents or any Prospectus, as so amended or supplemented, will comply with law. Before amending the Registration Statement or
supplementing the Incorporated Documents or any Prospectus in connection with the Offering, the Company will furnish the Co-Placement Agents with a copy of such proposed amendment or supplement and will not file any such amendment or supplement to which the Co-Placement Agents reasonably objects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Copies
of any Amendments and Supplements to a Prospectus</U>. The Company will furnish the Co-Placement Agents, without charge, during the
period beginning on the date hereof and ending on the later of the last Closing Date of the Offering, as many copies of any Prospectus
or any amendments and supplements thereto, as the Co-Placement Agents may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Free
Writing Prospectus</U>. The Company covenants that it will not, unless it obtains the prior written consent of the Co-Placement Agents,
make any offer relating to the Securities that would constitute an Company Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the Securities Act) required to be filed by the Company
with the Commission or retained by the Company under Rule 433 of the Securities Act. In the event that the Co-Placement Agents expressly
consent in writing to any such free writing prospectus (a &ldquo;<U>Permitted Free Writing Prospectus</U>&rdquo;), the Company
covenants that it shall (i) treat each Permitted Free Writing Prospectus as an Company Free Writing Prospectus, and (ii) comply
with the requirements of Rule 164 and 433 of the Securities Act applicable to such Permitted Free Writing Prospectus, including
in respect of timely filing with the Commission, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
Agent</U>. The Company will maintain, at its expense, a registrar and transfer agent for the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Earnings
Statement</U>. As soon as practicable and in accordance with applicable requirements under the Securities Act, but in any event
not later than 18 months after the last Closing Date, the Company will make generally available to its security holders and to
the Co-Placement Agents an earnings statement, covering a period of at least 12 consecutive months beginning after the last Closing
Date, that satisfies the provisions of Section 11(a) and Rule 158 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Periodic
Reporting Obligations</U>. During the Prospectus Delivery Period, the Company will duly file, on a timely basis, with the Commission
and the Trading Market all reports and documents required to be filed under the Exchange Act within the time periods and in the
manner required by the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Documents</U><I>.</I> The Company will enter into any subscription, purchase or other customary agreements as the Co-Placement Agents
or the Investors reasonably deem necessary or appropriate to consummate the Offering, all of which will be in form and substance
reasonably acceptable to the Company, the Co-Placement Agents and the Investors. The Company agrees that the Co-Placement Agents may rely
upon, and each is a third party beneficiary of, the representations and warranties, and applicable covenants, set forth in any
such purchase, subscription or other agreement with Investors in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Manipulation of Price</U><I>.&nbsp; </I>The Company will not take, directly or indirectly, any action designed to cause or result
in, or that has constituted or might reasonably be expected to constitute, the stabilization or manipulation of the price of any
securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment</U>.
The Company acknowledges that any advice given by the Co-Placement Agents to the Company is solely for the benefit and use of the
Board of Directors of the Company and may not be used, reproduced, disseminated, quoted or referred to, without any such
Co-Placement Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Announcement
of Offering</U>. The Company acknowledges and agrees that the Co-Placement Agents may, subsequent to the Closing, make public
their involvement with the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance
on Others</U>. The Company confirms that it will rely on its own counsel and accountants for legal and accounting advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Research
Matters</U><FONT STYLE="font-variant: small-caps">.</FONT> By entering into this Agreement, the Co-Placement Agents do not
provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the
Company hereby acknowledges and agrees that each Placement Agent&rsquo;s selection as a co-placement agent for the Offering was
in no way conditioned, explicitly or implicitly, on the Co-Placement Agents providing favorable or any research coverage of the
Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Co-Placement Agents have not directly
or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a
rating or a price target, to the Company or inducement for the receipt of business or compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 5.&#9;Conditions
of the Obligations of the Co-Placement Agents</B>. The obligations of the Co-Placement Agents hereunder shall be subject to the accuracy
of the representations and warranties on the part of the Company set forth in Section 2 hereof, in each case as of the date hereof
and as of each Closing Date as though then made, to the timely performance by each of the Company of its covenants and other obligations
hereunder on and as of such dates, and to each of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Accountants&rsquo;
Comfort Letter</U>. On the date hereof, the Co-Placement Agents shall have received, and the Company shall have caused to be delivered
to the Co-Placement Agents, a letter from RSM US LLP (the independent registered public accounting firm of the Company), addressed
to the Co-Placement Agents, dated as of the date hereof, in form and substance satisfactory to the Co-Placement Agents. The letter shall
not disclose any change in the condition (financial or other), earnings, operations, business or prospects of the Company from
that set forth in the Incorporated Documents or the applicable Prospectus, which, in the Co-Placement Agents&rsquo; sole judgment, is material
and adverse and that makes it, in the Co-Placement Agents&rsquo; sole judgment, impracticable or inadvisable to proceed with the Offering
of the Securities as contemplated by such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Registration Requirements; No Stop Order; No Objection from the FINRA.</U> Each Prospectus (in accordance with Rule 424(b))
and &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the Securities Act), if any, shall have been duly filed with
the Commission, as appropriate; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall
have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; no order preventing
or suspending the use of any Prospectus shall have been issued and no proceeding for that purpose shall have been initiated or
threatened by the Commission; no order having the effect of ceasing or suspending the distribution of the Securities or any other
securities of the Company shall have been issued by any securities commission, securities regulatory authority or stock exchange
and no proceedings for that purpose shall have been instituted or shall be pending or, to the knowledge of the Company, contemplated
by any securities commission, securities regulatory authority or stock exchange; all requests for additional information on the
part of the Commission shall have been complied with; and FINRA shall have raised no objection to the fairness and reasonableness
of the placement terms and arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Corporate
Proceedings</U>. All corporate proceedings and other legal matters in connection with this Agreement, the Registration Statement
and each Prospectus, and the registration, sale and delivery of the Securities, shall have been completed or resolved in a manner
reasonably satisfactory to the Lead Placement Agent Counsel, and such counsel shall have been furnished with such papers and information
as it may reasonably have requested to enable such counsel to pass upon the matters referred to in this Section&nbsp;5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Material Adverse Change</U>. Subsequent to the execution and delivery of this Agreement and prior to each Closing Date, in the
Co-Placement Agents&rsquo; sole judgment after consultation with the Company, there shall not have occurred any material adverse effect
or any Material Adverse Change or development involving a prospective material adverse change in the condition or the business
activities, financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration
Statement and Prospectus (&ldquo;<U>Material Adverse Change</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Opinion
of Counsel for the Company</U>. The Co-Placement Agents shall have received on each Closing Date the opinion of US legal counsel to
the Company, dated as of such Closing Date, including, without limitation, a negative assurance letter addressed to the Co-Placement Agents and in form and substance satisfactory to the Co-Placement Agents and the opinion of intellectual property legal counsel to the
Company, including, without limitation, a negative assurance letter, addressed to the Co-Placement Agents and in form and substance
satisfactory to the Co-Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Officers&rsquo;
Certificate</U>. The Co-Placement Agents shall have received on each Closing Date a certificate of the Company, dated as of such Closing
Date, signed by the Chief Executive Officer and Chief Financial Officer of the Company, to the effect that, and the Co-Placement Agents
shall be satisfied that, the signers of such certificate have reviewed the Registration Statement, the Incorporated Documents,
any Prospectus, and this Agreement and to the further effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
representations and warranties of the Company in this Agreement are true and correct, as if made on and as of such Closing Date,
and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied
at or prior to such Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
stop order suspending the effectiveness of the Registration Statement or the use of any Prospectus has been issued and no proceedings
for that purpose have been instituted or are pending or, to the Company&rsquo;s knowledge, threatened under the Securities Act;
no order having the effect of ceasing or suspending the distribution of the Securities or any other securities of the Company has
been issued by any securities commission, securities regulatory authority or stock exchange in the United States and no proceedings
for that purpose have been instituted or are pending or, to the knowledge of the Company, contemplated by any securities commission,
securities regulatory authority or stock exchange in the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
the Registration Statement became effective, at the time of sale, and at all times subsequent thereto up to the delivery of such
certificate, the Registration Statement and the Incorporated Documents, if any, when such documents became effective or were filed
with the Commission, and any Prospectus, contained all material information required to be included therein by the Securities Act
and the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material
respects conformed to the requirements of the Securities Act and the Exchange Act and the applicable rules and regulations of the
Commission thereunder, as the case may be, and the Registration Statement and the Incorporated Documents, if any, and any Prospectus,
did not and do not include any untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading (provided,
however, that the preceding representations and warranties contained in this paragraph (iii) shall not apply to any statements
or omissions made in reliance upon and in conformity with information furnished in writing to the Company by the Co-Placement Agents
expressly for use therein) and, since the effective date of the Registration Statement, there has occurred no event required by
the Securities Act and the rules and regulations of the Commission thereunder to be set forth in the Incorporated Documents which
has not been so set forth; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
to the respective dates as of which information is given in the Registration Statement, the Incorporated Documents and any Prospectus,
there has not been: (a) any Material Adverse Change; (b) any transaction that is material to the Company and the Subsidiaries,
taken as a whole, except transactions entered into in the ordinary course of business or that have been publicly disclosed; (c)
any obligation, direct or contingent, that is material to the Company and the Subsidiaries taken as a whole, incurred by the Company
or any Subsidiary, except obligations incurred in the ordinary course of business or that have been publicly disclosed; (d) any
material change in the capital stock (except changes thereto resulting from the exercise of outstanding stock options or warrants)
or outstanding indebtedness of the Company or any Subsidiary; (e) except as publicly disclosed, any dividend or distribution of
any kind declared, paid or made on the capital stock of the Company; or (f) any loss or damage (whether or not insured) to the
property of the Company or any Subsidiary which has been sustained or will have been sustained which has a material adverse effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bring-down
Comfort Letter</U><I>.&nbsp; </I>On each Closing Date, the&nbsp;Co-Placement Agents shall have received from RSM UP LLP, or such other
independent&nbsp;registered public accounting firm of the Company, a letter dated as of such Closing Date, in form and substance
satisfactory to the&nbsp;Co-Placement Agents, to the effect that they reaffirm the statements made in the letter furnished pursuant
to subsection&nbsp;(a)&nbsp;of this Section&nbsp;5, except that the specified date referred to therein for the carrying out of
procedures shall be no more than three business days prior to&nbsp;such Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lock-Up
Agreements</U>. On the date hereof, the Co-Placement Agents shall have received the executed lock-up agreement, in the form attached
hereto as <U>Exhibit A</U>, from each of the directors and officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Exchange Listing</U>. The Common Stock shall be registered under the Exchange Act and shall be listed on the Trading Market, and
the Company shall not have taken any action designed to terminate, or likely to have the effect of terminating,&nbsp;the registration
of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Documents</U>. On or before each Closing Date, the Co-Placement Agents and the Lead Placement Agent Counsel shall have
received such information and documents as they may reasonably require for the purposes of enabling them to pass upon the
issuance and sale of the Securities as contemplated herein, or in order to evidence the accuracy of any of the
representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any condition specified
in this Section 5 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Co-Placement Agents
by notice to the Company at any time on or prior to a Closing Date, which termination shall be without liability on the part of
any party to any other party, except that Section 6 (Payment of Expenses), Section 7 (Indemnification and Contribution) and Section
8 (Representations and Indemnities to Survive Delivery) shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section
6.&#9;Payment of Expenses</B>. The Company agrees to pay all costs, fees and expenses incurred by the Company in connection
with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including,
without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Securities (including all
printing and engraving costs); (ii) all fees and expenses of the registrar and transfer agent of the Common Stock; (iii) all
necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Securities; (iv)&nbsp;all
fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants and other advisors; (v)
all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the
Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Base
Prospectus, the Final Prospectus and each Prospectus, and all amendments and supplements thereto, and this Agreement; (vi)
all filing fees, reasonable attorneys&rsquo; fees and expenses incurred by the Company or the Co-Placement Agents in connection
with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the
Securities for offer and sale under the state securities or blue sky laws or the securities laws of any other country, and,
if requested by the Co-Placement Agents, preparing and printing a &ldquo;<U>Blue Sky Survey</U>,&rdquo; an
 &ldquo;<U>International Blue Sky Survey</U>&rdquo; or other memorandum, and any supplements thereto, advising the Co-Placement Agents of such qualifications, registrations and exemptions; (vii) if applicable, the filing fees incident to the review and
approval by the FINRA of the Co-Placement Agents&rsquo; participation in the offering and distribution of the Securities; (viii) the
fees and expenses associated with including the Shares and Warrant Shares on the Trading Market; (ix) all costs and expenses
incident to the travel and accommodation of the Company&rsquo;s employees on the &ldquo;<U>roadshow</U>,&rdquo; if any; and
(x) all other fees, costs and expenses referred to in Part II of the Registration Statement. The parties hereto acknowledge
that Section 3 of the Engagement Agreement (as defined below), pursuant to which the Company shall reimburse the Lead Placement Agent for reasonable out of pocket expenses incurred by the Lead Placement Agent, including fees and disbursements
of its counsel not to exceed $75,000, shall remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 7.&#9;Indemnification
and Contribution</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
Company agrees to indemnify and hold harmless each of the Co-Placement Agents, their affiliates and each person controlling the
Co-Placement Agents (within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees
of the Co-Placement Agents, their affiliates and each such controlling person (the Co-Placement Agents, and each such entity or
person. an &ldquo;<U>Indemnified Person</U>&rdquo;) from and against any losses, claims, damages, judgments, assessments, costs
and other liabilities (collectively, the &ldquo;<U>Liabilities</U>&rdquo;), and shall reimburse each Indemnified Person for all
fees and expenses (including the reasonable fees and expenses of one counsel for all Indemnified Persons, except as otherwise
expressly provided herein) (collectively, the &ldquo;<U>Expenses</U>&rdquo;) as they are incurred by an Indemnified Person in
investigating, preparing, pursuing or defending any Actions, whether or not any Indemnified Person is a party thereto, (i) caused
by, or arising out of or in connection with, any untrue statement or alleged untrue statement of a material fact contained in
the Registration Statement, any Incorporated Document, or any Prospectus or by any omission or alleged omission to state therein
a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading
(other than untrue statements or alleged untrue statements in, or omissions or alleged omissions from, information relating to
an Indemnified Person furnished in writing by or on behalf of such Indemnified Person expressly for use in the Incorporated Documents)
or (ii) otherwise arising out of or in connection with advice or services rendered or to be rendered by any Indemnified Person
pursuant to this Agreement, the transactions contemplated thereby or any Indemnified Person's actions or inactions in connection
with any such advice, services or transactions; <U>provided, however</U>, that, in the case of clause (ii) only, the Company shall
not be responsible for any Liabilities or Expenses of any Indemnified Person that are finally judicially determined to have resulted
solely from such Indemnified Person's (x) gross negligence or willful misconduct in connection with any of the advice, actions,
inactions or services referred to above or (y) use of any offering materials or information concerning the Company in connection
with the offer or sale of the Securities in the Offering which were not authorized for such use by the Company and which use constitutes
gross negligence or willful misconduct. The Company also agrees to reimburse each Indemnified Person for all Expenses as they
are incurred in connection with enforcing such Indemnified Person's rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
receipt by an Indemnified Person of actual notice of an Action against such Indemnified Person with respect to which indemnity
may be sought under this Agreement, such Indemnified Person shall promptly notify the Company in writing; provided that failure
by any Indemnified Person so to notify the Company shall not relieve the Company from any liability which the Company may have
on account of this indemnity or otherwise to such Indemnified Person, except to the extent the Company shall have been prejudiced
by such failure. The Company shall, if requested by the Co-Placement Agents, assume the defense of any such Action including the employment
of counsel reasonably satisfactory to the Co-Placement Agents, which counsel may also be counsel to the Company. Any Indemnified Person
shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense
and employ counsel or (ii) the named parties to any such Action (including any impeded parties) include such Indemnified Person
and the Company, and such Indemnified Person shall have been advised in the reasonable opinion of counsel that there is an actual
conflict of interest that prevents the counsel selected by the Company from representing both the Company (or another client of
such counsel) and any Indemnified Person; provided that the Company shall not in such event be responsible hereunder for the fees
and expenses of more than one firm of separate counsel for all Indemnified Persons in connection with any Action or related Actions,
in addition to any local counsel. The Company shall not be liable for any settlement of any Action effected without its written
consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the
Co-Placement Agents (which shall not be unreasonably withheld), settle, compromise or consent to the entry of any judgment in or otherwise
seek to terminate any pending or threatened Action in respect of which indemnification or contribution may be sought hereunder
(whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination includes
an unconditional release of each Indemnified Person from all Liabilities arising out of such Action for which indemnification or
contribution may be sought hereunder. The indemnification required hereby shall be made by periodic payments of the amount thereof
during the course of the investigation or defense, as such expense, loss, damage or liability is incurred and is due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that the foregoing indemnity is unavailable to an Indemnified Person other than in accordance with this Agreement, the
Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate
to reflect (i) the relative benefits to the Company, on the one hand, and to the Co-Placement Agents and any other Indemnified Person,
on the other hand, of the matters contemplated by this Agreement or (ii) if the allocation provided by the immediately preceding
clause is not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one
hand, and the Co-Placement Agents and any other Indemnified Person, on the other hand, in connection with the matters as to which such
Liabilities or Expenses relate, as well as any other relevant equitable considerations; provided that in no event shall the Company
contribute less than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities
and Expenses in excess of the amount of fees actually received by the Co-Placement Agents pursuant to this Agreement. For purposes
of this paragraph, the relative benefits to the Company, on the one hand, and to the Co-Placement Agents on the other hand, of the
matters contemplated by this Agreement shall be deemed to be in the same proportion as (a) the total value paid or contemplated
to be paid to or received or contemplated to be received by the Company in the transaction or transactions that are within the
scope of this Agreement, whether or not any such transaction is consummated, bears to (b) the fees paid to the Co-Placement Agents
under this Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section
11(f) of the Securities Act, as amended, shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise)
to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this
Agreement, the transactions contemplated thereby or any Indemnified Person's actions or inactions in connection with any such advice,
services or transactions except for Liabilities (and related Expenses) of the Company that are finally judicially determined to
have resulted solely from such Indemnified Person's gross negligence or willful misconduct in connection with any such advice,
actions, inactions or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
reimbursement, indemnity and contribution obligations of the Company set forth herein shall apply to any modification of this Agreement
and shall remain in full force and effect regardless of any termination of, or the completion of any Indemnified Person's services
under or in connection with, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 8.&#9;Representations
and Indemnities to Survive Delivery</B>. The respective indemnities, agreements, representations, warranties and other statements
of the Company or any person controlling the Company, of its officers, and of the Co-Placement Agents set forth in or made pursuant
to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of the Co-Placement Agents,
the Company, or any of its or their partners, officers or directors or any controlling person, as the case may be, and will survive
delivery of and payment for the Securities sold hereunder and any termination of this Agreement. Any successor to a Co-Placement Agent,
or to the Company, its directors or officers or any person controlling the Company, shall be entitled to the benefits of the indemnity,
contribution and reimbursement agreements contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 9.&#9;Notices</B>.
All communications hereunder shall be in writing and shall be mailed, hand delivered or e-mailed and confirmed to the parties hereto
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Lead Placement Agent to the
address set forth above, attention: Aaron Gurewitz, email: ecm@roth.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
to Arcadia to the address set forth above, attention: Michael Fontaine and Graham Powis, email: Michael.Fontaine@brooklinecapmkts.com
and Graham.Powis@brooklinecapmkts.com</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to Ladenburg to the address set
forth above, attention: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], email: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>With a copy to: </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ellenoff Grossman &amp; Schole LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1345 Avenue of the Americas, 11th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E-mail: capmkts@egsllp.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">200 Connell Drive, Suite 1500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Berkeley Heights, New Jersey 07922</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">e-mail: pmcbarron@cyclacel.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Paul McBarron, Chief Operating Officer, Chief Financial
Officer, and Executive Vice President, Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>With a copy to: </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.<BR>
666 Third Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York,&nbsp;NY&nbsp;10017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">e-mail: JIPapernik@mintz.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Joel I. Papernik</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any party hereto may
change the address for receipt of communications by giving written notice to the others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 10.&#9;Successors</B>.
This Agreement will inure to the benefit of and be binding upon the parties hereto, and to the benefit of the employees, officers
and directors and controlling persons referred to in Section 7 hereof, and to their respective successors, and personal representative,
and no other person will have any right or obligation hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 11.&#9;Partial
Unenforceability</B>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect
the validity or enforceability of any other section, paragraph or provision hereof. If any Section, paragraph or provision of this
Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and
only such minor changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 12.&#9;Governing
Law Provisions</B>. This Agreement shall be deemed to have been made and delivered in New York City and both this engagement letter
and the transactions contemplated hereby shall be governed as to validity, interpretation, construction, effect and in all other
respects by the internal laws of the State of New York, without regard to the conflict of laws principles thereof. Each of the
Co-Placement Agents and the Company: (i) agrees that any legal suit, action or proceeding arising out of or relating to this engagement
letter and/or the transactions contemplated hereby shall be instituted exclusively in New York Supreme Court, County of New York,
or in the United States District Court for the Southern District of New York, (ii) waives any objection which it may have or hereafter
to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the jurisdiction of the New York Supreme
Court, County of New York, and the United States District Court for the Southern District of New York in any such suit, action
or proceeding. Each of the Co-Placement Agents and the Company further agrees to accept and acknowledge service of any and all process
which may be served in any such suit, action or proceeding in the New York Supreme Court, County of New York, or in the United
States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified
mail to the Company&rsquo;s address shall be deemed in every respect effective service of process upon the Company, in any such
suit, action or proceeding, and service of process upon the Co-Placement Agents mailed by certified mail to each Co-Placement Agents' address shall be deemed in every respect effective service process upon the Co-Placement Agents, in any such suit, action or proceeding.
Notwithstanding any provision of this engagement letter to the contrary, the Company agrees that neither the Co-Placement Agents nor
their affiliates, and the respective officers, directors, employees, agents and representatives of the Co-Placement Agents, their affiliates
and each other person, if any, controlling the Co-Placement Agents or any of their affiliates, shall have any liability (whether direct
or indirect, in contract or tort or otherwise) to the Company for or in connection with the engagement and transaction described
herein except for any such liability for losses, claims, damages or liabilities incurred by us that are finally judicially determined
to have resulted from the willful misconduct or gross negligence of such individuals or entities. If either party shall commence
an action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall
be reimbursed by the other party for its reasonable attorney&rsquo;s fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Section 13.&#9;General
Provisions</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all
contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. Notwithstanding
anything herein to the contrary, the Engagement Agreement, dated February 17, 2020 (&ldquo;<U>Engagement
Agreement</U>&rdquo;), between the Company and Roth Capital Partners, LLC shall continue to be effective and the terms
therein shall continue to survive and be enforceable by the Lead Placement Agent in accordance with its terms, provided that,
in the event of a conflict between the terms of the Engagement Agreement and this Agreement, the terms of this Agreement
shall prevail. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the
same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or
modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless
waived in writing by each party whom the condition is meant to benefit. Section headings herein are for the convenience of
the parties only and shall not affect the construction or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges that in connection with the offering of the Securities: (i) the Co-Placement Agents have acted at arms length,
are not agents of, and owe no fiduciary duties to the Company or any other person, (ii) the Co-Placement Agents owe the Company only
those duties and obligations set forth in this Agreement and (iii) the Co-Placement Agents may have interests that differ from those
of the Company. The Company waives to the full extent permitted by applicable law any claims it may have against the Co-Placement Agents arising from an alleged breach of fiduciary duty in connection with the offering of the Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The remainder of this page has been
intentionally left blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is
in accordance with your understanding of our agreement, please sign below whereupon this instrument, along with all counterparts
hereof, shall become a binding agreement in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>Cyclacel pharmaceuticals, inc.</B>,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a Delaware corporation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing Co-Placement
Agency Agreement is hereby confirmed and accepted as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Roth
Capital Partners, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>

</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>BROOKLINE CAPITAL MARKETS, a division of ARCADIA SECURITIES, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>

</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>LADENBURG
THALMANN &amp; CO. inC</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>

</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>3
<FILENAME>tm2012395d3_ex4-7.htm
<DESCRIPTION>EXHIBIT 4.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="color: Black"><B>Exhibit 4.7</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>FORM OF PRE-FUNDED
WARRANT TO PURCHASE COMMON STOCK </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase; color: Black"><B>cyclacel
pharmaceuticals, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; width: 49%; font-size: 10pt; text-indent: 0"><FONT STYLE="color: Black">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="text-align: right; padding: 0; width: 51%; font-size: 10pt; text-indent: 0"><FONT STYLE="color: Black">Initial
    Exercise Date: _______, 2020</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">THIS
PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________
or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the
conditions hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and
on or prior to 5:00 p.m. (New York City time) <FONT STYLE="text-underline-style: double"><U>until this Warrant is exercised in
full</U></FONT> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the
 &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall
be equal to the Exercise Price, as defined in Section 2(b). This Warrant is one of the Pre-Funded Warrants to Purchase Common
Stock (the &ldquo;<U>Warrants</U>&rdquo;) issued pursuant to (i) that certain Co-Placement Agency Agreement, dated as of [ ],
2020 by and among the Company, Roth Capital Partners, LLC, Brookline Capital
Markets, a division of
Arcadia Securities,
LLC, and Ladenburg Thalmann &amp; Co. Inc. (the
"<U>Co-Placement Agents</U>"), (ii) that certain Securities Purchase Agreement, dated as of [ ], 2020 by and among the Company
and the Purchasers identified therein, (iii) the Company&rsquo;s Registration Statement on Form S-1 (File number 333-237180) (the
 &ldquo;<U>Registration Statement</U>&rdquo;) and (iv) the Company&rsquo;s prospectus dated as of [ ], 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><U>Section
1</U>.&#9;<U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings
indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market
value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Purchase
Agreement</U>&rdquo; means that certain securities purchase agreement, by and among the Company and certain Holders signatory
thereto, dated as of _______, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
or the New York Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>Transfer
Agent</U>&rdquo; means _______________, the current transfer agent of the Company, with a mailing address of _______________ and
a facsimile number of _______________, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or
OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the
Common Stock are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market
value of a share of Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority
in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be
paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><U>Section
2</U>.&#9;<U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within the one (1) Trading Day following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the
applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to
the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of
Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within
one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and
agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder,
the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face
hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was
pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than
the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any
exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate
exercise price under any circumstance or for any reason whatsoever, including in the event this Warrant shall not have been exercised
prior to the Termination Date. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.001,
subject to adjustment hereunder (the &ldquo;Exercise Price&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo;
in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained according to the following
formula:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35%"></TD><TD STYLE="width: 10%; text-align: left"><FONT STYLE="color: Black">Net</FONT> Number = </TD><TD STYLE="text-align: center; width: 10%"><FONT STYLE="color: Black"><U>(A-B)(X)</U></FONT></TD>
                                                                                                                           <TD STYLE="text-align: justify; width: 45%">&nbsp;</TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">A</TD>
                                                       <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
                                                       <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="color: Black">where:</FONT></TD><TD STYLE="text-align: center">&nbsp;</TD>
                                                       <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153pt; text-align: justify; text-indent: 1.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(A)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">= as applicable: (i) the VWAP
on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both
executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the
Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the
applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date
of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a)
hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(B)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">= the Exercise Price of this
Warrant, as adjusted hereunder; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="color: Black">(X)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">= the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="color: Black">i.</FONT> <FONT STYLE="color: Black"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within one (1) Trading Days following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder.</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect
of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the
Holder; <U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name
of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer
tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise
and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required
for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of
any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event
exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.
Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with
the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><U>Section
3</U>.&#9;<U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder's right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its
Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or
other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders
of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted
by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related
transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange
pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the
Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of
Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have
the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise
of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the
surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice
as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents
in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the
option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of
this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form
and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other
Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every
right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction
Documents with the same effect as if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries,
taken as a whole) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory
share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize
the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it
is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except
as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><U>Section
4</U>.&#9;<U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which
the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial
issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><U>Section
5</U>.&#9;<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall
the Company be required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common
Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens
and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either
party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action,
suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder
does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized
overnight courier service, addressed to the Company, at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, Attention:
Paul McBarron, facsimile number: <FONT STYLE="background-color: White">(866) 271-3466</FONT>, email address: pmcbarron@cyclacel.com,
or such other facsimile number, email address or address as the Company may specify for such purposes by notice to the Holders.
Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the
facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or
communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice
or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by
the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
and the Holder, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><I>&nbsp;</I><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<FONT STYLE="text-transform: uppercase"><B>cyclacel pharmaceuticals, inc.</B></FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>NOTICE OF
EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase; color: Black">To:&#9;cyclacel
pharmaceuticals, inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; color: Black">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; color: Black">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;
</FONT><FONT STYLE="font-size: 10pt">in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;
</FONT><FONT STYLE="font-size: 10pt">if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance
with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable
pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 20%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; width: 45%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The Warrant
Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 20%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; width: 45%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase; color: Black">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0; width: 1%; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; width: 99%; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0; width: 1%; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; width: 99%; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0; width: 1%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; width: 99%; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-top: 0; width: 1%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; width: 99%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-top: 0; width: 1%; padding-right: 0; padding-left: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; width: 99%; padding-right: 0; padding-left: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Black"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="color: Black"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="color: Black">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Address:</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">(Please
                                         Print)&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Holder&rsquo;s
    Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0; width: 15%"><FONT STYLE="font-size: 10pt; color: Black">Holder&rsquo;s
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0; width: 35%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0; width: 50%"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>4
<FILENAME>tm2012395d3_ex4-8.htm
<DESCRIPTION>EXHIBIT 4.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.8</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF WARRANT TO PURCHASE COMMON STOCK
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>cyclacel
pharmaceuticals, inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0; width: 49%; padding-top: 0; padding-right: 0; padding-left: 0; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: right; text-indent: 0; width: 51%; padding-top: 0; padding-right: 0; padding-left: 0; font-size: 10pt">Initial Exercise Date: _______, 2020</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS WARRANT TO PURCHASE
COMMON STOCK (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on
_____<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>[1]</SUP></FONT> (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Cyclacel Pharmaceuticals, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b). This Warrant is one of the Warrants to Purchase Common Stock (the &ldquo;<U>Warrants</U>&rdquo;) issued pursuant
to (i) that certain Co-Placement Agency Agreement, dated as of [ ], 2020 by and by and among the Company, Roth Capital Partners,
LLC, Brookline Capital
Markets, a division of
Arcadia Securities,
LLC, and Ladenburg Thalmann &amp; Co. Inc. (the "<U>Co-Placement Agents</U>"), (ii) that certain Securities
Purchase Agreement, dated as of [ ], 2020 among the Company and the Purchasers identified therein, (iii) the Company&rsquo;s Registration
Statement on Form S-1 (File number 333-237180) (the &ldquo;<U>Registration Statement</U>&rdquo;) and (iv) the Company&rsquo;s
prospectus dated as of [ ], 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on
a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading
Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as
applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock
are then reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices),
the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a
share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest
of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>1</SUP></FONT>
Insert the date that is the five year anniversary of the Initial Exercise Date; provided, however, that, if such date is not a
Trading Day, insert the immediately following Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company
formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
or the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means _______________, the current transfer agent of the Company, with a mailing address of _______________ and
a facsimile number of _______________, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported on the Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of
Common Stock as determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants
then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile
copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice
of Exercise</U>&rdquo;). Within one (1) Trading Day following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on
a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice
of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be
required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for
cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have
the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and
the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt
of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $_____, subject to adjustment hereunder (the
 &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained according to the following formula:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35%"></TD><TD STYLE="width: 10%; text-align: left">Net Number =</TD><TD STYLE="text-align: center; width: 10%"><U>(A-B)(X)</U></TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">A</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 135pt; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(A)</TD><TD STYLE="text-align: justify">= as applicable: (i) the VWAP on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on
a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated
under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day
immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal
Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise
if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two
(2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant
to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of
 &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(B)</TD><TD STYLE="text-align: justify">= the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(X)</TD><TD STYLE="text-align: justify">= the number of Warrant Shares that would be issuable
upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather
than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant
Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees
not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"> i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within one (1) Trading Day following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental
thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees
to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes
of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)
exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation,
any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual
report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon
the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the
number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of
any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of
shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event
exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.
Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered
to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with
the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon
exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied
by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(provided, however, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if
ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its Subsidiaries,
taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock
are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly
or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person
or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other
Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares
of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder
of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the
obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(a) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without
unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance
to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent
entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any
limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the
date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity
had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken
as a whole) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term
of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for
any period of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in
part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which
the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the
Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial
issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall
the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action
or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall
commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or
proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by
the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation,
any Notice of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized
overnight courier service, addressed to the Company, at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, Attention:
Paul McBarron, facsimile number: (866) 271-3466, email address: pmcbarron@cyclacel.com,
or such other facsimile number, email address or address as the Company may specify for such purposes by notice to the Holders.
Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered
personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the
facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or
communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice
or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by
the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand,
and the Holder, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>cyclacel pharmaceuticals, inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0; width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: &nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;cyclacel
pharmaceuticals, inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT> in lawful
money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&#168;</FONT> if permitted
the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 20%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; width: 45%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to
the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 20%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; width: 45%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 0; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; white-space: nowrap; width: 1%; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of Investing Entity:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; width: 99%; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; white-space: nowrap; width: 1%; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Signature of Authorized Signatory of Investing Entity</I>:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; width: 99%; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; white-space: nowrap; width: 1%; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; width: 99%; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-top: 0; width: 1%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; width: 99%; padding-right: 0; padding-left: 0; text-align: justify; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding-top: 0; width: 1%; padding-right: 0; padding-left: 0; font-size: 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; width: 99%; padding-right: 0; padding-left: 0; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED,
the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">(Please
    Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Address:</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P></TD>
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">(Please
                                         Print)&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">Holder&rsquo;s
    Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0; width: 15%"><FONT STYLE="font-size: 10pt; color: Black">Holder&rsquo;s
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-align: justify; font-size: 10pt; text-indent: 0; width: 35%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; font-size: 10pt; text-indent: 0; width: 50%"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>tm2012395d4_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><A NAME="exhibit_5-1"></A><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 40%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 20%; font-size: 10pt"><IMG SRC="tm2012395d4_ex5-1img01.jpg" ALT="" STYLE="height: 107px; width: 84px"></TD>
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Chrysler Center</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">666 Third Avenue</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
        York</FONT>, NY 10017</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">212 935 3000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">mintz.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 14, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">200 Connell Drive, Suite 1500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Berkeley Heights, NJ 07922</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have acted as counsel to </FONT>Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the
 &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the filing by the Company of a Registration Statement (No.
333-237180) on Form S-1 (the &ldquo;<B><I>Registration Statement</I></B>&rdquo;) with the Securities and Exchange Commission,
including a related prospectus filed with the Registration Statement (the &ldquo;<B><I>Prospectus</I></B>&rdquo;), covering a
public offering (the &ldquo;<B><I>Offering</I></B>&rdquo;) of (i)&nbsp;up to 2,564,102 shares (the
 &ldquo;<B><I>Shares</I></B>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B><I>Common
Stock</I></B>&rdquo;), (ii) pre-funded warrants to purchase up to 2,564,102 shares of Common Stock (the
 &ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo;), (iii) warrants to purchase up to 2,564,102 shares of Common Stock (the
 &ldquo;<B><I>Common Warrants</I></B>&rdquo;; together with Pre-Funded Warrants, the &ldquo;<B><I>Warrants</I></B>&rdquo;),
and (iv) up to 5,128,204 shares of Common Stock issuable upon exercise of the Warrants (the &ldquo;<B><I>Warrant
Shares</I></B>&rdquo;; together with the Shares and the Warrants, the &ldquo;<B><I>Securities</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with this opinion, we have (i)&nbsp;examined and relied upon: (A)&nbsp;the Registration Statement and Prospectus, (B)&nbsp;the
form of </FONT>Pre-Funded Warrant to be filed as an exhibit to the Registration Statement, (C) the form of Warrant to be filed
as an exhibit to the Registration Statement, (D)&nbsp;the Company&rsquo;s Amended and Restated Certificate of Incorporation and
Amended and Restated Bylaws, as currently in effect, and (E)&nbsp;the originals or copies certified to our satisfaction of such
records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us
to render the opinion expressed below; and (ii)&nbsp;assumed that the Securities to be sold by the Company
will be sold at a price and on terms established by the Board of Directors of the Company or a duly constituted pricing committee
thereof in accordance with Section&nbsp;153 of the Delaware General Corporation Law. As to certain factual matters, we have relied
upon a certificate of an officer of the Company and have not independently verified such matters. In rendering this opinion, we
have assumed the genuineness and authenticity of all signatures on signed documents; the authenticity of all documents submitted
to us as originals; the conformity to originals of all documents submitted to us as copies; the accuracy, completeness and authenticity
of certificates of public officials; and the due authorization, execution and delivery of all documents where due authorization,
execution and delivery are a prerequisite to the effectiveness thereof (except we have not made such assumption with respect to
the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our opinion herein is expressed solely with respect to the General
Corporation Law of the State of Delaware and, as to the Warrants constituting valid and binding obligations of the Company, the
laws of the State of New York. We express no opinion to the extent that any other laws are applicable to the subject matter hereof
and no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. With regard
to our opinion concerning the Warrants constituting valid and binding obligations of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Our opinion is subject to, and may be limited by, (a)&nbsp;applicable
bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance, debtor and creditor, and similar laws which relate
to or affect creditors&rsquo; rights generally, and (b)&nbsp;general principles of equity (including, without limitation, concepts
of materiality, reasonableness, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at
law.</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Boston&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Los
Angeles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San Diego&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San
Francisco&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Washington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">MINTZ,
LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii) Our opinion is subject to the qualification that the availability
of specific performance, an injunction or other equitable remedies is subject to the discretion of the court before which the request
is brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) We express no opinion as to any provision of the Warrants
that: (a)&nbsp;provides for liquidated damages, buy-in damages, monetary penalties, prepayment or make-whole payments or other
economic remedies to the extent such provisions may constitute unlawful penalties, (b)&nbsp;relates to advance waivers of claims,
defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitations, trial by
jury, or procedural rights, (c)&nbsp;restricts non-written modifications and waivers, (d)&nbsp;provides for the payment of legal
and other professional fees where such payment is contrary to law or public policy, (e)&nbsp;relates to exclusivity, election or
accumulation of rights or remedies, or (f)&nbsp;provides that provisions of the Warrants are severable to the extent an essential
part of the agreed exchange is determined to be invalid and unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) We express no opinion as to whether a state court outside
of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in
the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With respect to the Warrant Shares, we express no opinion to
the extent that, notwithstanding its current reservation of shares of Common Stock, future issuances of securities, including the
Warrant Shares, of the Company and/or adjustments to outstanding securities, including the Warrants, of the Company may cause the
Warrants to be exercisable for more shares of Common Stock than the number that remain authorized but unissued. Further, we have
assumed the Exercise Price (as defined in the Warrants) will not be adjusted to an amount below the par value per share of the
Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On the basis of the foregoing, and in reliance thereon, we are
of the opinion that (i)&nbsp;the Shares, when sold and issued in accordance with the Registration Statement and the Prospectus,
will be validly issued, fully paid and nonassessable, (ii)&nbsp;provided that the Warrants have been duly executed and delivered
by the Company and duly delivered to the purchasers thereof against payment therefor, the Warrants, when sold and issued as contemplated
in the Registration Statement and the Prospectus, will be valid and binding obligations of the Company, and (iii)&nbsp;the Warrant
Shares, when issued and paid for in accordance with the terms of the Warrants, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the reference to our firm under the caption &ldquo;Legal
Matters&rdquo; in the Prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">Sincerely,</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">/s/ MINTZ, LEVIN, COHN, FERRIS, GLOVSKY &amp; POPEO P.C.</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Boston&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;London&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Los
Angeles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New York&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San Diego&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;San
Francisco&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Washington</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">MINTZ,
LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>6
<FILENAME>tm2012395d3_ex10-18.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.18</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of ____ ____, 2020, between Cyclacel Pharmaceuticals, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including its
successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to
the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act
of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), the Company desires to issue and sell to each Purchaser, and each
Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)
the Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than
the second (2<SUP>nd</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Common Warrants shall be exercisable immediately and have a term of exercise equal to ______
(__) years, in the form of <U>Exhibit A-1</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><U>&ldquo;Common
Warrant Shares</U>&rdquo; means the Common Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., with offices located at 666 Third Avenue, New York,
New York 10017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Co-Placement
Agents</U>&rdquo; means Roth Capital Partners, LLC, Brookline Capital
Markets, a division of
Arcadia Securities,
LLC, and Ladenburg Thalmann &amp; Co. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time)
and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following
the date hereof, unless otherwise instructed as to an earlier time by the Co-Placement Agents, and (ii) if this Agreement is signed
between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York
City time) on the date hereof, unless otherwise instructed as to an earlier time by the Co-Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company
pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors
or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the
Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement,
provided that such securities have not been amended since the date of this Agreement to increase the number of such securities
or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits
or combinations) or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions
approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &ldquo;restricted
securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration
statement in connection therewith during the prohibition period in Section 4.12(a) herein, and provided that any such issuance
shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company
or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities and (d) up to $_______
of Units, including the Shares, the Pre-Funded Warrants and the Common Warrants issued to other purchasers pursuant to the Prospectus
concurrently with the Closing at the applicable Per Share Purchase Price or Pre-Funded Warrant Purchase Price, less such aggregate
dollar amount of Units sold pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per
Pre-Funded Warrant Purchase Price</U>&rdquo; equals $_______, subject to adjustment for reverse and forward stock splits, stock
dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $_______, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised
in full, in the form of <U>Exhibit A-2</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-237180, which registers the sale of
the Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Shares, Prefunded Warrants and Common Warrants
(as applicable) purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and
next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct
or indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market,
or the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means _____________________, the current transfer agent of the Company, with a mailing address of ___________________
and a facsimile number of _______________, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means, collectively, the Common Warrant Shares and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $______ of Shares and Common Warrants; provided, however, that, to the extent that a
Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates, and any Person
acting as a group together with such purchaser or any of such Holder&rsquo;s Affiliates) would beneficially own in excess of the
Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares, such Purchaser may elect
to purchase Pre-Funded Warrants in such manner to result in the same aggregate purchase price being paid by such Purchaser to
the Company. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser, 9.99%)
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the
Closing Date. Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser
shall be made available for &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) settlement with the Company or its
designee. The Company shall deliver to each Purchaser its respective Shares and/or Pre-Funded Warrants (as applicable to such
Purchaser) and a Common Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the
other items set forth in Section 2.2, deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth
in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree.
Each Purchaser acknowledges that, concurrently with the Closing and pursuant to the Prospectus, the Company may sell up to $______
of additional Shares, Pre-funded Warrants and Common Warrants to purchasers substantially concurrent with this Purchase Agreement,
less the aggregate dollar amount of Shares, Pre-Funded Warrants and Common Warrants sold pursuant to this Agreement; provided,
the Company will issue to each other purchaser Shares, Pre-Funded Warrants and Common Warrants in the same form and at the same
Per Share Purchase Price or Per Pre-Funded Warrant Purchase Price, as the case may be, as issued to a Purchaser hereunder. The
Company covenants that, if the Purchaser delivers a Notice of Exercise (as defined in the Pre-Funded Warrant) no later than 12:00
p.m. (New York City time) on the Closing Date to exercise any Pre-Funded Warrants between the date hereof and the Closing Date,
the Company shall deliver Pre-Funded Warrant Shares to the Purchaser on the Closing Date in connection with such Notice of Exercise.
Unless otherwise directed by the Co-Placement Agents, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the
Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly
to the account(s) at the Co-Placement Agent identified by each Purchaser; upon receipt of such Shares, such Co-Placement Agent shall
promptly electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by such Co-Placement Agent
(or its clearing firm) by wire transfer to the Company). Notwithstanding anything to the contrary hereunder, to the extent that
a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser's Affiliates, and any Person
acting as a group together with such purchaser or any of such Holder's Affiliates) would beneficially own in excess of Beneficial
Ownership Limitation on the Closing Date, such Purchaser may elect to receive only the Beneficial Ownership Limitation at the
Closing with the balance of any share purchased hereunder, if any, held in abeyance for such Purchaser and issued immediately
following the Closing provided in no event shall such Purchaser's beneficial ownership ever exceed the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement, duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
legal opinion of Company Counsel, in a form reasonably acceptable to the Co-Placement Agents and Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to the last sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject
to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
Shares equal to such Purchaser&rsquo;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such
Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Common Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to ____% of
the sum such Purchaser&rsquo;s (i) Shares and (ii) Pre-Funded Warrants sold hereunder, with an exercise price equal to $____ per
Common Warrant Share, subject to adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for
each Purchaser of Pre-Funded Warrants, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number
of Shares equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Pre-Funded Warrants divided by the Per
Pre-Funded Warrant Purchase Price, with an exercise price equal to $0.001 per Share, subject to adjustment as described therein;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Preliminary Prospectus and Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Purchaser&rsquo;s Subscription Amount with regard to the Shares (and accompanying Common Warrants) purchased by such Purchaser,
which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such
Purchaser&rsquo;s Subscription Amount with regard to the Pre-Funded Warrants (and accompanying Common Warrants) purchased by such
Purchaser, if any, by wire transfer to the account specified by the Company in Section 2.2(a)(iii) above, or as otherwise agreed
by the Company and the Co-Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed
a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the
issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects
or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect
on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document
(any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction
revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by
it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company
and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith
or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the
terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance
with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any
of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution
or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit
facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company
or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)
subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction,
decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal
and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected;
except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)
the filings required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus (or any amendments
or supplements thereto), (iii) application(s) to each applicable Trading Market for the listing of the Shares and Warrant Shares
for trading thereon in the time and manner required thereby, and (iv) such filings as are required to be made under applicable
state securities laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum
number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration
Statement in conformity with the requirements of the Securities Act, which became effective on&nbsp;_______, 2020 (the &ldquo;<U>Effective
Date</U>&rdquo;), including the Prospectus, and such amendments and supplements thereto as may have been required to the date of
this Agreement. The Registration Statement is effective under the Securities Act and no stop order preventing or suspending the
effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission
and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission.
The Company, if required by the rules and regulations of the Commission, shall file the Prospectus with the Commission pursuant
to Rule 424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this Agreement
and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects
to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus
and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued and at
the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth in the Registration Statement, which also includes the
number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company
has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the
exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees
pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first
refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the
Transaction Documents. Except as a result of the purchase and sale of the Securities, and except as disclosed in the SEC Reports
(as defined below), there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character
whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any
Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares
of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not
obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers).
There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise,
conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary.
There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become
bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom
stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company
are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities
laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or
purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for
the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with
respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among
any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with
the Preliminary Prospectus and the Prospectus, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on
a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject
to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect
at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries
as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of
unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included
within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that
has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
(contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP
or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) except as disclosed
in the SEC Reports, the Company has not declared or made any dividend or distribution of cash or other property to its stockholders
or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not
issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The
Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance
of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has
not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company,
threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities
or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither
the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim
of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been,
and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company
or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of
the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure
or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant
in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of
its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance
with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and
conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is
bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any
court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as
could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&#9;<U>Environmental
Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to
pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or
subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment,
or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses,
notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental
Laws</U>&rdquo;); (ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws
to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or
approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually
or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation
or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens
for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP
and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by
the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the
Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark
applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports
and which the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual
Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2)
years from the date of this Agreement except as stated in the SEC Reports or except as could not have or reasonably be expected
to not have a Material Adverse Effect. Neither the Company nor any Subsidiary has received, since the date of the latest audited
financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have
a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is
no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken
reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except
where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and
in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the
Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party
to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case
in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses
incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of
the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the Closing Date, except where any noncompliance
could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company and the Subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed
in accordance with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted
only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The
Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized
and reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers
have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of
the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;).
The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers
about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the
Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal
control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth in the Prospectus, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the
Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with
respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this
Section that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will
not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as
amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject
to registration under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act
of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the
Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as disclosed in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not
in compliance with the listing or maintenance requirements of such Trading Market. Except as disclosed in the SEC Reports, the
Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such
listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust
Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and
the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel
with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
in the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting
transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding
the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were
made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement
taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and
when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties
with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)&#9;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry
on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in
respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).
The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation
under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U>
sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which
the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)
any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether
or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance
with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)&#9;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local
income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject,
(ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due
on such returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of
all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid
taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or
of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)&#9;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent
or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns
from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any
provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)&#9;<U>Accountants</U>.
The Company&rsquo;s accounting firm is set forth on <U>Schedule 3.1(dd)</U> of the Disclosure Schedules. To the knowledge and belief
of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall
express its opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal
year ending December 31, 2020.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)&#9;
<U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the
transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby
and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents
and the transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company
further represents to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">(ff)&#9;<U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers
have been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short,
securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities
for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without
limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement
transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and
counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or indirectly, presently
may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to have any affiliation
with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands
and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period</FONT> that
the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant Shares deliverable
with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing
stockholders' equity interests in the Company at and after the time that the hedging activities are being conducted.&nbsp; The
Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)&#9;<U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any
other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&rsquo;s Co-Placement
Agents in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)&#9;<U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal
Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the
failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint,
or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received
any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket
clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing
of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall,
suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any
Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries,
(iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent
decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have
a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA.&nbsp; The Company has not been informed by the
FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed,
produced or marketed by the Company nor has the FDA expressed any material concern as to approving or clearing for marketing any
product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance
with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value
of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has
been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock
options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their
financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)&#9;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)&#9;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)&#9;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act
of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
 &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly
or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or
more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)&#9;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money
Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they
shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and
performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance
with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation
and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise
in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary
course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on
which it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7) or (a)(8) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it
has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the
offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company
and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate
its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without
unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&nbsp;
Such Purchaser acknowledges and agrees that neither the Co-Placement Agents nor any Affiliate of the Co-Placement Agents has provided such
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&nbsp;
Neither the Co-Placement Agents nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities
and the Co-Placement Agents and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser
agrees need not be provided to it.&nbsp; In connection with the issuance of the Securities to such Purchaser, neither the Co-Placement
Agents nor any of their Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof.
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio
managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment
decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s
representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents
and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in
order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company acknowledges
and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right
to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt,
nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing
shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Shares</U>. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover
the issuance or resale of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares issued pursuant
to any such exercise shall be issued free of all legends. If at any time following the date hereof the Registration Statement (or
any subsequent registration statement registering the sale or resale of the Warrant Shares) is not effective or is not otherwise
available for the sale or resale of the Warrant Shares, the Company shall immediately notify the holders of the Warrants in writing
that such registration statement is not then effective and thereafter shall promptly notify such holders when the registration
statement is effective again and available for the sale or resale of the Warrant Shares (it being understood and agreed that the
foregoing shall not limit the ability of the Company to issue, or any Purchaser to sell, any of the Warrant Shares in compliance
with applicable federal and state securities laws). The Company shall use best efforts to keep a registration statement (including
the Registration Statement) registering the issuance or resale of the Warrant Shares effective during the term of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>. Until the earliest of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the
Company covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject
to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules
and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits
thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the
Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any
of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees or agents
in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such
press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company
and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated
hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement
without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each
Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except
if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice
of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any
Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without
the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with the filing of
final Transaction Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations,
in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities
under the Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting
on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt
of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent
that the Company delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company
hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public
information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder as described in the Prospectus
and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade
payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within
the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or
agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not
an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless
such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially
determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party
in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company
in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate
in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the
extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed
after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable
opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser
Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.
The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected
without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but
only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any of the
representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein
shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation
of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common
Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list
or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant
Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action
as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as
possible. The Company will then use reasonable best efforts to take all action necessary to continue the listing and trading of
its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic
transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely
payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until 90 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any agreement
to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof until such time as no Purchaser holds any of the Warrants, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means
a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price
or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the shares of Common
Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange
price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the
occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the
Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line
of credit, whereby the Company may issue securities at a future determined price; provided, however, after the ninetieth (90th) day following the Closing Date, the Company&rsquo;s issuance of Common Stock pursuant
to an at-the-market offering facility shall not be deemed to be a Variable Rate Transaction hereunder. Any Purchaser shall be entitled to obtain injunctive
relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration
is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect
to the purchase, disposition or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither
it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending
at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4.<FONT STYLE="color: windowtext">&nbsp; </FONT>Each Purchaser, severally and not jointly with the other
Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company
pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain the confidentiality of the existence
and terms of this transaction and the information included in the Disclosure Schedules.&nbsp; N<FONT STYLE="color: windowtext">otwithstanding
the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and
agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions
in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting
any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the
transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in
Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company
to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4.&nbsp; </FONT>Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only
apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the
Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="color: windowtext"><U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the
Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required
in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance
with the terms, conditions and time periods set forth in the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company
and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery
of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Preliminary Prospectus and the
Prospectus, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been
merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered
via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto
at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth
on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant
to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries,
the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the
initial Subscription Amounts hereunder or, in the case of a waiver, by the party against whom enforcement of any such waived provision
is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group
of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver
of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver
in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed
amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative
to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities
and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. Each of the Co-Placement Agents shall be the third party beneficiary of the representations and warranties of
the Company in Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action
or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal service of process and
consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or
overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and
agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under
Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable
attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action
or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo;
signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full
force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the
case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock
subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid
to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or
in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall
also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation
the defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only, each
Purchaser and its respective counsel have chosen to communicate with the Company through EGS. EGS does not represent any of the
Purchasers and only represents Roth Capital Partners, LLC. The Company has elected to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It
is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the
Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19&#9;<U>Saturdays,
Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>WAIVER
OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>Cyclacel Pharmaceuticals, inc. </B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice:</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With a copy to (which shall not constitute notice):</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">CYCC</FONT>
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Purchaser:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 99%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Purchaser</I>&nbsp;&nbsp;:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; width: 99%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; width: 99%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; width: 99%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address of Authorized Signatory: &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify; width: 99%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile Number of Authorized Signatory: &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 99%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice to Purchaser:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 99%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Securities to Purchaser (if not same
as address for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrants:_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Warrants: ______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 32; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>tm2012395d3_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>Consent of Independent
Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We consent to the incorporation by reference in this Amendment No.
1 to Registration Statement No. 333-237180 on Form S-1 and related Prospectus of Cyclacel Pharmaceuticals, Inc. of our report dated
March 5, 2020, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing
in the Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also consent to the reference to our Firm under the caption &ldquo;Experts&rdquo;
in the Prospectus, which is part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>/s/ RSM US LLP&#9;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">April 14, 2020</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2012395d4_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2012395d4_ex5-1img01.jpg
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M!S^%1>+-!;P[XFO--&6CC?,+==\;<H??@BOI#P!X>_X1GP;8V+KMN"GFS_\
M71N2/PX'X5YG^T!_R%-&_P"N,G_H2UY'5BW^X?K4=S_Q]2_[Y_G4=?7NA?\
M(OZ=_P!>L7_H(KG_ (D^#F\9:##;V^U;J"X1XW;LI.U_T.?^ BO"/'^KPZGX
ME>"QXT[3HULK11TV)QG\3DY^E<S7L'@O2(?B!%X=O[AD-QH4GV>]5CS+$HW0
MGWY^7\Z]LKP_]H#_ )"FC?\ 7&3_ -"6O(ZL6_W#]:CN?^/J7_?/\ZCKZ]T+
M_D7]._Z]8O\ T$5==0Z,K#*L,$>U?)GBS0W\-^*+_3&!VP2GRR?XD/*G\B*R
M*^@_@CX?_LSPG)J<JXGU)]PS_P \UR%_,[C^(KTFO#_V@/\ D*:-_P!<9/\
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ML/Q/LB_='TKC-"_Y*OXJ_P"O>T_] -=E)(D4;22,J(@+,S'  '4DUP>EQ/\
M$'Q$FMW2$>'].D(TZ%QQ<RC@S$>@Z#_]>>^KB?@__P DUTW_ 'I?_1C5M>-O
M^1&UW_KPF_\ 0#2^&?\ D1=*_P"P=%_Z+%8WPB_Y)II?_;7_ -&-3?AC_P >
M?B'_ +#MU_[+2?%NQMKGP+<7$T*O-:RQ/"YZH2ZJ<?4$UVR_='TKC-"_Y*OX
MJ_Z][3_T$U'\89Y8/AQ?F&1D+O&C%3C*EQD?0UX%#XN\06T$<,&M:A%%&H5$
;2X8*H'0  T__ (33Q)_T'M3_ / E_P#&O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>lg_cyclacelreg-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_cyclacelreg-4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"L@=$ P$1  (1 0,1 ?_$ 0   0 " @(# 0$
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M)80F\<+41;7AI&;DA:7E1O_:  P# 0 "$0,1 #\ O\
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M5-,U?'67I638RL5\IVKD+D'7V2@Y+]$YT=0[P
M
M
M
M
M
M                          !@+;?:;KMHE#O\K&X<'P^8TE2SHY5NW890
MM"$$XM4?$J9-EDTI*4J3ZMQ%ERI)?:HB/+MN[!WGNQK^KVFY63:?W:ATVOLW
MI]-I?9FN3]C,!W=W3[=[$B_ZV:Q@X=Y*OE2N*=]T5>%BWUWI>'*V^:]J(QMK
M?.+H'&52H6I]=YYM*<RI2&;.V<A:]Q>47!DAZ-*FMWN3+21^IH>J8QF7Y?\
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M^^,DFOLHD!AYN'J&/',P+MJ_B358SMRC.$E[8RBW%KY&<D. [(
M
M
M
M
M
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M0E*4Y.<VW-NK;XMM\VW[3\#]/P
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MV
M
M
M
M
M                               1Y=B_D[ZJ=>#G5#V8?RGYS$]UD\+U
MBY"R%Z),;4IDX]]D?U3.,4:H\A/C(97*<GLD1F499EXGN39?8K?^\NC)CC?4
M-*E1^=E=5M.+XUMVZ.[<JN,6HJV_OUS(\]QO4[VJ[>>9ASS/QIKL*KZMA.-U
MQDN%+M[J5FU1\)Q<W=CQ?E/D01]@_F%[0;=.=3ZZ?K]#8A)-UM#&&NJLLW?B
M.$9$W.SRPC,RHK[9\*2]4Q*ETC+@U&7/,L=G>F[8FW.C)UI3U;48T=;RZ;":
M\8V(MIKVQO3NKW(@CW!]8?=#=_7A[=E;T'2)55,=]>2XOPEE32E%KFI6+=B2
M]K(K[F[N<CM)MYD-O9WUU9/')L;BYGRK2TL)"DI2;\VPG.ORY3QI21&IQ:E<
M$7J-^XV+C86/'%P[=NSBP5(PA%1A%>R,8I)+W)$5LW-S=2RIYVHWKM_-NRK.
MY<G*<YOVRG)N4G[VVSC!SG6
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M\83491=4TFCOP\@]\
M
M
M
M
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MAR-#!MLT*
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M9DP
M
M
M
M
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M1YC<A'D
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MC)?(SG1U#O@
M
M
M
M
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MWQ;;JV>L.0XP
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MC29)(
M
M
M
M
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MFT#=^D6M>VSEV<W2+ZK"Y;E5>%8R7"4)QK25N:C.#X2BGP.\CRCW
M
M
M
M
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M#V7L_;*2VYI6G8%%_P#+XUFR_LNW"+;?BVVWXF2QX9DP
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MUQ33Y-/V&EYPG;F[=Q.-R+:::HTUP::?%-/FCQCZ/D
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M._6S>\. HZ=-8FZ+<*W\&[)>9&G.=F5$K]FOW<4I1X>;"VY1KO"-5F\0
M
M
M
M
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MDEX(E+M[:6UMI8OU/:^G86GXU.,<>S;M=7ODX13F^'&4FV^;;9D,>,9"
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MS2HC2I)FE25$9&DR/@R,C]2,C&V4TU5<C0S33H^9_!^@
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MII0LY?"&/ERY*-Q*D;&1+P7"S=E50\N3A:E-L(N$VP
M
M
M
M
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MY?V+B3MO[$F;_P!M=R^WV\:1VQK.G9MZ7[';OVW=X^VRVKL?LP1F\8L9N
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M&FN3/(/D^@
M
M
M
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M8I))+P27!+W(TA>OWLF[+(R)RN7YNLI2;E*3?-MNK;?M;/6'(<8
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MU/%E)UE<PFU'H]K^JS<8)M_K5VU!*EMLF[$6R;H
M
M
M
M
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M6M:U&I:UJ,U*4I2C-2E*4?)F?J9C;B22HN"1H1MR;E)MR;XL_(_3\
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M#3@U5-<4T^33]A#F<)VYNW<3C<BVFFJ--<&FGQ33YH\8^CY
M#<'H-MF3IGMYHW+FY7TU;.S:MPK(S6LT1EXYGCGZ)6KLPO-"7&:QNV3-21\D
MEV,A7!FDAK?N[MZWN;MSJNG./5?ABROV_;YECZ:"7OET='R2:\3<'8+=EW9G
M=[0M7C+IQKF;#&O5?P^3E/R)N7M4%<5Q>R4(OFB\6*KB\8
M
M
M
M
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M%M1M1=.#GTN<E\Z4GQ, C+S
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MT&]^T^J?4-U8K6'.35G*MUGC7TN/T=RBI*G%VKBA=BN+ATM-ZPC.S6
M      '9\)6\WF>(N1UN-OMY/0+86RI27D/)M8BFUM*09+2XE9$:3+U(_L'0
MU11EIF1&='!V+E:\J=#K7W'IZ(YQUG$E;;5Q95JC7.O7&E*<:UY'T)13J?T)
M@
M
M
M
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M7F7'<NM.CFUP-7QGAJ\
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M.J-MP3?W4XKBVD[RXJJ+S
M
M
M
M
M   ,5[KW+@F@-9Y3M?8]I^%XOBD!4I\FB0[8VLYTR9K*&EBK<:*;=74Y:(\9
MLU(1YK\G%H;2M:??VOMK5MWZYC[?T2WYF?D3HJ\(PBN,KDW1],(1K*3HW142
M<FD\5WKO+0=@;9RMV;DN^5I>);ZG2CG.3X0M6XMKJN7)4A!52JZR<8J4E2;[
M6=G\][9;;N-G9L\J)$/SK,-Q-F0MZKPS%67G'(-+!,TMD_(4:S>F230E<J4M
M:^$(\&T6A]O]B:1V]V[;T+2UU7/G7KK5)7KK7Q3ESHO"$:M0BDJMUDZ3>ZW<
M_7^[.[KVY];;A9^9CV$ZPQ[";<;<>57QZKDZ)SFW*B73&.M8S<UJ
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M'VC*L7TR2R\B+_;;D6_*@USLV9<G*-R[=BZ*(T2*(C
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MW<K_ )$F:^U3:VY]#K^.M.S\.G/S\>[:I\OF0B=$'K'A
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M14S C.3,
M
M
M
M                                                /2LK*OIJZ?;V
MTZ)6555"E65G93Y#42#7U\%AR5-G393ZD,QHD2,TIQQQ:B2A"3,S(B'+8L7L
MF]#&QX2N9%R2C&,4W*4I.D8Q2XMMM))<6^!PY.3CX>/<S,N<+6+:A*<YR:C&
M$(IRE*4G11C%)MMNB2JRG#\C_>*Q[<[0.FQ67,B:.U[.EQ,$K%>[&+)[%/N1
M9VP;>(LR6<RT;-3=>VZE*X5<9)\&WGY7G91V5[5V>W6@_6=0C&6ZLR"=^7!^
M5'G''@_9#G<:X3N<:RC&W2F_U']\<GNYNCZEI4YPV-ITY1Q8<8^=/C&67<B_
MNIJJM*23MV>%(SG=K&\-V$;P        WDZ5=$MH=Q\M\:AMW%=5T4YEG-ME
M3HWN0H7))>71XY%<6T>091(CGR3*#)F(A27)+C9+:2[JKN?W8T'MKIU<AK(U
M^[!NQC1?Q2\.NX^/EVD_%_%-IJ"=)..\NRG8G='>/5J8B>)M6Q-+)S)1K&/C
MY5F+IYM]K[E?#;34KLHJ4%.W]H3KYJOK5K^NUQJ;'&J.EB$AZQGOFW*R#)K;
MVDMR+[)[8FF7+2VE^/JKQ0RRGAIAMIE"&TUQ[NWCK^]]8GK6X;SNY4N$8KA;
MM0K56[4*M0@OLR;^*<I2;D[?]A=O=J]M=OV]M[3QE8PH4<YNDKMZY2CNWKE$
MYW)>VBC%4C;C""C%9J&+F:@    $<?=WY'=5=1J^3B]8J%L/=DJ)YUN!0)R3
MAXZ;[25Q;3/I\52UTT12'$NM0D\3YB#2:4M-+^H3NGM;V5U_N+>CGW^K#VO&
M7Q9$H\;E'QCCQ?SWX.?ZW!UJY270XX][_4=M7M'CRTO&Z-1WM.'P8L)?#9JJ
MQGE2CQMQHU*-M?2W%2BC"7F*IWOKL/MOLKG$K/MNY7,R*V6;S557)4N-CN+U
MKJR6FFQ>D2XN)3UK?@GR)'+KZR]U]QUY2G%6#[2V;MW9&E1TC;N/&SCJCG+G
M<NR7W=V?.<OEX17PP48I)5.[][B;M[E:Y/7]W9<\C+=5"'&-FQ!NOEV+=>FW
M!<*T^*375<E.;<GA,9282           !Y6&'Y3[,6*R[)DR76V(\=AM;S[[
M[RR;9999;)3CKKKBB2E*2,U&?!>H^9SA;@[EQJ,(IMMNB27-M^"7BSZMV[EV
MY&U:BY79-))*K;?!))<6V^"2YF[6I?CD[D[D3&EX[I7(L>I9"D?]?[#.-@%<
MAAP^$S&8V3NP+RSB']I+A0Y7)>I$9#5VX>]/;3;3E;S-4LWLI?L>/7(E7V-V
ME*$7[ISB;MVEZ<>\N\E&[IVB9./A2:^ERZ8D*/[I1O.%V<??:MS]Q)'K+X(<
MME$Q*W%O6@I/0E/TNN,=GY$XOR+U;3D62.XVW%6W^4_PV0DS^ST]3TGKOJQT
MZVW;VWI-Z[[)Y-R-O_X=M76_PL226V?0AJUU1N[QUW'L>VWAV9WF_=YUYV5%
MK]QFO^DWZU]\.72K"T,*O\<S?:$QHR<.3G&;6,5I3OH?I P5O#(2V$J_8MNH
M>+Q]%FOU,]1:QZD^Y^IMK$OXN!;?A8L1;I^JO^=*OM::]U#?NWO1QV5T6,7G
MXV=JEY<>K)R9Q5?U&*L>-/8I*7#@W(W6PCJSULUO[:L'T1J?'9+2FEHLH6"8
MXJY-;'^04Y=R8#]N\ID^32:WU&E1F9>IF9ZOU3?V]];JM5U;4+UMU^&5^YT<
M>?P*2@J^-(_]!NO0^UG;;;='H>@Z3C74U\<<6SYG#E6XX.XZ>%9.CJ^;9G=M
MMMEMMEEM#3+2$-M--H2VVVVVDDH;;0DB2A"$D1$1$1$1#$Y2E*3E)MR;JV^;
M9G<8QA%0@DH)427!)+DDO8?L?A]            80S7K1UWV.AXLZT=JC*'G
MT>VJ?;8%C,BV;3Y&OF-<?AJ;6&OR,_O-/(5ZF7/!GSE.E[XWEHK7XIU74+$4
M_FPR+J@_EAU=#^1Q:,(UOMGV[W&I+7=#TG*G)4ZKF+9=Q?J;G1YD7[XR3Y^T
MTPV%\0727."><JL*RG6LUY*O.9@.:6[:?<-))0ZBKRX\MI8_MDDON,QFD'ZF
M9&9F8V;H_J.[HZ52.1E8^=:7W.19AR]G59\F;^5R;^P:7W#Z0.R6N5EB865I
ME^2^=BY-Q<?:H9'UBVJ>R,(KVJO$T&V=\#]LW]1+TSOFNF<^?TM#L[&Y-;[?
M')H^HRW%7+;WO/G@_&E;\>.?O<\%MW0O5ECRZ;>YM)G'VW,6XI5^2S=Z*?9O
MNON\=!;G]!^7'JN[,UZW/[VUFV90I[*Y%AW*_8QE3GQK11O[8^,SNCJ/ZF39
M:;N,SIH_D97FL'V,]CO-HX]QXJ>D4YED5ELE<J7)KF$DGD_L2HRW7M[OEVQW
M%TPL:G;Q<E_<92>.U[%USI:;?LC<E^BB-^[/3-WHVCU7,G1KV;AQ_9<)K*32
MYOR[=;\4O%SLQ5*ODG312= G5<R17V<*773XCALRX,Z,]$F1GD_LFI$:0AMY
MEQ//JE22,AM>U>M7[:O6)1G9DJJ46FFO:FN#7R&BK]B_BWI8^3"=O(@Z2C).
M,HOV.+HT_<T>J.0X@              #N. ;"S?5F64^=:[R>XP_+J&0F35W
MM)+7$F1UEZ.,N<>3,N%)1RA^.\ER/(:,VW$+0HTGYFKZ-I>OZ=<TG6;%O)TZ
M]&D[<U6+]_M4ESC*+4HNCBTTF>QH&X=;VKJUG7=NY5[#U?'EU0NVI=,E[4_"
M49+A*$DX3BW&47%M%GCHI\M&'[K73:M[#.T^OMKR%,5M)EZ5(KL%V!,6:6H[
M#IO*)G$<IFK,DICN+.#,>]([C3CC4005[K^GG4MKJ[K^S5<S-OJLIV?G7\=<
MVU3C>M1Y]277"/SU)1E<+/.Q/JTT?>SL[6[ANSI^[)-0MY'"&+ER?!)UX8]^
M7)0;\JY+];E&4HV2:,1C)I  :8]P^CVHNXN*(@Y=&_1O8%-$<9P[9U/$9<OZ
M/R<-\JZR84Y';R/&G7S,W(,A:? W%KCN1W5J</9O;;NIN/MMJ'FZ=+S]'NR3
MO8LV_+N>'5%\?+NI<IQ7&B4XSBE$TQWB[';0[Q:4K&KQ^K;@LP:Q\VW%.[:X
MUZ)JJ5ZRWSM3:I63MRMS;D5=>QWQO]H^N,NQF6N"SL_P.(M2F-AZ[BRLBIOI
M#,_&1=UD5I=_BYMI\4NJFQFXI.J)#;[OHHYX[*[U["WK;A:Q\N&'JTEQQ\AJ
MW.OLA)OR[ON4).5%64(\BKKN/Z;^Z7;B[<O96#/4-!@^&7B1E>M]/MN0BO-L
M4X*3N04.ITC<GS>A8VV:%  [/AV$YCL/((.*8'B]_F.36:R;@4.-5,VZM9)^
M24J4W"@,OO\ M-FLC6LR)""]5&1>HZ&I:IINC8<]0U:_9QL&VOBN79QA!?+*
M32J_!<WX'J:-HFL;AU"WI.@XN1F:G==(VK-N5R<ODC!-T7B^2YMI%B_H-\1A
M839T6Y.T\2OLLDKW8MMBFGFUQ;2GIIC:2>C66?RV_?@W-E$?,EM5D=3D-I;:
M5/NR/(V&X7]W/45^-+%W;6P93AA33A=S.,)S7)QQUPE"+7!W94FTVH1A13E8
MOV#](OXDR;&\NZD+=S4K;C<L:>G&=NW)<8SRY*L;DXNCC9@W;BTG.=RKA&?8
M1%)]@ 0M_(]\^?QS_&9.L<(W!L^=LG>L&*E]77[1T*!G.QJYQ]LEQ6\TDO6M
M1AFN5.H<:>^GN[2%9.1'4OQXDA!I\@*GV\?^-V[%6EG/:ZU])]+8/3(5[=7-
MWCF^<[3LY*$DLOJY]7@3^G8L)3RC2KZ=N9()HB-/O.<^1 8'QO\ XU[Y)HMM
M'>R_K7T>O*)*D'+KL;P_?6*VSR2>:4X4>ZM.P&90XJE1R6E)J@/$E:DJ,C))
MH4!-%TS_ .,]Z<;9MJW$^Y&BMA=4K*<]&B%L/$K5>\]51UN/*:?GY"U4X]C&
MR<<BI0I"TMPJ2^,B\_-Q))2:P+>NIMOZLWSK[&ML:5V)ANU=9YC!*QQC.L!R
M&LRC&+N)YK9=5!MZB3*B./19#:V7VC43L=]"VG4H<0I) 9&
M
M
M
M
M                  %=#YA.]!ONS^H^JK=1-,*8<W;D%;(4GW7B\9$/6L:0
MTI/DVS]R1<^)F2E&U$-7W9;1S0]-_:GIC#N)N"W\3K]1MR7)<GDM/Q?&-FOA
MU7$N-N17/ZPN^G7*YVCVK>?1%IZE=@^;YQPXM>"X3R*<WTV6^%Z!7B$R2O$
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MVV589/8((B]"?EN$1F9_:9\QTW%OK>&[9N>XM1RLJ+=>B4^FTG^ELPZ;4?\
M%@B76T>V/;_8=I6]HZ1A84TJ>9&VI7FO9*_<Z[\U^JN/Q]K,ZC%#.P
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M$=+KS)2&#6PZ]'6T\X!LR
M
M
M
M                                                 C]^17N1"ZC:
M4D2Z*3$>V]L!,['M9U;IMN+@OI80FXS:7&6E:7*[$F)3:T(4E2'Y[T=E1&VM
MU2-P=F.VMWN+NB-O+C);<P^FYDS7#J5?@L)^$KS33::<;:G)/J44X_>HKO)8
M[1;)E=P90>[]04K6%!T?2Z?29,DZUA84DTFFI796X-=+DU3"LK*PN;&?;VTZ
M79VMK-E65G93Y#LN=86$Y]R5-G393ZEO29<N2ZIQQQ:C4M:C,S,S%FEBQ9QK
M,,;'A&WCVXJ,8Q248QBJ1C%+@DDDDEP2X%,&3DY&9D7,S+G.[E79RG.<FY2G
M.3<I2E)U<I2;;;;JVZL](<IP@      2J_''\=-KVNND[*V4W/H] XY9KBR5
ML..P;;9%S"-"I&.4$E'@_#HXBE$FRLFS)23YC1E?4>Z[$T!WJ[SX_;[%_$>B
M.%W=]^W55I*&-"7*Y<7)S?.W;?ZN:Z.F-R5?IQ].F5W7S5N7<JN6-@8UWI=&
MXW,RY&E;-I\XVH\KUY<5QM6GYG7*U;9Q?%\=PG':7$<1I:[',8QRNBU-'1U,
M5N'6U=;#;)J-$B1FB2AMMM"?_E4?)F9F9F=>&?GYNJ9MW4=1NSO9UZ;G.<VY
M2E*3JVV_'_\ (N!;9I>EZ=HFG6-(TBQ;QM,QK<;=JU;BHPA"*HHQ2X))?;YO
MB<\.H=\   /4GSX-5!FV=G-B5U;71)$^PL)\AF'!@08;*Y$N;-ER%MQXL2+'
M;4MQQ:DH0A)J49$1F.2S9NY%V-BQ&4[\Y*,8Q3<I2;HHQ2JVVW1)<6^".*_?
ML8MB>5E3A;QK<'*<Y-1C&,564I2=%&,4FVVTDE5\"L/\C7RF6&TUW^B^N%Q(
MJ]8?YQ4YIL>"MV+:;%:6A<>=28^I3;4FJPE?DI#SY&F1:I^Z7A$-294Z^RW8
M2SH"L[KWK;C<UWA.SC2HXXSYQG<YJ=_QC'C&USXW*.W6'ZC?5-D;IED;%[<7
MI6ML<;>3F1;C/,5*2M6N"<,9\5*7"=]</ALMJ[!L)5$&@         "23K%\
M6W9GL9^'WUC2?R/:XF>T]^F>P84N)86$)SA7OXOA?,:]N_<:6EQEU_Z"O?0?
M*)1GZ#26^N_6QME]>)9N_C+6HU7DX\DXQE[+M[C;AQX-1\RY%\[9)+MCZ6NY
MO<;R\_(L?B?;DZ/ZQEQE&<XOQL8W"[<JJ.,I>5:DOFW2P9US^+?JKU^^@N)&
M*?RMYW$\'?TNV:S$NH\247@OW:/$/9+%ZKV'T$N.\Y'E3XZOV,H_M$/-Z=^M
M_P"\.O&AD?B[29</)QFX-KV7+U?-G5<))2C;EXVRP;MSZ6^U7;[R\RYB?C?7
MH<?K&:HW%&7#C:QZ>1;HU6$G"=V#Y721I"$-H2VVE*&T)2A"$))*$(21)2E*
M4D24I2DN"(O0B&EVVW5\6R1J2BE&*2BEP1^A^'Z   '$W=]1XU6R;K([FIQ^
MGAI)<RVN[&'55L5!GP2I,Z>\Q%829_E4LB'8Q<3*SK\<7"M7+V3+E"$7.3^2
M,4V_L(ZF;GX.F8TLW4KUK'PX*LKER<;<(_+*345]EF@FUOE0Z5:J.5&/:B=C
M6\7R_P"J-4UC^9%(\5&@_I<D0N#@[O*D^G_6I<EZEZ&1C;NW^P7<_<'3/\7_
M %+&E]WER5FGRVOBOK\$:!W7ZJ.RFU.JT]56I9D?V/!@\BOZF\G'&?X?W\B.
MS8WSPH(WHVH] J47W_I[K8V6$@_V7#?O8QC,)?VH]3\;?T,^/7CD]SZ+Z3'P
MGN+5_EAC6O\ HNW9?^"1VW'Z\5\5K:.WW3PN9E_[5;%F+_0R/\)HSG7S!]WL
MQ4X53F>(:XCNJ,UQ<%P2E4GVS(R]EN9FR<TM&$D9D9*;D)<]/V7')'M72?3?
MVMTU+ZQC9.;->-^_/[=+'DP?R.+7N-&:[ZPN]^L-K$S</3;;?&.+BV^7L4LG
MZS-?*II^_F:BY=VY[1YV;A97V$W%:QW2(EU_\H.30:@^#7]XJ6NL8=2E9DX9
M&HF24:>",^"(BV+IW;K86DI?B_1M-MS7W7U>U*?^7*+G_P!HU%J_=WNEKS?X
MUW#K%VV^</K=Z-OQ_8X3C;KQY]-:<.1@6QM+*WDJFVUC.M)BR\5R[&7(FR5%
MY*7PI^2XZZHO-9GZG]IF?Y1EUFQ8QH>5CPA;M^R*45]I41@61E9.7=\[+N3N
MWG]U.3E+[;;?B>B.4X       .\XOL_96$&TK"]AYSB"F#)3*L7RV_H#9,C6
M9&T=581#;,C=5]G'[(_\)CRL_0M#U5-:GAXF2GS\VS;N5^7KB_8OM'N:7NC<
MNAM/1=1SL-QY>1?NVJ<^7ESC3F_MLVAPOY'.[F!FR51V(SFS;:-'+6:*J=@D
M\A)>)MO/9S69!*43B/0U$X3G)^1*)7"BP/4^RO:W5J_6=&Q+<GXV>O'I\BL2
MMK]"GA2G VCHOJ.[W:#3ZGN+.NQ7AD^7EU]S>3"[+C[:U\:UXFYVOOG$[)X^
M;,?8& :OV)";,C=DQ(EUA>02"X(E)7/@6-K1(+TY+QJB,C,^>2X(M9:QZ5]D
M9E9Z/F9^%=?)-PO6U_BRC"Y]N[_^_<^WO7%W*T_IM[@T_2]1LKG*,;F-=?\
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MRS++RVR;)\CO)LBRNL@R&^GR+2ZN[>QEK=E6%I:V4IU^0^ZI3CKKBE*,S,S
M'!@       +CO_!Z?(K>:/[BY%T&S;()"M0=LJ^XR/7=9.E/?AN+=A,$QU^X
M3+KD+(XE?_*1KRAEUTT^4+FSZNH:29J2E*@/IM@
M
M
M
M
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M69]J?3+VZ[8*UJ$K*U7=4$F\O)BGT2]N/8^*W8H_FR^.\JM><TZ$BHTP2+
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M$ /NN@
M
M
M
M                               "MS\T/<%5M;0^I>!VG-72.5V1[AF0
MGR-$ZZ-*)V-80XMM7"V:=I;=E-;/R2<IR*G[KD=Q(FQZ9.VZQ\>7</5K?T]U
M2MX<9+YL/FW;ZKXS=;<']ZKCXJ<65N>M'O"\O+AVET&[_%;#A>U"47PE<X2L
MXSIX6U2]<7%=;M+A*W)%?D3!*_       -V^C'3#+NXVTVJ"-];2ZRQ=R%8[
M-S5ELDE5U3SJO8HZ9YYA^*]E=^EEQ$1M:5(:0AR0XE2&C0O5O=;N;IW;70'F
M3Z;NN9"E'%L/[J:7&<TFFK5NJ<VJ-MQ@FG*JW;V,[,:OWCW4M/M]=C;.*XSS
M<E+YD&^%JVVG%W[M&K:::BE*Y).,*.Y[KO7N':HPG&]=X!10L;Q#$ZQBII*B
M"V2&F(S)&:WGG#Y=ESYKZEOR9#IK>DR'%NN*4XM2CK+UG6=2W!JE_6=8NROZ
MED7'.<Y<VWX+P48JD8Q5(QBE&*221<_MW;VC;4T3&V[M^Q#&T?$M*W;MQ7!)
M<VWSE.3K*<Y5E.;E*3<FV=T'F'M   !XWGF8[+LB0ZVPPPVMY]]Y:6F666DF
MMQUUQ9I0VVVA)FI1F1$1<F/J,93DH03<VZ)+BVWR27M/F<X6X.Y<:C;BFVVZ
M))<6VWP22YLJL?)O\D4O>EK:Z(T?>N1])U,DHN59/6N.L.[4M8CODXRS((T.
M'@==(;+V&R(DV+R/?7YLDP13\[%]E+>U,>WNS=5I/=%R-;5J5&L6#7-K]ODO
MG/G;3Z%27655^ISU(WM]95W8FQ[[CLFU+IOWH-IYUR+XI/@_JL&OA7*])>8Z
MP\ND+PDV0O       [/AF$Y=L7)JC#,$QNYRW*KZ4F'44-# ?L;*<^HC4HFH
M\="U):9;2:W7%>+;+:5+6I*$FHNAJ>J:=HV#<U/5K]K'T^U&L[ER2C&*][?B
M^22XMT23;2/4T71-7W%J=G1M"QKV7JM^73;M6HN<Y/W)5X)<9-T44G*32398
MZZ9_#5CF*%5;"[7+@YAD1(8FP-15DA3V)4K_ )$\V696S"D*RJ<S]TEPHYHK
M4K):5KFMJ+B%?<SU+9NH>9HW;]3QL*KC++DJ7IKE]#!_K47QI.5;K5&E:DBQ
MSLSZ-=-TGRMP]UW#,U&BE# @ZX]M\U]8N*GGR7"MN%+*=5*5Z+X3NUE96TM=
M"J*:O@U-36Q685=5UD2/ KJ^%&;2U'B0H45MJ-%BL-))*&VTI0E)$1$1")U^
M_?RKTLG)G.YD3DY2E)N4I2?%N4G5MM\6VZLG?C8N-A8\,/#MPLXEJ*C"$(J,
M(12HHQC%)1BEP2222Y'O#B.< #^*422-2C)*4D:E*49$22(N3,S/T(B($FW1
M<S\;257R(L.TGRS]=M!'/QK!)*-Y;%CD\RJJPZTC)PVFEHY1[>09PVW.@*=:
M=(R7'KFY[Z%H-#WL&9&-^["]/.\]W=&=JT7I6BNCZ[T7YTU_H['PRHURE<=N
M+33CUD6.Z7JT[=;!=S3="DM=W'&J\O'G'ZO;DN%+N2E*%4^<+,;LDTXS\M\2
MO5V1^13M!V8<G5V3YL[AV"RB6R6NM>KF8YC+L52B_-7;R);]WDYN$A)K382G
MXY.%Y-,M$9I$QMD]F=B;&C"]@XJR=6CQ^LY%+EU/VP5%"UXT\N$94X2E+F5Z
M=R?45W0[F2GCZGG/#T*=5]3Q.JS9<?9<:D[E^M%579RA7C&$*T-&!M8T8
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MH(<)TXR'9!-RI%@E"C;2I?"OND9\$ /O.
M
M
M
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M]2,[[]L7T6:I-6D^+CT&Y"/0
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MB>EEV+&R"PV$E%W'9=-!OU^-SS0?DT /K7
M
M
M
M                                                           J
M&?+5VK/??8&1KK&+,Y.M-'2+/%Z_Z=P_H[S.5/(8S7(.4*]N6U%EPT5L1?WT
M>U$<=:/QDJ\K&?3SL!;1V>M:SX=.N:JHW95^="Q2MBW[FTW=FN#K-1DJP5*A
M?5KW5>_NX,MN:7=ZMLZ'*=B%'\-W)JEDW?9)1E%6;;XKIMRG!TNNL4PD 13
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MQ222\$E0KRS]0SM5S;NHZG>NY&H7IN=R[=G*=R<GQ<ISDW*4GXMMLXD=DZ@
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M_P "]Z\3;F:=D:BO41$;T+%];3+@EF?F1H;L[;+Z,VB2?B?D<1?EZEXEZ*&
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M[T/<K[S3/P%S^&.7^Y-V<_;=:_VFU_\ HQZ4_P"$3J!+92W'R7>E6M+A+.1
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MP
M
M
M
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MEQBDJ(\"I:<03QL+DFY(< DW
M
M
M
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M)G?;NWG=WM\7=9K.&WL;JLX-E\.BPG^N2CR5V^TKESFU\-OJE&W%FEPV<:7
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MYR_,\MR"8Y/N\CR;()[]G<W-G+=^\_,GSI*W%GZ$1JX(B(B(@.G@    M_\
M_"F_,3E'5KLGC'Q];LRN5.ZR=F,J.EU4JYFI5$TUV"R1YIO'BJ'Y*E.P\1V]
M:H143*]K\RB_F0YR"9\[%<@#Z?(
M
M
M
M
M -0>]G89OK+UEV)L>))1'RR5!+#]>H4KA;N<Y.U(AU$EI/BI+IT,=$BT6V?B
M3C,!:>2,R&Q^T^S7OG?.%HMR+>GQGYV1[K%IJ4T_9YCZ;2?@[B9J#OMW#CVR
M[9:CN2U)1U:4/J^)[7DWTXVY+V^4NN^UPK&U)5JRCJ\\](>=D2'7'WWW%O/O
MO+4Z\\\ZHUN.NN+-2W''%J,U*,S,S/DQ:A&,814()*"5$EP22Y)+V%'4YSN3
M=RXW*Y)MMMU;;XMMOBVWS9XQ]'R   '*T-%<91=T^-X]6R[B^R"S@4M+4P&E
M/S;.ULY34*O@1&4_>=DRY3R&T)+[5*(=?+R\; Q;F=F3C;Q+-N4YSDZ1C"*<
MI2;\$DFV=K P<S5,ZSINGVYWL_(NQMV[<564[DY*,(Q7BY2:27M9=YZ0=6:;
MJ3H?'-=M(ARLSLB3DFR[^,25G<YE8,-?6,,2O::=>IJ%E*8,$C2GEEGW323C
MKAJJU[I[^R>X>[;VLR<HZ9#Z/&MO[BS%NC:JTIW'6<^?Q/IKTQC2[WLAVLPN
MTFP\;;L%">M7/ILRZN/F9$TNI*5$W;M*EJUP7PQZFE*<J[?#7!M\     KS?
M-!W%5$8C=1\!LU(?EMUF1;FL(3Q)-N&LT6.,X"M1$:R5*X9M9Y%X_FBAMDI2
M7)#93(],G;97)R[B:O;^"+E;PHR7C\V[D?8^*U;]_F.B:@RO+UH=XW:A'M'H
M%UJY-0O:C.+Y1^?9Q7^J^&_=Y?#Y,:M2N1*Y@FB5S     $X'Q:?',6WIU5V
M+WC2+_DMJ)R)>O,0L&S0C8MS72>2O+B*ZW^?P:JELFE#1_=M)*#0OF*VXB1%
MCOWWH_JY:N;+VK=7X_N0ID7HO_5H27S(-<K\T^+YVHNJ^D:<)P>EKTY_UOOV
MNXV^;#_JM9FI8F/-4^N7(2_7;D6N.-"2HH\K\TTZVHR5RT6E))(DI(DI21)2
ME)$1)(BX(B(O0B(A UMMU?,M%225%R/Z!^@ :M=M.VFM.HFM).=YW)*?=3RD
MPL&P:%)::O<UO6FDK*)$):73@U$$W4+GSUH4U#:47HX\XPP[GO;SMYKG<;7(
MZ3I,>C%A25^_)-V[%MOF^75.5&K=M-.;3XJ*E*.K>[7=K;/:';,M=UV7F9MS
MJCBXL9)7<FZE\V//IMQJG=NM.-N+7"4Y0A.F1V%["[+[-[+N-H;0N#GV\\SC
M555&-UJBQ6B:=<<@8YCD!QQTH-7!)TS]34Z^ZI;SRW'G%K59ELW9NA[%T.WH
M.@V^C'AQG-T=R[<:75<N2HNJ<J>Y1248I122IC[A]P]S=SMS7MT;HO>9EW/A
MA"-5:L6DVXV;,6WTPC5^+E*3<YN4Y2D\'C*C!P    "4CI_\5N[^R::W,<V1
M)T[J23[4EJ_OZYT\LRB$HU*)6(8M(^G>.(^A)>-A.5'BFAQ+C!2B(T#0O<?O
M]M;9+GINEN.I;BC5.W;DO*M2_P!-=555>-N'5*J<9^7S)2=G_2MOCN2K6LZV
MI:-M&5)*[=@_/OQ_^SV'1]+\+MUPA1J5M755%F?KAT^T)U7I$UNJ,+B1+I^(
MF)=9U<DU;9SD*243BRL[]UEMQF(XZDE?1Q$1H25$1I9(_40:WKW(W=O[*\_<
M&5*6*I5A8A6%BW^IMIT;2X=<W*;7!RH6:=N.S^P>U>#]6VGA0AFRATW,JY2Y
ME7?%]=UI-1;X^7;4+2?%03XFSHP4V<   '\4HDD:E&24I(U*4HR(DD1<F9F?
MH1$0)-NBYGXVDJOD:-[O^1SJ'H94R!DNU:W*LFAFZAS#]:H3G%ZF2PHT/0IC
M]6\6.TDYI1<*9L9\-?\ R#:NUNRO<;=JC>P=/GCX,J?39/T%NCY22DO,G%^V
MW;FC1V^/4=VAV$YV-2U6UEZG"J>/A_QF[5<'&3@_)MR7C&]=MLB>VW\[.3RU
M2X.C-*4],Q]]$7(]GVTF[FN(62DD]^BN,O5,.!);(R4DE6LQOR_9)47H<@]N
M^D_!MJ-W=>J7+L_&WBP4(_)YMU3<D_W*#]C1$[=WKMU.ZYV-C:)9LPY1O9MR
M5R37M\BR[<8M>%;]Q5YIK@1N;)^2/NKM!;Z;?>^5XY >\DMU>O/H=>1H[*CY
M5'3,Q&+574ILSYY.3+?<-)FDU&GT&[-$[)]L-!2>-I./?O+[K(ZLAM^WIO.<
M$_U,(KQI4C=N7U)=Z]T.2S->R\;'?*&)TXB2]G5CQMW)+]7<DZ<*TX&F=YD-
M_DTYRTR2\N,@LW?\K8WEG-MISG)F9^Y+GOR)"_4^?50V9BX>'@VE8PK5NS87
M*,(QA%?8BDC3&=J&?J=]Y6I7[V1DOG.[.5R3^64FW^B<0.R=0        .6I
M+^^QFP;ML;N[?'[5DC2S9TEE,JK!I)J2HR;F0'H\ELC4@C]%%ZD7^ =;*P\3
M.LO'S;5N]COG&<8SB_EC)-?H';P=0S],R%EZ;?O8^5'E.U.5N:^246FOMFXV
MMOD;[I:N.,W2;ZS"^@1S(CJ]@.1-B17F",N(IR,RC7%K%CI(B))1Y+"D)+Q0
M:2]!K;6^RW;'7NIY6D8UJ\_NL>N.T_;2RX0;]O5&5>;39N/;?J.[T[6<8X.O
MYE_'C]QEN.7%K[VN1&Y.*]G1.+2X)I$DNI/G9RV&N)!WEI6CO(YJ;;EY%K"V
MF4$YEE)F2I!8MDSUW#LI:T<&I*;2 UY\F1)29)3I+<7I/TZXI7=JZI=M3\+>
M5!7(M^SS;2@XK_W5QTYU?%R3VEZ[=6LN%C?.B6+]NJ4KV%<E:DE[?(O.[&<F
MO!7[4:UI1<%+'I/Y(.H&]EPH&.[6KL3R6;XI1B.RFOT(NO?<,B;AQY=FZ>,V
MTUPS^ZU L):S/\@CWNCLIW'VFI7LW3YY&#']FQGY\*>+:BO-A%>VY;@B6.R?
M4AV@WVX8^G:K;Q-3GRQ\Q?5KE7RBI3?DW)/PC:NW&;SI42B)23)25$2DJ29&
M2B,N2,C+T,C(:I::='S-YIIJJY'] _0 -,NT/0WKOVNA29.>8HBCSPV":@;/
MQ!$6HS..MII+45NTE%'=B9/7L)0E"8]BU()MOR)A3*C\RV9L/NUO+M]=C#2<
MAW=)K66+>K.RZNKZ55.U)\^JVXU=.M22H:8[H=ANW?=>S*[KV(K&O=-(9N.H
MV\E45(J<J.-^"HDH7HSHJJ#@WU%8CMU\;N^NJ#DW(I,'^4C4S3BC8V5B<"4;
M%7'-:&VOTVHO*7,Q%Y:W$I)U;DBO6M24HE*<,T%.OMUWLVEW!4<*$_J6X6N.
M-=DJR?CY%S@KRX5HE&XDFW;2XE8G=WTW;][3RGJ-V'XRVFGPS+$)4@JI+ZS:
M^*6.ZM+J;G:;:2NN3Z5'N-Q$>P      .Y:ZSBYUEG^%;%QUPVKW!LJH<LJ5
M$XII*IU!9QK..RZI)&?L2%QO;<3P9*;49&1D9D/,UK2L;7=(RM%S57$R\>Y:
MGX_#<BXMKWJM5[&DSV=N:YF[9U_"W'ISIG8.5:OV^-/BM3C-)^YN-&O%-I\#
MZ!M;/CVM= M(AJ.+90HL^,:R(EG'F,-R&3625+22O;<+G@S+G\HI^OV9X]Z=
MBY^N0DXOY4Z/]%'] ^-D6\K'MY5JOE7(1FODDDU^@SW1Q',     ?,>_XT;?
MUWG/R%Z+Z^MV+SF&Z$ZW5>1,U2G9'LQ=@[ER[(+'*YZ&5***2IV&X;C#?DA'
MF?TYDI9D24H IT      #DJ:XM,>N*K(*.?*JKNCLH-Q3VD%U4>;6VE9*:FU
M\^&^@R6S*ARV$.-K+U2M)&7V #[L/4;<<CL3U1ZQ=@9:&6I6].O6EMQR6H["
MXT=N1L[6^-9L\AB,Z1.1V4.79DE"B)2$\$?J0 V%
M
M
M
M
M             5:?FS[!?IONO%M"4DWW*'3U4FWR9MI7YI_/<PAQ9I,NFDU(
M?_ L5.(39EP;;TZ2VHN2/B>WI>V?^*]KY&[LJ-,O4KG1:;YK'LMQJO9YEWKK
M[5;@T5:>MGN#^.]ZXNPL*=<#1[7F7DN3RLB,94?@_*L>73V2NW(OBB$D2C(2
M     $]OPM=2$91E%KVJS>K)VCPN5+QK5$::PHV;#+W(YM9!EK;;R$MOL8S
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M_7='N2YV=P:G=MZ5-O\ BN-6QC4^]E"#ZKJ7@[\[LE[33P;)-/
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M,R &XH
M
M
M
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MDM,C/JMXEFMO%M\Z-6ZOKG&K2N7I7+J3:ZZ<#5$;!-4
M           !M-UL[E[_ .JMRF=JO,Y",?>?]^WU_D/OW.!WG/JX<NB<D,G
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M%,?L?Q#'=:N2?;]ARVVSD-:BJ*.3C<A-3^(3&C,X9D8'V-
M
M
M
M
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M&[ ZYWDU9Y-]W,/96--+(RNGC.7!^1C]7"5UIIRDZPLQ:E-2DX6[EP'5VK,
MTO@]'KG66,UV)XACT<F*^JKFO$EN*X5)GSY*S7*LK6>[RY)E/K<?D.F:EJ49
M\BN'7M?U?<^JW=:UR_/(U*]*LIR?VHQ7*,(KA&$4HQ7!)(N!VMM70-EZ'8VY
MMG&MXFCX\:0A!>/C.<G\4[DWQG.3<IRJY-LR"/',@  Z_E>5XS@V.7&7YE?5
M6,8OC\)RQNK^\G,5U560FN"6_+F25MLM)-:B2DC/E:U$E)&HR(^YI^GYVJYM
MO3M,LW+^?>DHPMPBY3E)^"BN+]ON56^"//U75M,T+3KVKZSD6L72\>#G<NW9
M*$(17C*4FDO8O:VDJMI%9WO'\O>5;(.WUCU?E6N#8$OWX%QL[AZLSC+&?(VU
MHQDB-N7AE&^DN2?(TVKZ3+UB%YM.3C[5^G+3]$\O7=]QMY>KJDH8O"5BT^?T
MOA>FOO>-J+K^N<)*L[OEZO=5W)YVV.U\[N#H#K"YF\89-]<GY/*6-:?WW"_)
M4XVEU1E!PXXX\XX\\XMUYU:W'77%J<<<<<4:EN.+49J6M:C,S,S,S,Q*F,8Q
MBHQ244J)+DD0;E*4Y.<VW-NK;XMM\VW[3\#]/P   /TA"W%I;;2I;BU)0A"$
MFI:UJ,DI2E*2-2E*4?!$7J9C\;257P2/U)R:C%-R;X(W.U)\>G<+="(DS$])
M9364DQ+;K>1YPB/@=*J(Z1FB;%=RIZKFVT1?Y%06)1GSR1&7)C66XN\?;?;#
ME;U#5,>YE1X.W8K?G5?<M6E*,'[IRB;GVEZ>N\.]%"]I.B95K!FDU>R4L6WT
MOE*+ON$KD??:C/Y"2'7'P1;"GDU(VUO3$<83PAQRKP''+;,GW"41&J.JVOI&
M%L0G4$9\K3%EHY+@B,C\BTIK7JQT:RW#;VDY-_\ 39%R%E+W]%M7G)>YR@_D
MY$D-M^A#<-]*YNW7</%7-PQ;-S(;]WF77C*+]ZA<7LKS-V<*^$WJ-CJ&7,IM
M]K[!EDCB2BVRFMHJEQSR(_.-#Q:BJ+.,CQ+CQ7.>/U,_+[.-7:IZH>XN:W'
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MGLSVBL0\N&U]ON-?NM/Q9O\ RIVI/]$[!(ZO=:)4,J^5UWT7)@)2TA,&1J3
M'H:4,>/LI*,YCZF22SX%XEX\)X+@=.&_-\6[GG6]9U:-[C\2R\A/CSXJY7CX
MGH7.UW;.[9^KW=NZ%+'HOA>!BN/#E\+M4X>'#@=4M.D_4"W02)?6/1;*2;=:
MYJ]8XC1K\7B(EF;E+55[AN$1?=69^:#]4F1CT+'=#N/C.MO7=6;JG\65>GR_
M5SEP]JY/Q/)RNR?9_,73=VQH25&O@PL>US]]NW!U]CYKP:,-9-\6G13*$N&_
MHJ!3R5<^W+QG+<\Q]3!J-GR-N%79.U4K\D,$GAR.X2?)1I(E*-0R;![]]U\!
MI0U:=V'LNV;%RO/[J5IS\?"2KPK5*AANI^EGL3JB;GH5NS=?*5G(RK5.7*,+
MZMOE3C!TJVJ-MFJ^<?!OULNDNO8-L3;&#S%^?@S.F8YE](SR9FCPA2*2GN%>
M//!^5BKDB+[#Y,\^TKU4[WQ6HZKA:?E6UXQ5RS-_XRG.'VK9JO7/0WVVS4YZ
M%J.K8-Y\E*5G(MKV4B[=NY]N\_\ I;T8V7\&N_L=;DRM8[-UWLJ.P2U-P;>/
M:Z^OYA$GE"(L1\\FH$NK5Z&3UHR@O3[Q_DVMH?JJVAFRC;UW!S<&;YR@X9%N
M/RM>5<I^IM-^XT9N7T-;_P!.C*[MC4].U.W'E&XKF)=E^IB_.M5_57XKWD:.
MW^H_930OU+NUM-9MB]9$5X/Y&FM*\Q%*C\?$OTPQUVVQ@U+)1<)^K\O^3DCX
MWAMSN)LC=O3';^IXM^_+E;ZNB]^!N*%W_L4(T;P[1]RMA=4]UZ-FXN+!\;W1
MYN/_ +19=RQ]CS*FN@S0UR      !_4J-)DI)FE23)25),R-)D?)&1EZD9&/
MQI-4?()M.JYDV'1_Y=<VU*Y4:U[)R+?8NLTG'KZS/#4Y89_A$8N&VSLEK\Y&
M;4$8N/)#BOQ..WY&VY()#<41?[I^G32]PJYK>R(V\+7.,I8_"./??/X?"Q<?
MM2\J3IU1A65PFQV/]7>M[2E9VUW)E>U';*I"&5QGE8RY+KKQR;2\4WYT%5QE
M<2C:+.6%9MB.Q\6I<WP3(JG*\3R*$W84M]22VYM?/C+,TF;;K9F;;S#J5-O-
M+)+K#R%-N)2M*DE!;5-+U'1<^[I>K6;F/J-F73.W-.,HOY'X-<4U52333::9
M9UHFMZ1N32K&MZ#D6LO2<F"G;NVY*4)1?L:Y-.JE%TE&2<9)232[2.@>H<)D
M6-8YE]/,Q[+,?I,HH+%!-6%'D55 NZ><V2B43<RLLF),*4@E$1\+0HN2':PL
M[-T[)CF:?>NV,R#K&=N<H3B_TLHM27V&=+4=,TW6,.>GZMCV,K3[BI.U>MQN
M6Y+V2A-2C)?*F:(Y;\6'1?+[!=G(TC%HICJU+>+$LLS7&:]9*4M7@BEJ\A9H
MXB$J6?'L1FCXX+GQ(B+;.G=_>ZVFV58AJDKMM+AYUJQ=E_ERMN;_ ,:3]O,T
M/J_I7[%ZQD/*N:)&Q>;X_5[^39@_<K<+RM17'[F$?9R21EC3/1GJCH*SBWVL
M=,XS59+")!Q,HN7;;,,CAR$I2E<NLM\NL;R72RGN#\E03C%PHTD1)/Q&/;F[
MJ]P-WV)8FNZG?N8,N=J"A9MR7LE"S&"FEX=?5[>?$RS9G8SM1L#)CG[8T7&M
M:G#YM^X[F1>B_OH7,B=V5N3\7;Z.;227 VQ&O3;( $-/R"_/=\:?QMW%C@V\
M-RS,VW/5MDY-T/HRE:V1L^OY:4\4?(^;.CP3!K!Q!MFW$R"\J9;R'D.-MK:\
MG$@09/\ _&Y=-TWAQXO3/LR]C?U3:$VS^2ZLC7APC)'NR#QYN\E0"E(,U>+/
MXF:%<%RZGGT FO\ C\_X@[XROD:R&GUWJ;;]EK'==\IIFFT=V IX>M\^R":\
M;B6JS$)S-Q?Z_P ZNG?96M-=2WD^R]I)N*CI01F0$V@  "BO\U__  FI[ARS
M+^TGQ@LXOB^:Y',L\EV+U.OK2-C.*91D-E,>GV5WH_)[)UG'L*L+&5)-;N.6
MCL*C3RM4.9"0AN"X!0V[#=2.T'4S)W\.[,: VYHW(&ICT%B-LO!,AQ:':NLF
M[R]CUS906:7)J]Y+"ULRJZ1*BOMI\VW%(]0!@BJJ;6^LH5-1UEA<V]E(;B5U
M550I-C93Y3I^+4:%!AMO2I4AU7HE#:5*4?V$ +"7QP_\,[\D'?#(J"[SO6F0
M=0NOTB0P_>;;WSC%GCF23*A9&X:]=Z?METN<YE,FL^*HLF0W5T;J%>?XA^Q0
ML#Z>/Q[_ !X]:_C.Z\T?73K1BSU701I2[W,LRO5Q9^?;0S64PRQ8YIGEY'BP
MTV5L^RPAB.RTTS#@0VFX\9IIE!) &\H
M
M
M
M
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MSL=<1V924%352G8KCC3RXSDB!$8>7'6\PA9H,S2:D)/CDB ':
M
M
M
M
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MC%*,8KW)))>XH>S<S*U',NZAG3E=S;]V5RY.7&4YSDY3DWXN4FV_>SC1SG6
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M/%?BI('VM0
M
M
M
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M44U[9KVE=_KHWY2&E=M\.?%MYV2D_!=5K&@Z>U^?.47[+4N/!E=,3/*Z0
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ML/QFJV^EXE&IR-TB2[)LFF2,EN) 'V>
M
M
M
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M]?)G18L>,X\Q!1+E 68@
M
M
M
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M8R2DO%$0-R;4W-L_4'I>Z<#*P,]5^"_;E;<DG3J@Y*DX>R<'*+\&S'X]@Q\
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MD.R<BKT.H)PF9UK(;)SE?'D9F8&[8
M
M
M
M                                                       X7)*2
M/DN.WV.2U>,6_I;2DDJX6KQCVL%^"\KQ:=8</AM\_1*T*_P*(_4=K"RIX.99
MS;?ZY9NPFOEA)27--<U['\C.EJ6%;U+3LC3KO"UD69VY<^4XN+Y-/D_!I^]$
M 'P>9,]BN5=G="Y%XP\GJ9N/Y,U5F2?>0]C-C=X9FODHT)=4F!82ZIOUY(C<
M/T(S]9>^JC!CJ&GZ%NW"^+!N1N6G+PI=C"]8]WQ15U_8\2O_ -#NISTK5=S[
M"U&D-3LSM7E#QK9G<Q\GW_#.5A?9\/&PR(<%AI2)TWC=!F/R XABN54]?D&-
MY!V;<J;NDMHS4VLM:R;GTIF7!G1'DJ:D19#2C2M"B,E$?!BTG<N;F:;V?R=0
MT^Y.SFV="ZX3@W&4)1QTU*+7%-/DRD39NFZ?K'J!P]*U6S;R--R-SNW=M7(J
M4+D)94E*,HO@XM<&GS)[_D&^/'3%UUES2_T3I[#,)V1KM*,\KW,*Q^%33LBI
M*-F0>48[)3 8)5@EZA>>E1F22;BYL1E"#+S42HC]GN\FYL7?.+B;LU+*RM$S
M?H)>?<E.-N<VO*N+J?PTN*,).M%"<F^2I/?U!^GC9>;VRS=0V)H^%@[DTY?6
MH/&M1MRO6[2?GV9="^.MIRG"-*NY;@ES=8ZOA8[*'K[<M[U^R&8EO%]RLG98
MPI]Q#;5=L;'8+SK;*#6IM"$Y5CS+L=?)J6Y*APVT)Y6H;G]3NR/QQMFUO##C
M7/TQ]-VBXRQKDDF__=7&I+DE"=R3?!$=?17W*>WMYW^WVHS2TO68]=FKHH9E
MF+:2K1+S[*E!\VYV[,8KBRTX(#EIQ7?^<G)EY-E76/1] :IN3SWLGR9VJ;<,
MEN+R>QH<1PTR:(S)2IUA76C:5&7)&V9%]JA,KTJX*P=/UW=69\.#!6K2G[/*
MC<O7N/Z6,K3?R_(5W^N74WJ>J[8V/I]9ZI<E>O.VGS\^=K'Q^'Z:<+Z3]W#F
MR>S]"J_^3O\ DY\_^JOT+_0KW/%[_L_\#_ O/P^K^H_YOZ\>_P"?_P!)S]X1
M(_&E[\<_CJGT_P!:\^G#YW7YGLIS_2T]W@3V_$F/_5W^KE?XK]2^K5X_,\KR
MJ_.KR_35_35XG&[@SEG6.IMF['D.(;:P/ ,PS U.$2TFK',?L+=MLFS(_=6\
MY$)"4$1FM2B21&9D0Y]MZ5+7=PX.BP3<LO,LV?PER,&_=1.K?@N)UMX:[#;&
MT]3W)<:4<#3\C(X_Z&U.XE3Q;<:)>+=%S/G^O//2'G9$AUQ]]]Q;S[[RU.O/
M/.J-;CKKBS4MQQQ:C-2C,S,SY,6^QC&$5""2@E1)<$DN22]A_/\ 3G.Y-W+C
M<KDFVVW5MOBVV^+;?-GC'T?( ')TE-99'<U&/4T1R?<7MG IJF"R1&],LK26
MU"@Q&B,R(W)$I]"$_P#*8X,K)L86-<S,F2AC6K<ISD^48Q3E)OW))L[.%AY.
MHYMG3\*#N9E^["W;BN<ISDHQBO>Y-)%_'3NN*W4&J-<:MJ%(=@:_PK',2:DH
M;)KZ]RDJHL&59N((BXD6DME<AT_M4XZHS]3%1&Y-:O[CW!FZ_D55[,RKEYJM
M>E3FY**]T4U%>Y(OYV=MS&V?M33=K8C3L:?A6;"DE3J=JW&,IM>V<DYR]\FS
M) \0R0     KW?.YMCV*71VCX4GE5C8WFTLCBDKQ4VU5QU8KB#AD1&;C<IVS
MNN2,R)*HZ3X49\IF)Z3MO=>5JNZKL>$(0Q;;]\WYM[Y&E&S_ )3Y>->_KNW9
MT86A['L2XW+EW.O1]B@O(QW[U)SR?D<%S\*X@FJ5P@ =\U;KR]VULC!=8XRC
MSOL]RNCQ2L4;:G&H\B[L6(/UTDDFDTPJ]MY3[ZS-*4,MJ49D1&9>1KVLXFWM
M$R]=SG3$Q,>Y=E[6H1<NE?II4Z8KQ;2/>VMM[.W;N3 VQIBKGY^7:L0X52=R
M:CU2_2P3<I/@E%-MI(OO:ZP3']7X%ANN<4BE#QO!\9I<6I6.$DY]!20&(##L
MA22+WIDE+'N/NGRMUY:EJ,U*,SJ0UG5LS7M7R=:U"75FY5^=V;_33DY-+V)5
MI%<DDDN"+[]NZ#I^U] PMN:5'HTW!QK=BVO'HMP4$W[9.E92YRDVW5MG<AYA
M[( 'I65C!IZZ?;6DIF#65<*58V,Z2LFX\.#"8<DRY3[A^C;,>.TI:E']B2,Q
MRV+-W)O0Q[$7._<DHQBN+E*3HDE[6W1'#DY-C#Q[F7E3C;QK4)3G)NBC&*<I
M2;\$DFV_84..SVYYW83?NT]P35/>SF65SI5''D$:7H&*5Y-U&(UKJ36LDO5^
M,U\1ESQ,DJ<0I1$7/ MGV)MFUL[:&!MNU3JQL>*FURE=E\=Z2]TKLIM>YI%#
M?<_>E_N%O_5=X7G+HS<N4K2?.%B%+>/!\^,+,+<73@Y)OQ,#C+3 SW*VNGW%
MC J*J')L;2TFQ:ZMKX;2Y$N=/G/MQH<.*PV2G'I,F0ZE"$)(U*4HB+U,<5^]
M9QK,\C(E&%BW%RE)NBC&*JVV^"22;;\$<V-C9&9D6\3$A*YE79QA"$4W*4Y-
M1C&*7%N3:22XMLO"='NLM;U3Z]8?KDXT4LRG1T91LNRCFRZJQSFXC1UVC)2V
M>42H-"TVW71%I/Q7'BI7QY+49U8]U-\W^X&\<G6NJ7XL@_*QHNJZ;$&^AT?*
M5QMW)KFI3:Y)%X78[MEC=J>WN'MSIC^.9Q5_-FJ/KRKB76NI?.C:25FVUP<(
M*7.3-O!KDV\ !B#?6Y\4Z^:BSC;V9OI138;2OST0_>0S(NK9TTQ:/'X"E\D<
M^\MGV8S7H9)4YY*X2E1ED>TMLZAO'<6+MS3%7)R;JC6E5""XSN2_2VX)R?MI
M1<6C$-^[STGM[M'.W?K,DL+"LN2C5)W+C^&U:C7[N[<<81]C=7P3**^V]I9=
MNO9.9;4SJ>JQRG-KR7=63ODX;$8GU$B'5UZ'5N+CU-- ;:B1&?(R9C,H07HD
M6N;=T'3MKZ)C:!I,.C Q;2A%<*NGSIRI2LYRK.;\92;\2BK=NZ=7WKN7-W5K
MMQW-4SK\KDWQI&OS803;I;MQ4;=N-?AA&,? QT/:,=-O^E743,.X6WH6#TQR
M:G"Z/Z2XV7F:&R-G&<:7(4CV8BW6W6'LDO39<8K8ZDJ\W4K=6GV&'U(UQW/[
MBZ;VWVY+5<GIN:G=K#&LUXW;M.;HTU:MU4KLN%%2*?7.*>W^RO:+6.\.[X:'
MA=5G1;'3<S<A+A9LUI2-4T[UVCC9@TZR3FUY=N;5U/6>M<*T_@F-:UUW11,;
MP[$JY%92U,0C\6FO-Q^3*DO+,WIEC8S'G)$J0Z:GI,EU;KBE+49G6'KFMZIN
M35K^MZS=E?U+(GU3F_%\DDN48QBE&,511BE%))(NJVSMK1-GZ#C;:V[8AC:-
MB6U"W;CX*K;DWSE.<FYSG*LISE*4FVVSO0\D]T "ME\EORARL@D9'UXZV7_L
M8RA,RBV3M*I>,I&1.&HXUCBN$3VE$;&/MD2V9MDT?G8&:FHZDQB-V5-OL?V'
MMX<+.\M[V:YSZ;F-BS7"VN<;M^+YW.3A;?"WPE-.Y2-NMCU+^J*[J%S)[=]M
M<CITQ*5K,SK;XWGRG8QIKE:7&-R]'C=XQMM6JRNP "7Q   "0[J/\:V_NU9P
M<D:@EK/4[ZT+<V/ET&2E-M&/P-2L)QWRBS\L6:5_=?)<:MY0M)RR<3[9Z:[B
M=[MH=O\ KPI3^O;A2_U:S)? _P#3W.,;7OC25WBGY?2ZDA^T?IKW_P!UG;U*
M%O\ %FTY/CF9$9?21_\ LUGX9WW[)5A9X-.\I+I=ECK+\>'6CK!'@6.,X>SF
M.P8S;*I&RL[9BWN1IF()*EOT$9UDJC$FR=\O;^@8:D^THD//O\>1P@WSWEWQ
MON<[.=DO&T>3=,:PW;MT]EQI]=YTI7S).->,81Y%EG;+T\=M.U]NWDZ9AQS-
MPQ2KF92C=O=7B[2:\O'5:T\J,9]+Z9W)TJ;S#51O,               Z+L/
M6.N]MXW(Q#9N%8WG6-2E$XY3Y/4P[:(W(2E26YD0I32W(,]@E'[<AA3;[1^J
M%$?J/5T;7=9V[FQU'0LJ_B9T>'7:FX.GBG1_%%^,95B_%,\+<6V-N[MTV6D;
MGPL;/TV3J[=ZW&Y%/PE'J3<9KPG%J4?!H@:[6_"='6W:YEU.OULO$<B:O4.:
MV/N,+(_)PH6&9G*/W6321$AF+<*<\C,S7/21$DY:]O\ U0S3MZ9W"LIQX1^N
M6(\?U5ZRN#]KE9I3DK+YD#>ZWHFMN-W6>T^0U/C)Z?DSJGX].-DRXKV1AD-U
MYRR%R*_F:X-F.M\FM<,S[&;O$,JI)!QK2AR"ODUEE$<X\D*7'DMMJ7'?;,EM
M.H\FGFU)6A2D*)1R_P!+U73=;P;>IZ1?M9.GW56%RW)2BU\J\5R:?&+JFDTT
M5^ZWH>L[;U.[HVOXM_#U6Q*D[5V#A.+\*J27!KC&2K&2:E%M-,ZJ/0/*  EX
M^&C>5_@':6)J0Y[AX9NNENZZ?5O.G]%&RK%:*SRC'[QA!K)+4]46KE5_IZ/)
MFD2B,T-FB.?J7VKB:OL*6XE!?C/2[L)1DE\3M7;D;5R#]L:SA<]W0Z4K*LO/
M1GOG/T#NE#:3N/\ $NMV;L)0;^&-^Q:G?M75[)],)VOTRN)--QBU;4%>1;4
M    ?#V^3SL[E7<7Y >VW8;++B9<+SK>&=M8K]8N0K\&UOC-W*Q766,Q6Y2&
MGF(>-X#2UT)"30VH_9-2DDM2@!H@   ^J=_P?W93,-X?%5.UKFDJ98O=7-^9
MOJ##K&6\J4IS75S08EM''ZYR2\\N2;E!<YU:066C234>M8B-MJ-*?!L"U4
M
M
M
M
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M-3TJS#H;\E':'3&04\R!B=YLC)-LZ:MGH:HT#)=.;0O+/*L*FU;Z6FHL_P#
M&9CM'/<82EI%O4RVB2CV_$@(K   'UKO^%:Z49KT[^*W%+G9M3,H,][5;$O>
MR\C'[-#C-ICV$9/C6)8EK.NG15-M%%<N,.PUB_2VKR?:3>$V\:5H-EH"R4
M
M
M
M
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MJ\;>7W OVVKM_G#'C-*MC'KP22X7+U%.Y\23C;?028C1Q)D
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M$E*4I21$E*2+@B+T(@!^@
M        '2,PV9K?7K/U&?; PC!X_M+D>_F&5T.-,^PT7+CWNW4^$CVFR]5*
MYX+\ICU--T/6]9ET:1AY65.M*6;5RZZODJ0C+C[CQ-8W-MO;T/,U_4,'!MT;
MKD7[5E47-UN3BJ+Q9K3D7R'=)\76INR['ZYDJ0OVS/'9T[+T&K\]ZI=Q.!=-
MK1^85]Y)FGU3Z_?3SG&%V;[H9ZK8T3-BJ?LD8V?9X790]O+GS]CIK/4?4/V3
MTN3CD[DTZ33I]#*60O'QL0N)K@^*X<O:JXEG_+AT+AK;3'W#:6J5I-2G(&LM
MH-H:,CX)#A6F(5KAJ47J7@E1<?:?(R&SZ=N[5Q-STVW;:^^RL5U_R;TOT:&)
MY'JX["V6E;UB[=37.&%FJGR]>/!_:3/0_O?.BG\Y>1_[-L\_[B'-_=R[K_\
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M_P"PONO^1KWX2Q_"GB_WG.Q/_,.-^!ROX ?WG'13^T+CG[W<\_BH']A?=?\
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MGPDD^'C[#9>G:MI6L6?K.DY./E8]$^JS<A<CQY?%!R7'PX\3L Z9Z
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M.G+P\_VOGR7C65Z\-5\[=F@Z)7_5].O7Z>SZQ>5NM*^/U6GS5RYNE(P.B6A
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M_P ZU])6C6):E1_5[;3:ZW1._<3XR2MQ?1!RG*@-!$J
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M.ZA^/(COH2ZR^P\TI3;S+S:B4E23-*DF1D?  \P
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MRK>V:U]9+-:5T.$S48#2%&5Z%"=AX@W3KL(J2].):Y"E<<J4H_4;_P! [/\
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M:7MOIG:K8^)M+3NF=^VO,R+R5'?R9I>;=?!.G!0MI\8VH6XMMQJ;)C"#90
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M%;/J-_.OG?N.-^\6RXOT@_F)TS^4YG\ZNDFPT82;
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MK2]=OS4]5M6OJN5QK+ZQCTA*4OTUV'1?I[+JY<C<P:S-S
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MSK?K#:A_H8;_ (<96)Y^E#_@W4OZ3_\  M%7'KK_ #AZ/_0J_G-\A $IB$
M%DGX%O\ 5'LI^Z/6?^C,S$)?5M_O'1/W')_SK)9)Z"O]T[E_E.%_F9)8#$0"
MP(                              J)?,YD*[KNK95JUK4G$=9X#CS25F
MZ:6T26;/*S0V3BU)2@W,G4KA!)3Y*,^/+R,[%O3-AK%[80OI*N3G9%Q\N-'&
MUQ_!4XU=/=0J(]9VHRS>]5S&;;6'IF+97/@I*=^BKX5OM\**K?C5N* 2#(H
M >Q#B2;"7%@0VE2)<V2Q$BL(X\WI,EU++#2?(R3Y..K(BY,BY,?%RY"S;E=N
M.EN,6V_8DJM_81R6;-S(O0L64Y7IR48KVMNB7V6SZ!VM,-C:ZUS@&OH9MG$P
M7"<5PV*;)&3)QL8HH%(P;1*2A1-FU!+QY(CX_(*?=<U*>M:UF:Q<KYF7E7;S
MKSK=N2FZ^^LC^@?;6C6]N[<T_;]FGDX&%8QXTY4LVHVU3W4CP.[#RSVP
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M4ITDN*5.<@FZ9J(E&:O7U '?@
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MW[A[R[BZI^-]XY][,R57HC)J-JTFZ]-JU&ENW'V],4Y<Y-OB87&3F%@
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M.X]X:I/6MT9N1G:I<YW+TW-I5KTQ3^&$%7X804817",4CH0]<\$
M      L&_ G!><R'LW9I2@V(E-J>"XLS+W$O6,W8,AE*$\<FA2*MPU'^0R+_
M  B'GJWNQ6'H5AUZY7<N2]E(QQT_\Y?HE@WH)L3EJ&Y\E)>7"S@1?MK.66U]
MCX'7[!8_$*2R    *I_SF_K::\_\NN)?[RMMB?\ Z5/S>9G]-7OYMB%4_KF_
M.UIW_IVQ_/,\AC$FB&(                %\+J!^J7U=_\ +KI/_=KC(J9[
MC_G#U[^FLW^<W2^'M!^:7:__ *=TW^9V38H88;%   "KE\ZWZPVH?Z&&_P"'
M&5B>?I0_X-U+^D__  +15QZZ_P X>C_T*OYS?(0!*8A  !9)^!;_ %1[*?NC
MUG_HS,Q"7U;?[QT3]QR?\ZR62>@K_=.Y?Y3A?YF26 Q$ L"
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M%8>%X=K%FTA.P+23K?7+%YE1U^36$"4[$>N;"TGRTQ5J;B)A)>D)> LD
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M$,35+O1M+5W"QE5?PVIU?D9+]BM3DXW'6BLW+DJ-QBBY**U"Y,
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MOYU\[]QQOWBV7%^D'\Q.F?RG,_G5TDV&C"38
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MHP[;K;6P[N^=0MTU?6Y_1MKXH8=F3C;2KQ7G7.NZZ<)VU8EQHB9D1G)F@
M                        !QMS<5>/4]KD%Y/BU5)1ULZXN+2<ZF/"K:NL
MBNS;"?,?69(9BPXC"W'%GZ)0DS/[ !\N3Y,O^+"[Y]@]R9?0=']A/=5^LM!=
M651@TG&L:QZ9MO9%+"D+C0LUSC+<LI;BQQ>5=H;.5'J:5%:FO8>3'DNS7FCD
M* V7^%7_ (J'MI4]D=6=<?D2SN#O'1^W<NI->5^YK?'L9QS96G,@R>6BHQBZ
MN;7%JO'ZS-<!7D,UANY7:,NVD"&\N8S+<1%*#( ^DL
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M?ZBFM/W1[)_AY>BMGU&_G7SOW'&_>+9<7Z0?S$Z9_*<S^=7238:,)-@
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MSK?K#:A_H8;_ (<96)Y^E#_@W4OZ3_\  M%7'KK_ #AZ/_0J_G-\A $IB$
M%DGX%O\ 5'LI^Z/6?^C,S$)?5M_O'1/W')_SK)9)Z"O]T[E_E.%_F9)8#$0"
MP(                              H/\ 99]Z5V-W_*DNK?D2=V;5??><
M4:W'GGL[OG'77%'ZJ6XM1F9G]IF+<=CPC;V5H]N"2A'2\1)+DDK%NB*#^Y=R
M=WN/N"[<;E<EK><VWS;>5=;;][9A,9082 !.G\$>.?5;LW=EOMD?X)JRKQSW
M?N<H_2G+:^S]LN7"<X<_0_D^$*3]PN32?!*BCZL<WR]KZ7IU?UW/E<I^Y691
M]E.'G>WQY/C2=/H1T[S=[:YJ]/UC2H6:\/V>_"=.=>/U?V-<.+7"MGD04+/0
M      *F/S:VOXCW$IH?NMN?@.E,*JO!">%,>]D><7GM/'_C.'^,^9'_ .@M
M)?D%A?I=Q_)[;7;E&O-U2_/Y:6[$*KW?!3Y4RICUMY?UCO%9LU3\C1,:WP\*
MWLF[1^_Z2OR-$0(D<1   O@=0<2/!NK'7C%EM^U)K-.:^58M\*(D6\_&:ZSN
M"22VV7"3^*S'N/)*5<?:7/(J:[C:C^-=_:SGIUMW-2R.E_I(W91AXO[B*Y.G
ML+X.T&D_B+M9MW2Y*EVUHV)UK_23LPG<YI/Y\I<TG[>)L8,+-C   !6.^=Z]
M^HW%HO&?+G\(UI>7OAPU]W](LI=K_+DC]X_/]%N/O%X_=^[Z^0G1Z3L3HVUJ
MV=^V9UNWX_L=I2^3]E^7V^!6-Z[\_P S>.A:9^TZ9=N^'[-?</E_8/'A[/$@
MD$L2"1*O\->"(R_NI2WKL?WFM::^SC-24KCVFI$N)#P.,M25*)+CB59J:FT\
M*42D^9%]SR3'_P!2VK/3NV%W$BZ2SLRQ8][2;OO['T%'[G3QHY6>C705J_>J
MQGSC6&F:?DY/N3E&.*OE?\9JEQ=5U+YM5;U%<Q;T   %;3YY,Q<D9AUYU^AS
MQ:J,:SC,932?,O><R*THZ2 X[R?MJ^F3B\DF^")2?=7SR1EQ-KTEZ:H:;K.L
M-?%<OV+*?L\N,YR2\>/FQK\B]Y6UZ\M9E<UC;NWXND;.-DY$EQXN].U;BWX<
M/(G3Q74Z\T5_A+\K^+??P[:N3K_IK09+(C>Q:[:RW*,ZE*<292/PZ-,3B%$T
MHS_^K.0,9^K9(O3QEFK[5&*X_4EKSUCN7>P82KCZ=CVK"IRZFO.N/Y5*[T/]
M13P+??1UM9;?[-8^IW(].5JV7?RI5Y]$9?5[2^1PL^9'W7*^)*B-!$J0 *RW
MSK[.79[1TQJ"-(4<7$,+M\[M&6UG[2[/-;8Z> B2GGQ5)@5V(+6WR7*&YI\?
MLS$Y?2AH2L:#J>XYKZ3)RH6(OQZ;$.N5/=*5Y)^UP]Q65Z[-SO*W3HNT+4GY
M6'A7,J:7)SR;GEP3]\88[:]BN/VD->E-7V^ZMMZYU/1&I%CG^7TF-(DI1YE7
M1+&:TW96[J/M5&IJPGI3O!&?MLJX(S]!);=&O8VV-NYNX<OC9P\:=VGWSC%]
M,%[YRI!>]HAKLK:^9O7=VF[3P:K)U#,M6>KGT1G)*=Q^ZW#JN2]T67WL4QBD
MPG%\<PW&X2*['<3HJG&Z*O;]40J>D@,5M;%29^JB8AQD)Y/U/CDQ4AJ&?E:I
MGW]3SI.>9D79W+DG]U.<G*3^RVV7WZ3I>%HFEXVC:;!6].Q+%NS:@N4;=J*A
M"/V(Q2.?'3/0                            #"G976-GNSKGO[3-)8QZ
M>YVWI3:FL:BWEFZ46KL\]P6^Q6!8R382MXH\&5:H=7X$:O%)\$9@#X5FSM9Y
MYIG8N<:EVAB]MA6QM;95>85F^)7L5<.WQ[)\<L'ZNXJIT=PB-+T2;&6GDN4+
M+A23-)D9@9DZ8]9-I]Q^TFC^MFFZBZM<[VIL+'<?AOT;;YR,9J56#,C),XG2
MV&W/PJEP>@9DVLV8LO"+&B+</]CP8'W6@
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MU)2@E8I2DDD24D24I(DI2DB(DD1<$1$7H1$0ABVVZOF6*))*BY'] _0
M              "E'\G'Z]?87]T>._P#Q06?]B_S4:-^XW/W^Z4H^IS\^VX?
MY39_FM@T/&VC0X %Q;X@_P!136G[H]D_P\O16SZC?SKYW[CC?O%LN+](/YB=
M,_E.9_.KI)L-&$FP                        "H)\O>_3W#VLM,*JIWU.
M):+@*U_ ;:6I45S+7'43\_G$A1G[<UFX)JJ>X))'^$(,B_*=C?IRVA_5OM_;
MU3(ATZCJT_K$J\_)ITX\?U+A6[']V?R*H'U>[_\ ZX=UKNBXMSJTC0K?U2"3
M^%Y#?5E2IX25SIL2_DZ^5Q7#?Q%< "[A\=^A"Z\=3]9XC-B'%RK)8)[&SE*T
M&V^649DQ%G*A2FS,_"30T;4&L7QZ*.%Y?E%7'>7=W]<NX6=J-J75I]B?U:QX
MKRK+<>I/V7+CG=7ZNA=QZ=]A?V=]I],TB_#HU7)A]<R:JC\_(49=,E]]:M*U
M9?M\NOB8\^5/1)[NZAYM)K81R\JU,ZUM;'2:0:I#D?'(TIK+(:#2M+CB'L/F
MS74M$2_=D1V2))J))E[/8'=BVMW&Q87Y=.GZBGB7*\D[C3LO[%Z,%7A2,I<:
M5KCOJJV(][]H<ZYC0Z]5TEK.LT7%JS&2OQ]K3QY7)*/'JG"'"J5*:0LN*:0
M)#_B[WT>B>W6!JL9QQ,0V@:]5Y8E:S*,E&42(Q8Q8.$M:6&3KLPC0%./J+EJ
M&N01&1+5SIKOQM);L[=9:LPZM1P/XU:]OT2?FQ7B^JR[E(KG-0]B)$>EW?KV
M)W=P'D3Z-(U2N#?KR^G:\F;XT71D1M5D_FVW<IS9<]%99<\
M$#GS,]Q'L+QB)U6P&S-G(LZK6KC:\^&^:'ZG"GW/^JL22XROS;E9<ZRMV:A1
MI,JUI#:DK;FGXRS],_;:.IY\M_ZO;KA8DW#$BUPG?7S[W'FK*:4'Q^E;::E:
MXP.]9G>*>BZ7#M7H%WIU'.M*YG3B^-O&;^CL57*60TY7$Z?0Q46I1O<*RPG,
M5E  >:-&D3)$>'#CO2Y<MYJ-%BQFG'Y$F0^XEIB/'8:2IUYYYU1)0A)&I2C(
MB+D?$YPM0=RXU&W%-MMT22XMMO@DEQ;9]V[=R]<C9LQE.].248I-MMNB22XM
MM\$EQ;+57QL?&A5Z(K:C=N]*:#;[KL8\>PQK&9[+$V!J>,Z2)##G@X3C#^?K
M+Q-Z2GDJW_(QU>?NNK@%WN[XY&[+]S:^U+L[>UX-QNW8MQEEM<&O!K'^]C^R
M?.FJ=,5:KZ;/3/B[$QK.]]]687M[7(J=FS-*4<"+HTZ.J>7RZIK]9^9;=>J<
MIG!&8F<                     !5/^<W];37G_ )=<2_WE;;$__2I^;S,_
MIJ]_-L0JG]<WYVM._P#3MC^>9Y#&)-$,0 +-?P/_ /A+OG^D7&_X-."#/JR_
MXBTG^17/WTLU]!__  EKW](V?WED\(B83Q                  "KE\ZWZP
MVH?Z&&_X<96)Y^E#_@W4OZ3_ / M%7'KK_.'H_\ 0J_G-\A $IB$  %DGX%O
M]4>RG[H]9_Z,S,0E]6W^\=$_<<G_ #K)9)Z"O]T[E_E.%_F9)8#$0"P(
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MM3\:4Y2/9_GMSDF3P,;>EP6'W*J%(BUBY##;RHYNH2L@)#P
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M5;*=B,EQQL.='&B\+F2J7)OFK7EP72W=4IGA&4F>
M   '5<YPK&=D8=DV YG51[O%<OI+#'[ZKDD?MRZVSC.1I"$K3PXQ(0ESS:=0
M:7&74I6A25I29>AI6J9VB:E8U?3+CM:AC78W+<US4HNJ^5>#3X254TTVCRM<
MT33-R:-E:!K-J-_2LRQ.U=@^4H33BU7FGQK&2HXR2E%II,HW=LNN&3=5]X9=
MJ3(?J)<*ND%:8=D#S1-HRG"[)QU=#=M^*4M?4*:;5'EH1RAF='>:(S)')VI]
MO=ZX._\ :N-N+#I&[-=-ZVG7RKT:>9!^-*TE!OC*W*,O$HV[L]N-3[5[XR]I
M:AU3LVY=>/=:HK^--MVKJ\*T3A<2X1NPG%5I4UN&;&MP +'7PJ]M_KH-KU*S
M:S-4NM1999IQ^4Z1F_6FIZQS'"F#4:5&NO>6NWB-D2U*9<G&9I0RVDX5^I[M
MWY5VWW#TNW]'-QLYB2Y2X1LWW^J5+,WP55:HFY298[Z*N[?GV+O:76[OTMI3
MOZ>Y/G#C/(QE[X.N1;7%N+OU:4(HL)"'182     :'?(CVOC]4.O=W?5$UEO
M9^<_4X=J^(KA;S-U+C_]9Y0;/WC.+B%8Z<KR4E32IJHK*_1\AMGLUV^GW!WC
M:Q,F+>A8E+V4_!P3^&U7VWI+IHG7H\R2^::']1/=BWVH[>W\_#G%;GSJX^%'
MQ5R2^._3[W'@^NK3B[CM0EPF4JI,F1,D2)DR0]+ERWG9,J5)=<?D29#[BG7Y
M$A]U2G7GGG5&I:U&:E*,S,^19["$+4%;MI1MQ2225$DN"22X))<$D4J7+ER]
M<E>O2E.].3<I-MMMNK;;XMM\6WQ;/"/L^#.G6W0N6=E]S85I[#T*:F9-8I.W
MMS9]Z+C6,P>).0Y)-2:VD*9J:U"UH;-:#DR#;80?N.H(\4WMNW3MC[9RMR:E
MQMV(?!"M'=NRX6[<>?&<J)NCZ8]4WPBS.NVVPM6[E[SPMGZ.FKV3<^DN4K&S
M9C\5Z]+BE2W!-I577/IMI]4D7FM6:TQ+3FN\/U?@M<FKQ/"*.'14\4O$W5M1
MDFJ1.FNI2CZFSM9KCDJ6\9>3\EYQQ7WE&*J-?US4=RZSDZ]JT_,U#*NNY-^%
M7RC%>$81I&$>48I)<$7F[6VSI&S=NX>U]"MJUI.#8C:MQ\:+G*3X=4YR;G<E
MSE.4I/BSOP\@]\   /7ERHT&+)FS7VHL.''>E2Y3[B6F(T:.VIY]]YU9DAMI
MEI!J4HS(B(N3'W;MSNW(VK2<KDFDDN+;;HDEXMOD<=V[:L6I7[TE"S"+E*3=
M$HI5;;\$EQ;*,_=7L58=H.Q>P-GN27G,:58KQS7T)PW2;K<"H'7H>/I;8>)*
MXKULCSLI39_L9DU[CTX(K5NV&S+.Q-EX>A**6=T>9D25/BR+B3N5:YJ'"W%_
M>0B49]ZNXN1W0[C:ANB4I/3'<=G$BZTABVFXVJ)\8NXJWIKPN7)^%#5,; -4
M@ 2P_%/TLC=D]J2ME[!JRF:<U).A/S8,MA+L'-LX43<VGQ1]MY)LR:BNC^,Z
MT1PHE-''86GPE&I,>_4!W.GLC0(Z'H]SIW+J,)*,DZ2L6/FSNJG%3D_@M/A1
M]<TZVZ.6'I3[*V^Y.ZI;FW!:Z]G:1.+E&2K')R>$K=AI\)6X*EV^N-8^7;:I
M=;5NI*221)21)2DB2E*2(B21%P1$1>A$1"NIMMU?,MU225%R/Z!^@
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MV5+#Q[CAIT)JJE>@Z7,NCX-69)V[+XTO*<TE.U"190$(RR@
M          *I_P YOZVFO/\ RZXE_O*VV)_^E3\WF9_35[^;8A5/ZYOSM:=_
MZ=L?SS/(8Q)HAB !9K^!_P#\)=\_TBXW_!IP09]67_$6D_R*Y^^EFOH/_P"$
MM>_I&S^\LGA$3">(                  5<OG6_6&U#_0PW_#C*Q//TH?\
M!NI?TG_X%HJX]=?YP]'_ *%7\YOD( E,0@  LD_ M_JCV4_='K/_ $9F8A+Z
MMO\ >.B?N.3_ )UDLD]!7^Z=R_RG"_S,DL!B(!8$
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M\-B<N2XOER7$S+MUAO4>X.A:>DV[^LX5NB:3?7DVHT3?!/CS?!>)?I%19?H
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M&R;T-Z!#![;ZCN"22R-0U5P3]MK&M04*_)<NW^'Z/%I36B,!-8
M               Z#M;-EZTU=LG8[=6J[7K_  ',<V12H?.*NW7BF.V-ZFK3
M*2Q).,J><#VB<)MPT&OGQ5QP8'P]NTG>/M/W)WM>]C=_[ES;,-G6M]+O*B<6
M06\&IP!M^2N1"Q_6=,S..)@>,TB%$U"AUY,I:0DE*-;BEN* ^F'_ ,*-W[[!
M]X.@&<4W9')<FV3FO6S;QZKH=NY7)D6F09O@MCB%!D^/5N59',4[.RC,L/>F
MR8TJ?)<<ER*]V J0MQ_W'W0+0@
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MUI^Z/9/\/+T5L^HW\Z^=^XXW[Q;+B_2#^8G3/Y3F?SJZ2;#1A)L
M              *\_P YF_C8@ZQZV4DTO.<L]I9XTRZ7DF+&5-H\)K)'M\F:
M)$K\1ENLK,N#8BN<'RDRF/Z5-H==W/WOE1X07U6PVO%],[\E\B\N":^^N1KS
M17GZYM_^78TOMKA3^*X_KV4D_N5U6L:#IX.7G7)1?WMJ5.3*Y8FD5R@ 6?\
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MOV>8B#_K@WO+2-DX&Q\2;61JV2[MY)\\?%Z9*,E[)WY6I1]ODR]A5R$\RKD
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MXW_!IP09]67_ !%I/\BN?OI9KZ#_ /A+7OZ1L_O+)X1$PGB
M     %7+YUOUAM0_T,-_PXRL3S]*'_!NI?TG_P"!:*N/77^</1_Z%7\YOD(
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M/[;BW]GPY%T_I?TV.E]BM M*G5=LWKS?M=[)O7%7ERC*,?L>/,WY&HC?H
M                     !XWF6I#3K#[3;[#[:V7F7D)<:>:<2:'&G6UDI#C
M;B%&2DF1D9'P8 I1]IO^"QZW[=WKDVR>N_;?*.LFK<KO'KY_1\K24';E?BKE
MA,^KLJ37^8+VSKJ918NUYK17Q9\&W=@H-*3?>0@D "SS\=7Q[Z!^,CK%C/5O
MKO$O',5JKBVR[*<MRR7#G9GL78&0MP6+W-LMEUL&KK%VDJ!4PH+#<:,PQ%KH
M$:.E)DUY* WG
M      !0^[=;.7N3LWO'8_U"I4/(=BY"BD?6HUJ5C-)*/'L52:C,_P#)8W4Q
M$<%Z%X\%Z$0ME[=:$MM;%TK1>GINV<*WUK_2S7F7?MW9S90]W=W.]Y=SM<W)
MU.=G(U&[Y;_T-N7E6/M6;=M?8X&N@S0UT !:-^#S336,:.V!NJ?$2FWVCEY8
M]325H\E_HA@;;D?W([BO5E,[*K2P;>2GT6<%HU&?BDDP,]5&Y99VZL/;%F7\
M7P,;S)K_ $U]UH_;TVHVW%OEURIS=;1O0[LV.F;&U#>N1!++U3,\JV__ +/B
MIJJ?AU7YW5)+GY46ZT5)OQ%DG                             %23Y:^
MG?\ ('N'^6#":OZ;5&Y[2;.4S$9\(.)['=)ZPO\ 'TH;3[,2!?-I<LZ]'W4D
M7U3+2$M14\V'^GCN3_6[;?\ 5O5+G5N#3+<8U;^*[C*D;=SVN5OA:N/C^QRD
MW*XRI+U;=G?Z@[Q_KAHEKIVIK5V4J15(V,QUG=M<.$8756]:7!?KL(Q4;2(C
MA(HB, !,'\07;?\ D4W*[I/,;3Z?6NZY\2)7.2Y'MPL;V<2&X5!9)]PS:89R
MIA**J49$DW'OHEJ42&#(XW^HWMW_ %HVRMT:;;KKFEP;E15E<Q>,KD?:W:=;
ML?9'S4DW-$P?2#W<_J3O-[)UB[T[:UNY&,')TC9S>$;4^/!*^J6)\JR\AMJ,
M&6R17L6R@ 0A_,IV\_DWUS%ZTX3:&UFNUZU4W/I$-TTOT.LS?7'.J=<;6DVI
M6=3([D=2/O<UL>2AQ))D-*5*7TT]N?QWK4M\:I;KI>GSZ<=-<+F32O6EXJQ%
MJ2?#Z64'%UA)*$/K*[O?U;VY'MIHEVFMZM:ZLIQ?&UA5:Z&UREE23@UQ^AA<
M4DE<BW5O$]"K< "5'XJNG)]D-TM["S.K^IT_IV?7W-TU+84J#EV8D9S,:Q!/
MN(.-,A1WF4SK5H_<2<1#<=Q))F(46@>__<K^I6V'H^F7.G<FI0E"#3^*S9^;
M=O<.,9--V[3X/K;G%UM-$J/2IV<_M(WJMPZU:ZMGZ-<A<N*2^'(R/G6<?BNF
M44TKM^/%>6HVY)*\F6^Q7(6_       5C/G4V@=QMO3VHHDHUQ,(PBSS.T8:
M6?M%<YS:_AT9F4@CX5*A5.(H=;Y+[C<X^#^^H3I]*.@K&V[J6X[D:7,K*C9B
MWSZ+$.IM>Z4[S3]KAQY(K&]=6Z'F;NT?:%J5;6#@SR9I/AYF5<Z(J2^^C;QU
M)>Q7>'SF03"6!!( "3_XBM-,[6[B8Q>6<0I5%IZDM-G2TNMDIA=S7N1:;$6S
M69EX2HF1W+%@UQR9G /\A&-$>HK<LMO]MK^+8ETY>I78XJISZ)5G>^P[<)6W
M^Z$G_2+LV&Z^\6+G9,.K T>Q/-E5<'<@XV\=5\)1O7(W8_N3\*EPT5NEPX
M                      !2C^3C]>OL+^Z/'?X!XH+/^Q?YJ-&_<;G[_=*4
M?4Y^?;</\IL_S6P:'C;1H< "XM\0?ZBFM/W1[)_AY>BMGU&_G7SOW'&_>+9<
M7Z0?S$Z9_*<S^=7238:,)-@                     >I/G0ZN#-L[&4S"K
MZZ)(G3YDEQ+4>)#B,KD2I4AU9DEMEAAM2UJ/T))&8Y+5J[?NQL68N5Z<E&,5
MQ;DW1)+Q;?!'%?OV<6Q/)R91ACVX.4I-T48Q592;\$DFV_841.UV[YG8OL+M
M+;S[CYP,IR:2G&8T@UDN!AU0ANGQ*";2R23+K-! CF\24I)4A3BS+R48MC[?
M;6M[+V=@;<@EYV/87FM?=7I_'>E7Q3N2ET\Z1HN2*(>Z^^+W<;N%JF[[CE]7
MRLF7DIUK#'MTMV(T\&K48=5$JS<G2K9KR,R->'9L*Q"]V#F.*X)C$7Z[(\SR
M*EQ:AB<J2F1;W]C'JZYI:D(<4AM<J4GR5XGXIY/CT'0U34<31]-R-6SY=&%C
M69W;C]D+<7*3^6B=%XGIZ)H^=N#6,30=+AUZEFY-NQ:C[;EV:A!/G1=4E5TX
M+B7X-0ZTH=-ZNP'5>,MDBDP+%:;&8;GMH;<FG60VV9=I*2@B2<ZWFDY*D*_Q
MWWEJ^TQ4?N/7,O<NO9>OYS_C67D3NR7-1ZFVHK]+"-(Q7A%)%^&T-LX&S=KX
M&U=,5,' Q;=F+I1RZ(I2G*GW5R59S?C*3?B9&'BF1@ :V=OM(,=B>M^V-3^P
MT];Y!B\J7B;CI(+Z;-*!;=[B3I/J0M<9IV]KF67UHX6<5UU'V*,CS?MQNF>S
M-[:?N&K6/9OI7:>-FY]'>5/%JW*4HI\.I1?@:U[O[(AW%[;ZMM/I3R\C%E*P
MWX9-JEVPZT;BG=A&,FN/1*2Y-E$M]A^*^]%E,NQI,9UQB1'?;6R^P^RLVWF7
MF7"2XTZTXDTJ2HB-)EP?J+8(3A<@KEMJ4))--.J:?)I^*?@RB6Y;N6KDK5V+
MC=BVFFJ--<&FGQ33X-/D>(?1\F8^O6WK;0F[=9;?IC=.3@F65MO+CL&27+*C
M6M4'):;R,R\47F.3)4-9\D9(?/@R/U&-;QVYC[NVMG;<R:=&7CR@F_N;GSK4
M_P#$N*$U[XF9=O=WY>PM[Z9O##KYN!EPN22YSM/X;UOY+MF4[;]TF7TZ&\JL
MGHZ;)**:S94>0U-=>4UC&42X\^JMH;,^NFL++T6S*B2$.)/\J5$*D\O%R,'*
MNX.7%PRK-R4)Q?.,X-QE%^]--,OIP,[$U/!LZE@3C=P<BU"[;FN*G;N14X23
M]DHM->YG+#KG;        "GC\O6SGMA=T\RI6Y'OU.J\=Q77M82%J]GWFJTL
MIO5>V9^*9+609/)C.*XY449)<F24BR/TY:%'1^V&-E-4R-0O7<B7MHY>5;X^
MQV[49)>'4_:RGCU>[GGN'O5FX49=6)I6-8Q(4Y54//N\/:KM^<&_'H7@D1@C
M>Q&  "=?X--,MY!M?:.\+.*3D776,PL.QMQU*3061YPZ^]9SHBN#4F35X[2N
M1U^I%[5K]A\_=BAZJ]S/#V_@;5L2I<S;\KUVG[78248OW3N34E[[7AXSL]#.
MS(ZANO5-\9,:VM.QHX]EO]NR6W.4?TT+-MP?Z6_X^%G405+.@
M             "J?\YOZVFO/_+KB7^\K;8G_ .E3\WF9_35[^;8A5/ZYOSM:
M=_Z=L?SS/(8Q)HAB !9K^!__ ,)=\_TBXW_!IP09]67_ !%I/\BN?OI9KZ#_
M /A+7OZ1L_O+)X1$PGB                  %7+YUOUAM0_T,-_PXRL3S]*
M'_!NI?TG_P"!:*N/77^</1_Z%7\YOD( E,0@  LD_ M_JCV4_='K/_1F9B$O
MJV_WCHG[CD_YUDLD]!7^Z=R_RG"_S,DL!B(!8$
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MYM?8<J(V9&#&S
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M(Z!';':3;VCJ/3<CI=FY-4I2[D1^L753V^;=G7Q]O$VD&!&T@
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MJSR,VSBQ?L6/:=Z:7ZKZS!OV],?83Z"(I/H
MI1_)Q^O7V%_='CO\ \4%G_8O\U&C?N-S]_NE*/J<_/MN'^4V?YK8-#QMHT.
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MOGPH^5%;WZ-MOQT?LM8U%QI=U3/R<EOQ:A-8L??2F/6*Y?$Y+YU7*N- $JP
M                       "J?\ .;^MIKS_ ,NN)?[RMMB?_I4_-YF?TU>_
MFV(53^N;\[6G?^G;'\\SR&,2:(8@ 65_@ONZ6JU1O5NTMZNM<=V'CBVD3Y\2
M&MU"<;<2I3:9#K9K21^AF7)<B$'JLQ<K(W#I,K%NY-+#N5Z8MT^E]R999Z%\
MW"Q=IZ['*O6K<GJ-EI3G&-?H7RJT3I?IAB/_ ,4XY_[[K/\ I0BE^+=1_P#I
M[W^1+_ 3I_'&D_\ U6-^%A_WA^F&(_\ Q3CG_ONL_P"E!^+=1_\ I[W^1+_
M/QQI/_U6-^%A_P!X?IAB/_Q3CG_ONL_Z4'XMU'_Z>]_D2_P#\<:3_P#58WX6
M'_>'Z88C_P#%..?^^ZS_ *4'XMU'_P"GO?Y$O\ _'&D__58WX6'_ 'A^F&(_
M_%..?^^ZS_I0?BW4?_I[W^1+_ /QQI/_ -5C?A8?]X?IAB/_ ,4XY_[[K/\
MI0?BW4?_ *>]_D2_P#\<:3_]5C?A8?\ >'Z88C_\4XY_[[K/^E!^+=1_^GO?
MY$O\ _'&D_\ U6-^%A_WCW(.04-F\<:MNZBPD$A3AL0;*'+>)M)I)3AM,/.+
M\$FHB,^."Y(<5W#R[$>N_:N0A6E91DE7Y6CFL:A@9,_+QK]FY<I6D9QDZ>VB
M;=#EQUSM@    %7+YUOUAM0_T,-_PXRL3S]*'_!NI?TG_P"!:*N/77^</1_Z
M%7\YOD( E,0@  LD_ M_JCV4_='K/_1F9B$OJV_WCHG[CD_YUDLD]!7^Z=R_
MRG"_S,DL!B(!8$                              4=?D"JG*;NGV2B.^
M[Y/;1O;4O>94POV[WV+MGA"N34T;-@GVU_8XCA9>BA:AV?R(Y/;'1+D:46!;
MAP=>-NL']FL>*\'P\"CKU XDL/O3N6S*M7JEVYQ5.%VEU</92:H_%4?B:>C9
M)IX "WI\-'ZDU'_2+L#_ ._X@KE]2_YT;O\ (L?_ #66]>C3\R5C^D<O_/B2
ML#0!*P      "K7\ZE,MCL?J;(#)SV[/24.F29FW[)KHL[S2:X2$E^=)PDY$
MGR,_NF1IX]24)Z^E')4]E:CA\.JWJCG[_I+%F/R4^C=/LU\"K7UU8<H=R-)U
M#CTW=$C;\*5M963)T\:_3*OARIXD(XE(0C-M^A<U^!W,ZU/QS23B]N8E"5Y)
M\B]BQGIKY)$1_8HXTI9$?Y#X/\@UWW;M0O=L]<A/DM.O2^S&/4OT4C;?86].
MQWFVU.W3J>KX\?L3GT2_0DR\J*JB\L     JZ?.O1G'[":?R3CTMM-)H_+S4
M?)X]F^4SS+VS22$^/Z3?:2C-7/!D7!<SR]*&5U[.U+!_:]3Z_P )8M1_\+_V
MJ5<^NO!\ON%H^I>%W1O*_!9-^?+_ -]]G['&#X2G(/EOGX;7WGND>-MNNK<1
M%V!L%B.A:C4EAE5LU)4TV1^B$'(D.+X+_&69_E%<GJ5A&/=*^XI)RP\=OWOH
MI5_827R(M]]&UR<^R.-&3;C'4,M+W+S%*B]U6W\K9*F- DJ0   IX?,%2'5=
MY]@SS:0W^DN*ZXNR6@W34\3&&U6.>ZY[B4H)9'CYH_-F:/%!>OEY$5D?IPRO
MK':G#M5;\C(R8>'"MZ=RBI^Z5X\:OV4*=_6#@O$[Z:A?HE]9Q<.[X\:8\+-7
M7Q^BIPX42\:G5?B>_7^T'_\ E3_W+;&'H>H/\T.K_P#X+_/<8\KTG_G_ - _
M_#O_ -FYA<Y%9A<Z   'SV\WHSQG-,OQLV2CGC^47]&;"5NN$P=3;2X!LDN1
M^?637T_CRO[Y\>OKR+BM*ROKVF8V:G7SK%N=>''K@I5X<.-?#A[#^>W7,%Z9
MK69IK72\?*NVJ<73R[DHTJ^+I2G'C[2\MT[>9?ZD]7EL.MO(3UZTRRI;2TN)
M)Z/KK'8\AHU(,R)QA]I2%I^U*TF1\&1D*JNY,90[B:\I)I_CG-?'V/)N-/Y&
MFFO:N)>7V=G"YVDVO*#3C_5[3EP=>*Q+*:^5--->#33XFQPPHV.
M
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M3LY^)=)EW4U^U35,ZVX8,9+C;QGPG?HUPED-=-MK]@3DFXWVE.^(FD\
M    H/=E+Q63]B]]Y&ISWOQW<^T+9+A)<;2;=AFUW*:)#;IJ<:;2VZ1)0H^4
M)(B_(+<=D8JP=EZ1A)4\K3,6'^38@GQ7!NJXOQYE!W<K.>I]Q=?U%NOGZUFW
M*\5PGDW9*B?%*CX+P7 PH,H,*  M\?#91LU/23'9[7CYY/L'8-Y(\?+GWH]J
MSC2?/R,R\OI\>;_8\%QQ^7D5R>I;*ED=T;UF7*QAX\%\C@[O_3<9;YZ-<&&)
MV1QLB-.K*U#+NOY5<5G_ *+*Y?\ 22J#0)*H
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M
M                       ([/EA_4!WY_\ DL_WTZY&YO3Y^=[2/_PK^99)
M'7U8?F U_P#_  '_ /:6&4QA9F4Q@ =YU@S#D[+UY'L?#\/?SG$F9WN.FPW]
M&[?UZ)/N/I6VIE'L*5RLE)-)>O)?:/)UZ5V&AYL[-?.6)><:*KZE;E3AQKQ\
M*<3W-KPLW=RZ=;R*?5Y9UA2JZ+I=V"E5U5%2O&JI[3Z"8I\/Z"@
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M"$)(B(B(B(B%4<I2E)RDVY-U;?-LO4C&,(J$$E!*B2X))<DE[#]C\/H
MZ9L;!*+:& 9KKC)F??Q_.L6O<3N$$E*G$P+ZMD5K[T<U?Y.7&1(]QE9<*;=2
ME23(R(QZ>BZMEZ#J^+K6"Z9F)D6[L/9U6Y*23]SI1KQ3:? \7<>A8.Z-OYNV
M]3CU:?GXMVQ<7CTW8.#:]DE6L7S4DFN**#.QL$O=7Y_FNN,F9]C(,%RF]Q.X
M025);5/H;*16OO1S5_E(DE<?W&5EREQI25),R,C%N>BZMB:]I&+K6"ZX>7CV
M[L/;TW(J23]ZK1KP::?$H,W'H6=M?<&;MO4X].H8&5=L7%X=5J;@VO;%TK%\
MG%IK@SI@],\8]NOL)U3/@VM9+?@659,C6%?.BNJ9E0IT-Y$F)+C/(,EM/QWV
MTK0HC(TJ(C(<5ZS:R+,\>_%3L3BXRBU52C)4::\4TZ->PYL?(OXF1#*Q9RMY
M-J<9PE%TE&46G&2:XIII-/P9?"ZL[KA]B.OVK-P1C9*5E^+1'<@C1S3[4#+:
MQ3E-EU>VE))-+,/(Z^2AKE*34R2%>)$HB%36_MKW=F[PS]MSKY>-D-6V^<K,
MJ3LR^5VY1;YT=57@7P]K-ZV>XG;[2MX6NGS<S%B[L5RAD0K;R(+W1O0FH\%6
M-'15,_C$#/P    ##'8[]7G?/]#&T?X#W@R;97_&6D_TGB_O]LPON1^;S7OZ
M%SOYM=*#0MS*#0   OA=0/U2^KO_ )==)_[M<9%3/<?\X>O?TUF_SFZ7P]H/
MS2[7_P#3NF_S.R;%###8H                        !5/^<W];37G_EUQ
M+_>5ML3_ /2I^;S,_IJ]_-L0JG]<WYVM._\ 3MC^>9Y#&)-$,0
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M\
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MQX)+PHKA?1YFK*[&X%A-MXV9F6VFZTK?E=HE7@J74Z<.+;IQJY0QH<E"
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MX%O]4>RG[H]9_P"C,S$)?5M_O'1/W')_SK)9)Z"O]T[E_E.%_F9)8#$0"P(
M                             KJ?/1B:R>ZW9TRURVIO8^)V+WB?W%H5
MB-Q2M>1$9'[A.3SX,R,O'TYY/B9WI*U!=.MZ5)\:XUV*_#0F_L?1_;*ZO7II
M+Z]MZ[!?"UF6)OY/J]RVOLUN_:X5XTKO"997< !9%^!:]2]BW9/&361+K;_6
MEZELTH(U)NZ[,J]Q:%^?FX2#Q])*+Q(D>1>I^7I"?U;8CCGZ)G4X3LY-O_(E
M9E]C]<?R\?861>@O/4]+W+IE>-K(PKM/W6&1!^]_K2KPX57M+ XA\6"
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MIO\ 9,6;C*,5]]*W?<G^EM>XLY""Q9R
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M?V2^7M/KD=R=LM UI2ZIW])Q7-_Z6-J,+J^Q<C-?8Y+D;!##S8(
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M8[3L?JZKVGY&5C3Y<&KTK\%P]EJ_;7MI1NO-R:#1A)H
M        JG_.;^MIKS_RZXE_O*VV)_\ I4_-YF?TU>_FV(53^N;\[6G?^G;'
M\\SR&,2:(8@ 6:_@?_\ "7?/](N-_P &G!!GU9?\1:3_ "*Y^^EFOH/_ .$M
M>_I&S^\LGA$3">(                  5<OG6_6&U#_ $,-_P .,K$\_2A_
MP;J7])_^!:*N/77^</1_Z%7\YOD( E,0@  LD_ M_JCV4_='K/\ T9F8A+ZM
MO]XZ)^XY/^=9+)/05_NG<O\ *<+_ #,DL!B(!8$
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MM7;5^U&_9DIV9Q4HR3JG%JJ:?BFN*9[ ^#D
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MHIW?#6^UMW;%R5<S1<V<*<Z6,EROVI>WC=>1%+V0X/P4Q C:3$
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MI6Z/BK4TY9,O;T^0I6FURE>@RG6+)2G4 #+.B]KR=&;:PC;D#&*#+[/ K?\
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M;_@TX(,^K+_B+2?Y%<_?2S7T'_\ "6O?TC9_>63PB)A/$
M   *N7SK?K#:A_H8;_AQE8GGZ4/^#=2_I/\ \"T5<>NO\X>C_P!"K^<WR$ 2
MF(0  62?@6_U1[*?NCUG_HS,Q"7U;?[QT3]QR?\ .LEDGH*_W3N7^4X7^9DE
M@,1 + @                             #43OO@:MD=-NQ.+MM^\^G6UO
ME$1DD$XI^=@3D;/($=I!_:\_,QMM#?Y26HC&QNT>K+1.Y>BY[=(?7H6F^5(Y
M"=B3?N4;K;]QJ'OYH+W)V;W%I<56XM-N7XJE:RQ6LJ"7O<K*2][11N%J91N
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MQ-\*HE$&AB40
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MC7'X?#=I;<FTHPO3DW1%QP5KEQP
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MLG^'EZ*V?4;^=?._<<;]XMEQ?I!_,3IG\IS/YU=)-AHPDV
M    %1'YA-^EMSM/*P&HG?58GHFL7A$9#2TKBN9G/6Q99[-:X,U(DQYJ(M2^
MD_'ARH]"_*=B_IOVA_5W8,=7R(=.H:M<\]UYJS&L<>+]SCU78^Z]]A5$>L+?
M_P#6[NG/0,2YU:3H-KZM&CK%Y,VIY4E[&I*%B2]N/]EQ0B01%
M           "6GX<]]_R4]HT:ZMIWTV*[TISQ)Q#JO&,UFM1]1;83+<XY4;T
MIPYE6TDBX4[9IYX(N2CSZD]H_P!8-AO6L>'5J&DW/.5.;L3I"^OD7P77[K3I
MS):>CG?W]5.Z*V[EW.G2M=L^0T_FK)MUN8TG[Y/S+$5XRO*O*JMQBNPMR
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M%KP::::]I>OAY>+J&):S\*<;N%?MQN6YQ=8SA.*E"47XJ46FGXIG(CA.R
M                    %4_YS?UM->?^77$O]Y6VQ/\ ]*GYO,S^FKW\VQ"J
M?US?G:T[_P!.V/YYGD,8DT0Q  LU_ __ .$N^?Z1<;_@TX(,^K+_ (BTG^17
M/WTLU]!__"6O?TC9_>63PB)A/$                  *N7SK?K#:A_H8;_A
MQE8GGZ4/^#=2_I/_ ,"T5<>NO\X>C_T*OYS?(0!*8A  !9)^!;_5'LI^Z/6?
M^C,S$)?5M_O'1/W')_SK)9)Z"O\ =.Y?Y3A?YF26 Q$ L"
M                /1M*V%<UMC463")5=:P9=;/BN%RW)A3H[D64PX1^AH>8
M=4DR_P !CEL7[N-?ADV&XWK<U*+7A*+JG]AHX,K&LYF-<P\F*GCW82A.+Y.,
MDXR3]S3:/GX;!Q"=KW/LWP&T)16>#Y?DN(6)+2:%E.QJZFTLLEH,DFA12(2N
M2,B,C%P6CZE:UC2,75['ZQE8UJ]']3=A&:_0D?S[[AT>_M[7\[0,JOUG!S+V
M//\ 56;DK<OT8LZ@/2/(-B^H><%K?M'H#-''OIXE/MC"2M7N4E[='9WD2HOC
MY41I]::>^7Y/_E+[1A?<;2OQWL/6-,2ZKEW3[_0OT\8.=O\ [<8FQ>T.N?U;
M[H[?UJ4NFS9U;&ZW[+4[L;=W_P"'.1?!%31?"        %9?YUM6JJMGZ:W%
M$CD4;,</ML$MW6D\)3:X7:?B]<]*/@B.185F6K;;/DS-N 9>A)+F<OI0UY9&
MA:GMJX_CQLF%^"?WE^/1)+W1E93?ON>\K+]=>UGB[HT;>-J/T69AW,6XU]_C
M3\R#E[YPOM+W6O<0-B6A TFO^#G9/Z.]B=B:UDOI9A;*ULJQB-FK[TK(\"MF
M)E>PE''!^./7UNZ9\\E[?'!\F91>]5.B?7=F86N05;N#G=+]UO(@U)_A+=E?
M9)L>AS<OXN[BZCMJ[)*QJ>F]<5]]>Q;BE!?@KN1+['OX6G1 <M.     (@/F
MBTN>PNKD#9=?$-^\TCED2Z=<0DENIP_+UQ<:R1EM!%[ADFU54RG%),R0S#6I
M1<%Y)D=Z9-S_ (GWY/0[TJ8NJ8[@EX>=9K=M-^'S/-@O;*:2]CA_ZT=E_P!8
M>UUO<V/#JSM$RXW&^;^KY#C9O)+G^N>1-M<HVY-JG%5,A865,EO7X=]QM[+Z
MA5&'3)1/9!IC)+G!IB%GS)<H9SZ\GQ68LB^X45N#<.5S/'!F5:?)<_>57+ZD
M=M/0^XUS4K<:8>IV(7U[/,BO*NQ^7J@KDOW5?(K>_1WO*.Y>T-G1[TJZAHN3
M<QI)_.=J3\ZQ)_I5&X[,?W%U]KE7&@"58   1X_)_P!?5;_ZFYJS4PSEYEK$
MRVCB26D)5)D.8U$E_I'5-?8ZZ=IBLF833*3Y=F-L>BC(B&Y.Q.\%M#N%BRR)
M=.F9W\5O5Y)76O+F_!=-U0JWR@Y\JD>/4_V^?<#M-FPQ(=>LZ7_'L>G-NS&7
MG6UXOKL.YTQ7SKBM\&TBGGKK.K[6&?89L;%WRC9%@N44>5TSBS7[1V%#8Q[*
M,S)2A23=AR%Q_;>;,_%QI2DGR1F0LBUG2<37=(RM%SUU8678G:FO'IN1<6U[
M&JUB_!I-<BGG;NNY^U]?PMQZ7+IU'!RK5^V_#KM34TI4YQ;5)+DXMI\&7WM7
M;$Q[;>N<(V=BC_OX]G>,4^3U9FKEUF/;0FI1PY)>*3;FP'5J8?09$IMYM23(
MC(R%1^O:-F;=UK*T+4%3,Q+\[4_8W"374OTLE247XIIE]^UMQ:?N[;F#N?2I
M=6G9^+;OP]J5R*ETR]DH-N,ES4DT^*.^#R3W@ -4^Z76NL[5]?,SU8_],QDA
ML%D>O;629(;J,\I&9#E$\\\;;IQX%F3SM?,6E"EIA3'307F2>-@=L=[W^W^\
M<77X]3P:^7D07W=B;2N)+A64:*Y!52<X1KPJ:I[T]M<7NMV^S=JSZ8ZET^=B
M7'RMY5I-VFW1TA.LK5QI-JW<FTJT*I_1GL;?=+.T,*=F#%C38O*LYFL]U8[+
M8>;EUE85G]%.FR8'M//(N,%OHJ99H2V;ZT,/QDFGWU&)_P#=;9>)W.V'*UIK
MA=SXVUDX5Q-4E+IZHQ4JI=%^VW"K?2G*$W7H15/V,[C9_9;NC"_K$;EG2YW9
M86I69)J4(=?3*4HT;5S%NQ5RB76U&=I4\QEU.',B6,2+85\J-.@3HS$R%-AO
MM28DR)):2]&E19+*ELR(TAE:5H6A1I6DR,C,C%8=RW<LW)6;T90NPDU*+333
M3HTT^*:?!I\4RZJS>LY%F&1CSC<L7(J491:E&49*JE%JJ:::::=&N*/9'P<@
M
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MZ/6?^C,S$)?5M_O'1/W')_SK)9)Z"O\ =.Y?Y3A?YF26 Q$ L"
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MH]J=QWO_ +XPK;>!.3_7L:*J\>KYW,=<;:XMX]4DHV&W.Z(G$[P
M
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MI/Z7&NM5<)*BZH-I^5=BNBXDZ4G&<(;/#!#9X
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M36G[H]D_P\O16SZC?SKYW[CC?O%LN+](/YB=,_E.9_.KI)L-&$FP
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M(N-_P:<$&?5E_P 1:3_(KG[Z6:^@_P#X2U[^D;/[RR>$1,)X@
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M3NNW8WCAQ4<S'3I5\$LBS%MMV+C^5VIUMRX=$Y[[#4AOL
M
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M6-_PE<$3/5E_P]I'\MN_O2)X>@__ (MU[^CK/[\RS6(,EFP
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M6C[AT^WJVA96/F:9=587;-R-RW+Y)0;55XJM4^#29V<=$],
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MFJHG%C96-FX\,S#N0O8EV*E"<)*4)Q:JI1E%M2BUQ33::Y'O#B.<
M          *I_P YOZVFO/\ RZXE_O*VV)_^E3\WF9_35[^;8A5/ZYOSM:=_
MZ=L?SS/(8Q)HAB !9K^!_P#\)=\_TBXW_!IP09]67_$6D_R*Y^^EFOH/_P"$
MM>_I&S^\LGA$3">(                  5<OG6_6&U#_0PW_#C*Q//TH?\
M!NI?TG_X%HJX]=?YP]'_ *%7\YOD( E,0@  LD_ M_JCV4_='K/_ $9F8A+Z
MMO\ >.B?N.3_ )UDLD]!7^Z=R_RG"_S,DL!B(!8$
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MC8WZ'^Y2O8>=VNU.Y]+9;R\)/QMR:63:C^IFXWHQ56_,O2Y1X6#1#PL'
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M1GP>Z@U@;J
M                                BB^1OXY*3M)22]GZPB5]%V HJ\B(
MS-F#6;0K(+/BQC^0/J]MB-D,9ALFZVR<,B(B3&DJ]CVG8D@NRW>G*V%E1T+7
M93N[0NS]\I8LI/C<MKF[;?&Y;7OG!=?5&Y%#U&^G+![I8,]T;7A;L=P+%OW1
MAFPBN%JZ^"5Y)4LWG[K5U^7T3M5+\JQ7),'R.ZQ#,*2RQO)\=L)%5>45Q%=A
M659815FA^-+C/)2MM:3]2/\ 8J29*29I,C.PO U#"U7"M:CIMV%_ O04X7(-
M2C*+Y--?^R?!\2I?5=*U+0]1O:1K%B[C:IC7'"[:N1<9PG'@XRB^*?Z#7%53
M. '<.@   &ZO7WY!^U/6UN'5X/L:5>X=")"&< V V]EV(LQVT\-Q*UB7)9N<
M<AI/[WMU4V"E2C,U$?)C5^\.SNP-[2E?U7"C:U*7/(QZ6;S;\9-)PN/WW87&
MO W7V^]0G=3MM&&+H>HROZ/#@L3+3R,=)<HP4I*Y9CXTL7+2;YU)@M2_.O@=
M@U&A;OTSDF-3/N-/WVMK.!E%6\M7[*2N@R%['K&KCH4?JA$RP<\2Y+D_NB.&
MX?2AJUF4KNUM3L7[7-6\F,K4E[O,MJY&;][A;7R<R8.TO79H.1&-G?&C9.->
MX)W<.<;\&_OG:NNS."7L5R\Z<57D;\X3\G_1W.6V?I=YU&.3'$H-VOS:DR;$
M7(JEJ0GVWK"XIX]$XI)N%R;,MU!$1GY<$9EJ+5.Q'=32F_,TJY>MKE*Q.U>K
M\D83=S[<$_=Q-^:)ZH.QVNQCY6NV<:\UQADV[V.X\N#G<MJT^?W-R2YNM$S8
MBF[0=:LB0RNA[":2MR?<98:17[4P:4\<A\D&S%4PU>J>;EK]U)>TI).$9D1I
MY]!AN3L3>^$VLO1]4MT3;ZL6^E1<W5VZ4X<^7O-B87=#MIJ*3P-PZ)>ZFDNC
M.QI.KI2-%=JI.J^%JON.W_ROZE_G1UU^_;&O^\QYO]7-P_\ T&;^ N_]T]C^
MN&TORIIW^TV?^^=%N.UW5_'V"D7/8O1M>VI+BVDO[5P8GY!,^W[I18R+Q4F6
MIOW4^26T+,O(O3U'K8W;[?F9/HQM%U6;X5IB7Z*O*KZ**M'S:/"S.Z_:_3X>
M9F;CT.W%ITKG8U72E>F/FUE2JJDGS->LU^4CHUA*74/[N@9+-1[GMP,*QS*\
MH5(-HR)1-6==2*H$<FHO$W)C9+^U)F1&99CI?87NKJC3AI4[%IT^*_<M6J5]
ML93\SY:0=/$UYK7JD[&Z(FIZY;R;RK2.-9OWZT]DX6_*^2MQ5\*\31?9WSLZ
MWKD2(NGM)Y?E,CQ4VQ;; NJK#H#3O!^,DJFB_2Z;81B5]C:I$)Q1?::#]!M?
M0O2?K=YQN;DU3&QX>,,>$[TFO9UW/)C%^]1FE[S1>Y_7;MO'4K6S]$S,JY2B
MN9=RWCP3]OEVOK$IKW.=MOVHBVW5\J'<?<R9D!.PF]78Y+2MM5!J>&YBJO:4
M9EPO*')5CFJE+:/Q<2BR;97Z_FR(^!OK;'8+MKMEQO/#>?FQX^9ER\WC^Y)1
ML<^*K;;7WQ%K>OJH[R;S4\=:BM+TZ:IY6!%V.'OON4\GEP=+RB_O2QS\7=U-
MR#HEH:UL779$UZ+L&/)DR'W9,B4Y7[8SNN.5(D/J6\[(E%$]Q:E&9FM1^HA9
MWYQK6'W8U;'LI*TI8[22224L2Q*B2X)*M%[D6.^EW-O:AV(T'*R&Y7W'+3;;
MDY.&?E0ZFWQ;ETU;?BS?P:A-_            5MOGI_UNZU_N<V9_I/#!-GT
MD_[NUO\ =L;_ #;Q6WZ]?][;:_DV;_GXQ7\$P"OT ">'X'__ !:WS_1UC?\
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M2HSR?-F1'SO%GV'4'Z$IMUJU4VM/)?:1F0\6>V=R6YNW<T_.C-<T[%U-?*G
MR.WO39UZ"NV=6TR=N2X-95AI_(U.C.'M>Q/7ZB]W\<WIIRF]AM+S_P"*[.PJ
MN]EE7[%UWZN[9]MM7Y%'P1CLX^S-X9=/JNDZE=JZ+HQ;\JOV*D'5G4R^XO;[
M K]>UW1K/2JOS,W&A1>U]5U47O,'Y;\BG27"R>.W[&:_G&QYDI.)2++/#6:%
MNMF3)X179 E[R4R?B:3-)D:5$?BI)GE.G=F.Z.IM?5]%S(5_;E&Q[.?GRMTY
M^/O7-,P?5_45V2T5/ZWN/3[G37_5W/*K2JX?5H7:\N%/<^33>FVQOF\ZQ8TA
M]C7V'[,V98()1QW_ ,-K<,QQ\R\B)+EE=39%^P:C(C_[)67B?^'T&R]%]+6^
MLYJ>L9.#@V7S75*]<7^+"*MO\,C36X_6]VPTR,K>W\/4]3R%R?1#&LOY9W).
MZO\ 9W_U$:NXOFH[0YZW)KM:U.&:6JGR<0B74POTQRY+3J20IM=[DS"Z5)I1
MSXN1ZB,\@U&I*R,DFG=^V_3#L/291O:Y<R=4R%3A.7DV:KQ\NT^OY5*]*+Y-
M4K6-6\?6IW1UZ,L?;5G"T7$E6DK<?K&11^#NWD[?R.&/"2YJ5:4VH^%;:V=[
M/VSV1M]EYOE>=938XE@<M%KE5U97LI$2'>Y,F1'COV$A_P"BB-/6C?M1VB0R
MA/HA*4I(A@'J>V_I.A;>T3&T/%Q\3 AD9"Z+4(VU5V[5&U%+J;4763JWXMMF
MU/15NO7=T;LW)E[ESLO/U6YB8LE<OW)W9*,;MZJ3FWTQ3FNF$:12X))(L/"&
MQ8>   %*/Y./UZ^PO[H\=_@'B@L_[%_FHT;]QN?O]TI1]3GY]MP_RFS_ #6P
M:'C;1H< "UG\6?8GK]KWICKW%L^WIIS!\FA7VP'IF.9?L["L:O8C,W-+J5#=
MDU%U=PK!AN7%=2XTI;9$XVHE)Y(R,5_=^]F;PUCN9F9^D:3J65@RLXZC<LXM
M^[;;C9@FE.$)1;333H^#5'Q+6O2SW%[?;>[,:=I>OZ[HV#J<,C+<K.1FXUF[
M%2R;DHN5NY=C-*46G%M<4TUP)#_ZW_4O^U%UU_VV:U_C,--?V<=P_P @ZU_L
M63_!$A_[7^TO_-&W?_,L/^&'];_J7_:BZZ_[;-:_QF#^SCN'^0=:_P!BR?X(
M?VO]I?\ FC;O_F6'_##^M_U+_M1==?\ ;9K7^,P?V<=P_P @ZU_L63_!#^U_
MM+_S1MW_ ,RP_P"&'];_ *E_VHNNO^VS6O\ &8/[..X?Y!UK_8LG^"']K_:7
M_FC;O_F6'_##^M_U+_M1==?]MFM?XS!_9QW#_(.M?[%D_P $/[7^TO\ S1MW
M_P RP_X8?UO^I?\ :BZZ_P"VS6O\9@_LX[A_D'6O]BR?X(?VO]I?^:-N_P#F
M6'_##^M_U+_M1==?]MFM?XS!_9QW#_(.M?[%D_P0_M?[2_\ -&W?_,L/^&/=
MK>UO5RYL8%14=D]!6MM:S8M;5U=;N+7<ZQLK&<^W%A0($*+D3LF9-F274MM-
M-I4MQ:B2DC,R(<5_M_OW&LSR<G1-7MX]N+E*4L/(C&,8JLI2D[:2BDFVVTDE
M5G/C=UNUV9D6\/#W+H%W+NSC"$(:AB2G.<FHQA",;SE*4I-*,4FVVDE4SZ,1
M,^  C)^67?O\BG4O)Z&KE^QEVZ)/\F%*EM?#S-)9QG9.<6)H)2%G'3C#+T$U
MI/EN18LJX,N2&\_3WM'^M'<.QEWXUT[3(_6I^QSBTK$?E\UJY3QC;DB,GJRW
M]_4KM+E8&+/IU?6I?4K=.:M3BWDSIP=/(4K55RG>@^)3I%DQ3H !(G\6VBOY
M<>WV _B$/ZK%=6^YM?)O<;\HZ_T5DQ/T8A.^9>P]]9F,R!YL*Y]V*V]]TTI5
MQIGOUNS^JO;C,\F73GY_\4M>WZ5/S9+Q7395RDERDX\:M$B?2WL3^O'=_ ^L
M0Z]*TJN?>JN'T$H^3%^#ZLB5JL7\Z"GP:3+G(K,+G0                ,<
M[>UK2;CU=L#5F1D7X/GV)W>+RWO;)U<([6"]'BV<="C27UE5,4W)9/DO%YI)
M_D'M;<UO*VUKV'K^%_K.'D0NI5IU=$DW%^Z:K&7N;,<W?MK!WEM;4-JZC_J>
MH8ERQ)TJX]<6HS2^^MRI./LE%,H/9IB-Y@&893@N313@Y'AN0W.+WL,R7_FU
MO0V$BLL&DFZVTXI")491),TI-2>#X+D6XZ9J.+J^FX^JX,NO"R;,+MM^V%R*
ME%\*^#7B4':UI&=H&L96A:G#R]1P\BY8NQX\+EJ;A-<4G3JBZ<%5'6AWCS0
M+HGQA[Z+?'4;7\BQG?5Y=K1L]5Y;[KJ7)2Y&*1HK>/6#YF27GE6F(R(#KCRR
M,W97O$:EJ2I0K([[;2_JEW%S(68=.G9S^M6:+A2ZV[D5X+IO*XE%<H]/!)I%
MT7IAW[_7SM%I]S(GUZOIB^HWZNLJV(Q5J;\7UX[M2<G\Z?7Q;39(0-.DA
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MK:W9UW4<#"O7-0M.,;^1:LN25EIN*N3BVD^#:JJDVG]8[KS_ #\Z8_VHX/\
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M+_M1==?]MFM?XS!_9QW#_(.M?[%D_P $/[7^TO\ S1MW_P RP_X8?UO^I?\
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M]424&Z6,I^W&G)\+CYO'F^O]KE=2ETRK#0!*L
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MN*"N25IMVZNC?!TKPK[Z<RT"T[KM1=Y)7NE=27%*5.*3\57D>P/@Y
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MR<?KU]A?W1X[_ /%!9_V+_-1HW[C<_?[I2CZG/S[;A_E-G^:V#0\;:-#@
M           &9NN/ZPVAOZ9]7?PXHQC.]?\ @W5OZ,ROWBX9GVW_ #AZ#_36
M#_.;1?F%1A?F !41^83?I;<[3RL!J)WU6)Z)K%X1&0TM*XKF9SUL66>S6N#-
M2),>:B+4OI/QX<J/0ORG8OZ;]H?U=V#'5\B'3J&K7//=>:LQK''B_<X]5V/N
MO?851'K"W_\ UN[IST#$N=6DZ#:^K1HZQ>3-J>5)>QJ2A8DO;C_9<4(D$10
M M7_  I:*_0+KQD6Y+6'[-]NO(U?A3KK?#R,&PA^?357@3A>ZQ^(9&]:/*X\
M4OL)CK^\1(,5_P#J@W9^-]Y6=M8\JXFEV?C2Y>??49S]SZ;:M+VQEUKAQ+6/
M11L3\0=O,C>67"F?K>3\#:XK%QG.W;Y\5UWG?D_"45;EQ23)G1&8F<
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M]K)E>BS?JV[W%O[.S)].G:YCT@F^"RL=2N6O<NNT[T/;*?E1K6B=KD5^%K@
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M]W?3AOWM1=N9URT]1VDFW'-L1;C&/_VFTG*6/)<*RDY6G5*-V3K%1]#<)'T
M               "SA\$+[RM/;UC*=6<=G95"^TR:C-MMZ1BZ&WW4(^Q*WD1
M6R4?Y207^ 07]64(K<FDS276\&XF_&BNNB^Q5_;99QZ$+DWL_7;3;\M:G::7
M@F["3?RM15?D1.X(G$[@   JG_.;^MIKS_RZXE_O*VV)_P#I4_-YF?TU>_FV
M(53^N;\[6G?^G;'\\SR&,2:(8@                6C?@I_5YV]_3.Y_ ?%
M! SU7_\ &6F_T9_X]TM&]"GYO-8_II_S:P3?B+).    *N7SK?K#:A_H8;_A
MQE8GGZ4/^#=2_I/_ ,"T5<>NO\X>C_T*OYS?(0!*8A                 !
M?EZX_J\Z&_H8U=_ >C%1F]?^,M6_I/*_?[A?EVW_ #>:#_0N#_-K1F<8R9H
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MV[!*_FW4O/N\FXQIPLV>I)JS!TX1=R5R<>LW&&MC<8
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M/L_M'B:'NS%N8>I0R<B<;5SHZXV[EQSCU*+;BVW)],Z35>*2H2%#3I(4
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M)Q^O7V%_='CO\ \4%G_8O\U&C?N-S]_NE*/J<_/MN'^4V?YK8-#QMHT.
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MR^=;]8;4/]##?\.,K$\_2A_P;J7])_\ @6BKCUU_G#T?^A5_.;Y" )3$(
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M3?BVVV3:PL+"TW$MX&G6;6/@V8*-NW;A&%N$5P480BE&,4N2227@<F. [0
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MZ_SG=F3+2ODXRL@Q"GK7&_S)^#C4#"3LO,U(61J3+07@OCQ)1$H8[F^JC?\
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M#]I?E[4?P-G_  C^X?U+_/SL7][>-?M@?WLMQ?DG"_"71_</VE^7M1_ V?\
M"/[A_4O\_.Q?WMXU^V!_>RW%^2<+\)=']P_:7Y>U'\#9_P (_N']2_S\[%_>
MWC7[8'][+<7Y)POPET?W#]I?E[4?P-G_  C^X?U+_/SL7][>-?M@?WLMQ?DG
M"_"71_</VE^7M1_ V?\ "/[A_4O\_.Q?WMXU^V!_>RW%^2<+\)=']P_:7Y>U
M'\#9_P (_N']2_S\[%_>WC7[8'][+<7Y)POPET?W#]I?E[4?P-G_  C^X?U+
M_/SL7][>-?M@?WLMQ?DG"_"71_</VE^7M1_ V?\ "2.],>GF-=,L$RG!<9S&
M\S2)E.6JRV1/O8$"!(BR%4]93_2,MUZE-K9]NL2OR5][R49?80TKW,[D9W<S
M5L?5L[&M8MS'Q_)4;<I2377*=6Y<:UE3[!(_LQV>TWLSH65H6F9E_-LY67Y[
ME=C"#B_+A;Z4H<&J03J^-6;B#6QN(   (X>YWQQ85W-SO%LZR;9&4X7+Q;$D
MXE'@4534SX\J.FXL[CZMYRP4EQ#WN6:D>*?N^*2/[3&ZNV?>K5.V>DY&DX.%
MCY5O(R/.<KDYQ:?1&%$H\*4C7[)'#O/Z<=$[S:[BZ[J>I96%>Q<3R%&U;MS4
MEYD[G4W/BG6;5%PHC3S^X?U+_/SL7][>-?M@V3_>RW%^2<+\)=-._P!P_:7Y
M>U'\#9_PC^X?U+_/SL7][>-?M@?WLMQ?DG"_"71_</VE^7M1_ V?\(_N']2_
MS\[%_>WC7[8'][+<7Y)POPET?W#]I?E[4?P-G_"/[A_4O\_.Q?WMXU^V!_>R
MW%^2<+\)=']P_:7Y>U'\#9_PC^X?U+_/SL7][>-?M@?WLMQ?DG"_"71_</VE
M^7M1_ V?\(_N']2_S\[%_>WC7[8'][+<7Y)POPET?W#]I?E[4?P-G_"/[A_4
MO\_.Q?WMXU^V!_>RW%^2<+\)=']P_:7Y>U'\#9_PC^X?U+_/SL7][>-?M@?W
MLMQ?DG"_"71_</VE^7M1_ V?\(_N']2_S\[%_>WC7[8'][+<7Y)POPET?W#]
MI?E[4?P-G_"/[A_4O\_.Q?WMXU^V!_>RW%^2<+\)=']P_:7Y>U'\#9_PC^X?
MU+_/SL7][>-?M@?WLMQ?DG"_"71_</VE^7M1_ V?\)-I@.)1\!P3"L%ARWK"
M)A6)8YB46?)0AJ1-CXY3PZ=B6^VURVV]);ADM24_=)2C(O01=U?49ZOJV5JU
MR*A<RLBY><5Q47<G*;2;XT3E15)M:!I-O0-"PM"LSE<LX6)9L1DTDY*S;C;4
MFEP3:C5I<*L[:/./7                  #^*22B-*B)25$:5)41&2B,N#(
MR/T,C($VG5<S\:35'R*-/>30:^MW9W9^MHT)</&/QE>48&9H\67<(R@UVM&S
M&7PDGD4I.N5KBR))'(A.<%P0M5[5;N6]MB8&MW)*6?Y7E7_:K]KX)M^SKHKJ
M7WLXE&G?+8,NVW<_5-MVH.&E^=Y^+['C7_I+2C[5;J[+?W]N1J4-B&I3;[HA
MO@NN?:75FQ)TLXN+O7/Z)9RHU$EC]#LM25-:S)/W5+6U0NR&;,DIX-3D%)<\
M&9'KCNSM+^NFPL_1K4>K/5KSK'M\ZS\<$O?<2=JO@IMFW^P^_%VY[IZ5N*_/
MHTMWOJ^5[/J^1]'<E+W6FXWJ+F[21>-2HE$2DF2DJ(E)4DR,E$9<D9&7H9&0
MJM::='S+QDTU5<C^@?H      'ADQH\R/(AS([,N)+9=C2HLEIM^/)COMJ:?
MCR&'4J:>9>:4:5H41I4DS(RX'U"<[4U<MMQN1:::=&FN*::XII\4T?%RW;O6
MY6;T8SLSBU*+2:::HTT^#37!I\&BD3WWZPR.JG8O+,$@Q9:,"NU%E^LY\@G'
M$2,1N'75MUGU2DD4B7C-@AZN>,S]Q91T.J(B=3S:3VCWW#N!LO'U:[*/XWM?
M0Y,5X7H)?%3P5V/3<7@NIQ7S64B=^^V%SM5W&R]"L0FM OOZQA2=77'N-TAU
M>,K,U*S+Q?0IM)31I>-G&ERYC\8?:5OLKUNI(M[8G*V;J9$'!,[1(=2N;9L1
M(A)Q7+E_?4ZZC(J9CP>=7PIRQB2_3Q))JK/[Z["ELC>UVYB0Z="U!ROV*+X8
MMOZ6S[%Y<W6*7*W.WXUI<SZ8>Z<>Y?;:Q:S[G5N?25'%RJNLIJ,?H,A^+5ZV
MJ2DZ-WK=WA2C<C8TL2-     ..N*BKR"IM*&\KXEM2W==.J+>KGLHDP;*KLH
MSL*PKYL=TE-R(DR(\MMQ"B-*T*,C]#'-C9-_#R+>7BSE;RK4XSA.+I*,HM2C
M*+7%.+2:?@T=;,P\74,2[@9UN%W"OVY6[D))2C.$XN,X23X.,HMII\&G0I<?
M(-TWM^H6YY=96QYDO4F<.SKS5U\\2W"37I=;78XA8R#-1*N\2=EMLK49\R8B
MV)!DE3JFV[..SW<K&[C;9C?ON,=Q8JC;RK:^^H^F]%?>7DFU][-3AQ44W2YZ
M@^S>9V@WI/&QHSGM+.<KN#==7\%4YX\W^V8[DHMUK.V[=S@YN,<==->U65]1
M=T4VR*1,JSQF82*38>)-/^VSE.(R7VURV&TN+1';NZM:2E5SZC+VY*"2H_9<
M>0OVNY>P-/[B[8NZ)E=-O.C\>/>:XVKR7!OQZ)?-N17.+JOBC%K'.S7=75>T
M6]+.Y,+JNZ9.EK+QTZ*_CMKJ2JZ*Y!_'9D^4U1OHE-.[;K_/L2VEA6,[#P2Y
MBY!B.7U$6ZH;:(9^W*A2D\^+C:R2[%F174J9D,.)2]'?;6TXE*T*257.L:1J
M.@:I?T;5K4K.HXUQPN0?-27L?)IJCC)54HM23::9=OM_7])W3HF+N+0KT<C2
M,RS&Y:N1Y2C+VKG&476,XM*4))QDE)-'<!YI[     !"S\D/QB0M[%=;RT-!
MAU.Y&8KL[*L-90Q#J]J*9)"E38KRG6(U3G/L)47NK+V+-1)2\;;OD^N3O93O
MK=VGY6U=VSE<VTY*-J\ZN>+7[EJC<[%:<%\5I5<>J-(*%GJ0],-C?:O[YV';
MA9WDHN5_'2489U/NHNJC;R:5^)_#>=%-QG6;KIZ8W7N7J7ME.88).L<.S;&I
MLJBR;'+J$^W$LXT68EJZP_,L?EDPX]$7(B^#S2R:DQ7T$ZRMF0VVXB9VYMK[
M:[A[>_%NK0ADZ7?BKEJY"2;BVJPO6;BK1T=4U6,HMQDI0DXNNG9F]MY=I=V?
MCC0IW,/6\:<K5ZS<BU&:C*ES'R+4J-Q;C247TSA)*4)0N1C)6\.F/>_4_<7%
MR.C?;Q/:-/":>S#6-I-:<M(7"6D/W..2#)G]),65)7X)DMH0]'4:4R6F5+;]
MRNCN;VFW#VVS_P"-)Y&@W9-6<J$7TRYTA<7'R[M./2VU+BX2DE*EO'9COOM/
MO'I=<&2Q-TV8)Y&%.2<X\D[EE\/.L5=%-)2@Z*Y"#E'JWB&JS>(      &L.
M\^FG6GL:E]_:VJ,<N;UYHVDYC6-.XWFC1DA*6%*RB@=K[:<B(:"-MF6Y(C%Z
MD;9I4HE9WM3N7OC9;4=OZA?M8B=?)DU<L/V_17%*$:^,H*,OTU4FM8;Y[-=M
M.XRE/=>DXU[/DJ?6()V<E>SZ>TX7)*-.$;CG#PZ6FTXBMO?!+4/F_.T1NN;7
M*_.*8QO:M4W8QU+6HE-I_2_%(T)^*PT7*>%4TE:BX,U\D?,BMN>K#(A2UNS2
MXS7C=Q)N+_ W7)-O]VBO=[(B;O\ 0EB7.J_L/6YVWQI9SK:FO=_&+"BXI<N.
M/-OV^W30^B?RA=89,B5JO]-SK(RU..3]'[1]VNGJ-1\DYB2;:DO[-#A_>-+U
M2M)GQR7(V8N['8??<%;U_P"J^?)44<[%I*/_ +[HG;C\JO+[1II]B?5#VPNR
MN[5^O?5HNKEIF=6$_EQ_,M79I\Z2L->WB>ZW\@GRD:.2<;9$',51*U'"V-OZ
M.35^VTV12E.2;AG&\6MY:%L)4KW79;AFTHS)7!),N)]G^PNZGUZ)/&\R;YX>
M=UU?+A!W+L%Q\%!<>#7.O-'U!>J38R\K<EO,=FVN6H:9T42^*KN*S8N25*OJ
ME<?PNJ=*-=[HOG2['Q4,HR+56EKGVU<.NU<3-J%Y]HF4H3Y&_E]XRB2;Y&M:
MTMDV9'XI;3QR/)R_2ELJXV\+4-4M5Y*3L7$G7W6;;I3@E6OBVSWL'UT]R+22
MU'2M%O4?%PCDVFU3WY%U)UXMI4\%%<SM?]_!MK^8;77[Y,E_:QY_]TW;WY7S
M?P5K_">K_?PW;^0=._#7O\!UZY^=;L*^2_T?U!IFL,R;]L[E&;WI(,C+WC64
M+*L=]PEI]$D1I\#]3\OL'<QO2ALZ%/KFI:G<YUZ/(M_)\ZU<^SSK[CS\SUU]
MPYU_%^CZ+:Y4\Q9-WY:]-^S6OARI[S#=I\L'R!;.?<J\(MZJDE/)6A<'6FK*
MVYG>VZT9&EK\?A9I8,*]ME:DK;4EQ)^2DJ+Q+QR6QZ?.S^A05_5;=R[;7W63
ME2A'@_'RY68OFDTZI\$UQ=<-RO5AZ@=SW'BZ'>M6+K5.G"P87)4:\/-CDS7!
M-IIIKBT^"IUN3J3Y5^TIFQDE'V3R*JG$E!P\_MK;7>'.,R#\E/,5.7V&)XPM
MAQ/!J6PP?FE)%Z\)(=Z&XNP&POCPKNB6<B'W6/"&1>JO!SLQNW:^Q2EPX^\\
MV[M'U6=TGY>I6-RY&+/[G+N7,3':?BK>1.Q9H_%QCQ22XT1L)JKX-]\9&J/+
MVULK ]95[G@IVOHF9^P,E:(B-3C3\=I6.XZRI7HE*VK*21<F9I/@B5AVX/53
MM+"3M[>P<O.O+E*XXX]I^]-^9<?R.U'V5]FPMJ>AO?FI.-W=NI8&F8[YPM*>
M7>7M32\FRO8G&]/VTX4<J^E/B1Z>ZC5#L;O$[+<>11C2Y^);1G-6M,EXT\.I
M:PRMCUF*R(:C]4MSXT]:/_SAGZB/^Z/41W(W$I6<7(AIN%+ATXL7"=/"MZ3E
M=3]KMRMI^PE9LGTD=GMHN&3G8EW6=1CQZ\Z2N6Z^-,>"A8<?8KL+K7WS)*JN
MJJZ.OB5%+6P*BJKV4QH%95PX]?7PHZ/V#$2%$;9C1F4<^B4)2DO\ TC?R+^5
M>ED94YW,B;K*4FY2D_:Y-MM^]LDIBXN+@X\,3"MV[.);C2,(14(12Y*,8I**
M]R21[XX3L       :_\ 8SLWJ#JU@K^=[9R-%;'63S5!CD F9F69?8M(2K\+
MQFE4^PN<^1N()UY:VHD5*R7(>:0?D,PV7L7<>_=66D[>L.<U1W+DJQM68O[J
M[.CZ5SHDG.5&H1D^!K_N-W.VAVMT*6O;MR5:MNJM684E?R)K[BS;JG)\5U2;
MC;@FG<G"/$PCTU^0#4_<Z1F-/A]+DN'97AK;%E+QO*?PYV18XY+D?21[VMEU
M<J5'=;8EFAF4TKQ7'<>;X-Q*R4,I[E]H-P]LH8V3J5VQDZ?DMQ5RUU)1N)5=
MN2DDTVJN#55)*7)JAA'9KU ;3[SW,S#T>QDX>JX24Y6;_0W.S)]*NPE"4DTI
M4C.+HX.4:=2E4WN&IC>X
M
M
M
M
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MJ$;\H5\JS"+<O(LU2E)=33N7))=;C'IC%1^*2@:1)*
M
M
M
M
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MW(6SNY']6-0N*&B:]&-CB^$<N#;QI?X[E.Q1+C*[!MTB6WQ7<6X
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M&W>/\?Z&^UVO7:ZQIMMSPI2?&[B+G97MGC-_"JU=B44DHV9,G.$4R<X
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M?1"-778X84;'
M
M
M
M
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M0VA*4(0A))0A"2)*4I2DB2E*4EP1%Z$0CLVVZOBV2X244HQ244N"/T/P_0
M
M
M
M
M
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M:Q=V]H]O-PM:A;=R%K*C;CYUN/SG:E;N7(N4$TYPDXRZ?BCUQC-QD'&G20@
M
M
M
M
M                                                       $!_S5
M]45Y)C%%VHPZN4Y<89&B8EM*/%:-2YF)R)AIQK)UMLM<J<QZTFKB2G5&I2HL
MM@S\6XIF)<>F#N"L'/N[!U*=,;*D[V*V^5Y+Z6UQ?[)"*G!*BZH2YRN$!_6M
MVH>I:78[J:-;;S,*,;&<HKC*PY?0WZ)<[4Y.W.3JW"Y#E&TRM&)PE:)YHTF1
M#D1YD.0]$EQ'FI,65&=<8D1I##B76)$=]I2767F74DI"TF2DJ(C(^1\3A"[!
MV[B4K<DTTU5-/@TT^#37!IGW;N7+-R-ZS*4+T))QDFTTTZIIKBFGQ37%,NS?
M'YVIC=L.O..Y=9263V-BGM8;M"$CVFUGD];&:-K(6XS2&DM0,NKE-SD>#:66
MGUOQT&KZ=1BKSO!L"?;[>5[3K$7^)<BM[%EQ_6I-UMMNM9695MNK;<5";IUH
MNS]/W=2UW8[>8VKY,H_UCQ*8^;'@GY\(JEU)4I#(A2ZJ)1C)SMQKY;9O -6&
M\          "KW\M?0IS6>16/9S4U,?\G>76GN[,Q^LBJ]K",LLWN?TD8882
M:8^+Y3-6?O'PEN'9.$DC\)+2&YW^GCNVM<PX;%W#=_\ OG&MTQKDGQOVHK]:
M;?.[:CR\9VU7G"3E5[ZMNPDMLZC<[G;2L_\ XNY=VN;:A'AC7YO]>27*Q?D_
MBY*W>=*]-V$8P;B51!LG!^)_Y 4ZFNJ_K7N.[]K663VA-:YR>S?/Z; ,GM)!
M^5%8273,HF(9).=(TN&9,UT]9N+\67WW68L>H/L^]PXL][[:M5UVQ;KDVHKC
MD6HK]<BESO6XKBN=RVNE5E",93@])_J!6T\VWVUWE?IMC*NTP[TWPQ+\W^M3
MD_FX]Z3X/A&S=;E*D+DY0M%B!I:,        &A/=SH+K'N-C7UDHF,.V]205
ML8ELB'$)QY;3:7G&,=RV,V:%7>-.R7/(N3^JA+,UQUD2GFGMM]K>[NN]ML[R
M[=<G;EV=;V-)\*\*W++?S+J2_4S7":JHRCH3O=V"VQWCTWSKO3A[OL0:Q\R,
M:MI5:LY$53S;+;K]_;=96VDYPG40WOU_VKUNSR=KO;6,R,?O(WF] EI\I-'D
M=63JVF;O&K8FT,6M5)-'HM))<:5RV\AMU*VTV+[3WAH&]M(AK.WK\;V++A)<
MKEN5*N%V'.$U[.37&+E%INH???;_ '5VVUZYMW=N++'SHU<)<[5Z%:*[9N42
MN6W[51Q?PSC&:<5LATM^0/;G3V[;K8#KF;Z@LIOU&1ZQMICC<5IQY:3DW6'V
M"DOJQG(#27WS2A<287I(96M+3K.%=SNS^W>Y&*[]Y+%W'"-+>5"-6TN4+T>'
MFV_95J</N)).49;([+>H+=W9[-6-8;SMH79UO85R344WSN8\^/DW?;1.W<Y7
M(2:A.%M#KGVBTUVFPMG,]2Y0S9>TVP5_BU@;$',<1F/)/_,,EHBD/O0U&M*D
MM2&U/0I7@HV'G4D9BO/>FP]R[!U-Z9N&PX5;\N[&LK-Z*^ZM7*)/P;BTIQJE
M.,7P+:.W/='9O=/15K.TLJ-RB7FV)TCD8\G]S>M5;CQJHS3E;G1NW.253848
M<;#          .!R3%<8S*ID4.88Y0Y712_^=4N24]?>U,G[BV_\XKK2/*AO
M?<<4G[R#]%&7Y3';P<_/TS(67IM^]CY<>4[4Y6YKY)1::^PSH:EI6EZSB2P-
M8QL?+P9_.MWK<+MM^'&$U*+X-\UXFA^R?BPZ1[(5(DKU$U@UI(,S_$];7=OB
M26",S,RCT#$F3A[1<G_^#3,N."X+T&V=$[^=TM$48+47EV(_<Y,(7J_+<:5Y
M_A#0^Y/2QV1W(Y7'I"P<J7W>'=N8]/DM*3QU^!-&<X^!W7LOW7-:[_S+'B(W
M%,Q<XQ*DS'W"X_-,NSZ&=@OLGY?LG"C.>GV-_P"':VE>K/6;=%K>CXU[VNQ>
MG9I[6HW(WZ_)U+Y31FN>@[;UZLMM;@S<?G2.38M9%?8G.U+%I[WT/]2:KY3\
M&792N6ZO$MFZ:R>,A7"$64[,,9LWD&;"4J1%+%;RO2HC6X:R5,21(01I-2E>
M)9]@>JO9%Y):C@ZG8N/[V-F[%<_'S82]E*0YOC1*IJO5/0QW*QVY:3J>C95I
M/AURR+,WR^Y\B[#Q=:W%P7"K=%@ZW^'SO-6DLX6 8GD'BTIQ)5&Q\/9-Q:34
M11T?CUE2$3JR21D:O%O@RY41\D658WJ0[4WZ>;F9%GC3X\:\Z>_Z.,^'Z/N,
M&S/1[WSQJ^3I^)D45?H\S'5?<O-G:XOWT7M:.C3_ (KN^]<RE^1H":XA3A-$
MF!L'4]H\2E)6LC5'K,\EOH;X0?*S22"/@C/DR(_5M=_>T=Z73#6(ITK\6/EQ
M7VY6$J^ZM3P[_I6[^8\%.YM^;BW3X<O F_M0RI.G#G2GA6K1_('Q7]]K)M;L
M?K_.;2VOVU%/S_5%4X:O$E<H9L\[AO.(X5^R2DT\^G/)&/V]W][1V9*,]8@V
MU]SCY<U]N-AI?)S/RQZ5^_>3%RM[?FDG3XLO!@_M3RHMKWI4.ZU'Q =Z;(FS
MFZYQC'S6VM:DV^R,)>-I25^),N?@-Q=I-QQ/WB-)J1Q]JB/T'EY/J.[46*^5
MFW[U']QC7U7W_20AP^6C]Q[>'Z/^^N2EYVFXN/55^DS,9T]S\JY=XOGPJO:T
M^!F_&O@T[-V"T+R?8^EL;C*\B4F%:YCD-DV:341&J*G#ZN :5\$9&4LSX/U(
MC+@8MG>JO8ME-8&%JE^Y^FA9MQ^WYTY?]@S?3?0SW.R&GJ>I:+C6OTL\B[-?
MXOU>$./[I\OL-J,)^!S!XJFG-C]@\KO4FKR>AX3AE1BBD(X3RTU97MMF9.JY
M(S]PXB"]2+P].3P#5/5GJMQ..BZ/CVGX2OWIW?LN-N%FGR=;^7V;4T3T&Z':
M:EN/<.7?5>,<;&MV*>Y3NW,FOR^6ODX<=XM:_%-TDUNMF4K5CNP+-@TFBPV5
M?VF3(42>.4O4#3M;B3Y+47)^=<H_R%P1F0U7KGJ [HZVG;6>L.P_N<:W&U]J
MXU*\OL7#>6VO2EV2VW)77I3U#)C]WF79WE]FTG#'?V;+^T;YXIA>'8)5(H\'
MQ/&<-I&C)3=/BE#5X[5-J))((T5]1%AQ$&2$D7HC["X&I=0U/4M6R'EZKD7\
MG*?.=VY.Y-_XTVW^B;YTK1=&T'%6#H>)C86$N5NQ:A9@ODA;C&/Z!V8=$],
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MY4\R3@[:E"LBR\(/%EX
M
M
M
M
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M*2BEP1^A^'Z
M
M
M
M
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M1],7J1M[ZQK>Q-\WXQWI:C3'OSX?7K<5RD^3RH)/J7!WH_&DYJX32",9-(
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M*%NJ5+5M0MJBDXN=9/:P:_-K
M
M
M
M
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M!+31-P:#N7"6I;=S<7.T]NBN8]V%V%>=.JW*237BGQ7BCMX\T]@
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M*4I2DB2E*4EP1%Z$0CVVVZOBV2Q244HQ244N"/T/P_0
M
M
M
M
M                                               #H>T-:XAN+7V7
M:PSVL3;XCFM+*H[J$9DAWV)!)6S,A/FA9Q+.LEMMR8CZ2-<>2RVXG[R2'K:#
MK>I;;UC'UW2+GEZCBW5.$O"JYJ2\8R3<9QY2BW%\&>#NC;6C[QV]E[8U^TKV
MD9MF5JY'DZ/E*+X],X22G;DN,)QC)<4BC_VMZU9EU3W-DNJ<L2Y+BQ'/Q/$,
ME)A3$/+L0FN.'3WD4CY0A\T(4Q,92I11IK+K7DHDDM5IO;_>^F]P-LV-P:?2
M-R2Z;UJM96;T4NN#]WW4'PZH.,J*M%1_W6[:ZSVIWGD[4U9.=J#Z\>]2D<C'
MDWY=V/A6B<;D4WT7(SC5I)O6\9L:W-]/C[[FV_3[<3%I9.3)VI,X7!I=HT$<
MEO.)@-.NIK<NJHZ>?.]Q1R6XXA!$?U41Q^/]U3K;K6I.\/;/&[D;:=BPHPW%
MBJ4\6X^'Q-+JLS?[7=22;^XFH3XJ+C+?7I][S9G9[>,<K)<[FT<YQMYUI5;Z
M4WT9%M>-VPY.27W=MW+?!RC*-T*AO:;**2GR7';.%=4&05D"ZI+BM?;E5]I4
MV<5J;7V$*2T:FY$29$>0XVM)F2DJ(R%9.7B9.!E7,'-MRM9EFY*$X25)0G%N
M,HR3XIIIIKVET.!G8>J8-G4M.NPOZ?D6HW+5R#4H3MSBI0G&2X.,HM--<TSE
MAUSM@         &%]]Z UAV3UY::TVKC[5U1SB6_7S6_!B[QFY*.]'AY%C=B
M;;BZVY@$^KP7XK:<0:FGD.,K6VK)]H[OUW9&LV]<V_>=K*APE%\87853=NY'
MAU0E3BN#3I*+C))K"]^]O]K]R=NW=M;KQU?P9U<)*BN6;E&HWK,Z/HN1JZ.C
MBU6,XRA*473@[C=+-I=.LY_ \M85>X->292L$V-717D4N1PFG'#1"FD?N(IL
MIBQDDJ57K<6:.?-I;K)I<.RCMMW.T'N3I7UK3GY6JVHKS\:377;DTOBC]_:;
MX1N)*O*2C*L2G#O'V5W3V=UWZCJT7?T*_*7U7,A%JW>BFZ1ES\N_&/&=IMT^
M=!SA23T[2HTF2DF:5),E)4DS(TF1\D9&7J1D8V2TFJ/D:<3:=5S+"OQZ?+*J
MO*BTCVLOENPN8M1A>Z+):G'8:>#8AT^RI/WEO12/VVF;M1>31<'/,T>Y+1#G
MO'Z>E>\W=/;^RE=XSO84>4O&4\9>#YMV.3Y656EMV%^GGU9O'5C9'=:^W8^&
MWC:C/BX^$;>9+FX\HQR7QCSOMKJNQL81I,>9'CS(<AF7$ELM28LJ,ZV_'DQW
MVTNL2([[2E-/,O-*)2%I,TJ29&1\"%\X3M3=NXG&Y%M--4::X--/BFGP:98Q
M;N6[UN-ZS*,[,XIQDFFFFJIIK@TUQ37!H\P^3[          ,2[=T/IW?5!^
MC6X-=8QGM4A+Q0_QN 1V=2I\DI>?H;Z(N+?8]+=2DDJ>@R8[II]/+@9#MS=F
MY-I9?U[;>;?Q,ATKT2^&=.2N6W6W<2^]G&2]QB6[]A[.W[@?BS>&G8N?BI/I
M\R/QVZ\W:NQZ;MJ3Y.5J<)4X5(2>P'P:U,PYUYUJV6NG>4;CS6 [/)Z;6<JX
M7]/5YO3Q7+*&TV1&EIJ97S%K-1>Y*21&HY1[/]561:4,3>^"KD>">1BTC+Y9
M6)OIDWS;A<@EQI;?(A)W ]#6)>=S.[:ZF[,^+6+FUE#Y(9-N+G%+E&-RU<;J
MNJZJ-N%C=O3[LGUX>E'M;4N54-/&7X_I;"B%D&%/(4\;,=:<NH5V-$PN5Z*0
MP^^S)(E%YM)5Z%)W:W<C9&\HQ6W]1Q[V3)?K,GY=]<*OZ&YTW'3QE&+C[)-<
M2%>]^SW<KMW.3W7I&58PXO\ UB,?-QGQHG]8M.=I.7-1E*,^*K%/@8:PG86>
MZTN6\BUWFF58+?-$E*;C$;^TQZQ-M*B7[+DNJE17G6%&7WFU&:%%Z&1D,FU3
M1M(US&>%K.+CY>(_N+UN%R/RTFFD_>N*,-T3<.O;:S5J.W<W*P<]?LF/=G9G
M3V.5N46U[4^#\428ZC^9+MYKPH\+,IN([CIVB)M2,SHFZN_0R1I,BC9#B2J1
M3CY>)E[LV/.49*/GD_$RT;N+TU=N=9K=TR.3IN2^/T-QRMU]]N]U\/="4%^C
M63&T?63W>V[TV=9GAZSAKA3(M*%U+]+=L>55_IKD+KX\:\*26:Q^<O0^0?3Q
M=J:PV#KB:[XI=G4,BKS_ !YA7V+=D2$_HQ?(;/[22U72%%]G_*>D-=]*F[</
MJN:!GX>;:7*-Q3Q[C]R7TMNORW(DEML>N;8>H=-K=6EZAIMY\Y6G#+M+VMOZ
M&ZE[HV9LWYU_\@?3/9:&/T<[#:\AR)'BE$#,;)[7T\WE$7^;HBYU&QUQ]\E'
MXD37N$H_V)J^T:BUCL_W,T-OZ[HV9*"^ZLQ61&GMK8=Q)?+2GC0W[M_U!=F=
MRJ/XMW#IT+DN4<B;Q)U]G3E*RV_#X:U?*IME3WE)D4%%GC]Q5WM:Z?BU84]A
M$LX+BO%"^$2X3S["S\'$GZ*^Q1'^4:^R<3*PKKL9ENY:OKG&<7&2^Q))FV</
M.PM1L+*T^]:OXSY3MSC.+\>$HMKDUX^)R@ZYV@        ]"SM:NEAO6-Q90
M*FOCI-<B?9S(\"&PA*34I3TJ4XTPTE*4F9FI1$1$.:QCW\JZK.-"=R]+E&*<
MI/Y$DVSKY.5BX5EY.9<MVL>*XRG)1BOEE)I+[+-8<[[S=0-;E(+*^Q&KFY$0
MB.37T&21\SMV#47)(=IL,*_MD.FDR/P-GS\3(^.#(SSK2>U7<?6W'\7Z-GN$
MN4KEMV8/Y)WO+A3W]5#6&N]\^T&VU+\:[BTM7(?.A:O+)N+W.WC>;<K[NFM*
M.E&:,;&^;CJWC"7F,!QC9>SYZ4K./(8J(.'X\ZI)\)2[89%,3?,>?VD953G!
M?;Z^@VMHOI<W[GM3U>_@X%KQ3G*]<7R1MQ\M_A4:,W'ZW.UNEJ5O0,74]4OI
M<&K<<>R_EG>EYJK^X,CMVK\W_8[*RDQ-781@&IH#Q*]F;);E;!RJ(?)^)MV5
MPU5XPX1)^TG*17)^OH7H-S:!Z6=E:?TW->RLS4;RYQ36/:?RQ@Y75]B^B.VZ
MO6_W'U7JM;6P=/TG'?*34LN_'Y)W%"R_LXS_ .HC%VOV1WUO%]UW;.VLYS=A
MUU+Y5-O>RTXY'=0OW$+@XO#7%QRN-*_4O8BMD1D7^ AO3;^R=I;5@H[>T[$Q
M9I4ZX6UYC7Z:[*MR7^--D8MU]R=^[YN.>[-7SLZVW7R[EV7DI\ZQL1Z;,./W
ML$8FIJ2YR.RB4V/5%G>W$]PF8-330)=I93'C(S)J)!A-/RI#AD7[%"#,9%DY
M6-A6)9.9<MVL:"K*<Y*,8KVN4FDE\K,2P\+-U')AA:?9NW\RXZ1MVX2G.3]D
M8Q3DW[DB370_Q$]L]OJA666T4#2&*2/!UVRV*IUO)EQU%][Z+!('NWK<U!F7
MYFS.J29<_?Y(B/1F[?47V\VXI6-.NSU74(\%'&H[5?TU^5+?3[[7F_(2;V'Z
M1.[.\'#)U>Q;T/294;GF55ZGZ7%A6ZI+[V]Y"Y_%X.;_ *[?$GU9T@J!=974
M2-X9M$]IW\8V%'CKQ>-+;)7FY58!'6[1$RLS)24V:K5UI22-#J3$6=Y^H??V
MZ5/%T^Y'2M+E5=&.WYK7LGD.EROOM*TFGQBR<';OTD]K-D.WFZM9EKFMPH_,
MRTG8C)>,,15M4?-*\[\HM5C)$G\:-'AQX\.''9B1(C+4:+%C--L1XT=AM+3$
M>.PTE+3+++222A"2)*4D1$7 T1.<[LW<N-RN2;;;=6V^+;;XMM\6V2?MV[=F
MW&S9C&%F$4HQ22225$DEP22X)+@D>8?)]@           :C=GN[W7[J5&KD[
M3R2;(R2W;5(JL%Q&&Q>YC,A()1'8N5SLVOA5=<IQ/@V_.DQ6WG.4MFLT+\=B
M[$[6;P[ASF] L1CA6W2=^])V[,9?>]2C*4I>+C",G%4<J55=1]S^]_;_ +26
MK:W5DSEJ5Y5MXN/%7<B4?OW!RA&$*\%*[."DZJ+=)4]+JKWIT)W 3>Q=6V.0
M5N38U&:L+C"LUJHM-D\>H>>:C-73#=;9W=/8UGUCJ67%QICRH[JD$\EOW63<
MY-_]J=W=MW:N:_"S/!OR<87[$W.TYI-N#<HPG&72NI*4$I)/I;Z94X.U7?38
M7>!7[6UKF1;U/&BIW,;)MQMWE;;45<2A.[;G#J:BW"Y)PDXJ:CUPZMQAK8W&
M
M
M
M
M                                                     &B7?WII
M2]PM.R*6$F%6[6PQ,VZU?D<GAII-FME/UN+6\@DJ6C'\H0PAIU?!G%D(9D$E
M9-*:<VQVA[EY7;?<BRKO5/;^3TPRK:XOIK\-V"_;+56TONHN4*KJ4HZ)[_\
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MQ4)2O0Z+5FO*4W)^;T^$;3DZ/IK;'%>Y;(
M
M
M
M
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MVR=#L[<VOBVL32+"I&$%S?C.<G64[DN<YS;E)\6V9$'C&1
M
M
M
M
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MY)+V'['X?0
M
M
M
M
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M/>7VLU:6Y-MV[EW8&7=;B^,GA7)MTQ[CJV[;Y6+LN:I:FW<2E<BK&_R*IW#
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M=XMO]&0[6-O7$@OK6,G125:+(L)\969NG4JRE9F_+FVG;G<D"&GR0(
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MIMC]JM+_ !=M+$C;ORBE=R+E)Y-]KQNW:)TKQ5N"A:B^,81-DAA)LD
M
M
M
M
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M;GN-;3VEJN-D9;578D_*R8\*NMBZHW6EXRC&4/9)FR0PDV2
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M&BR3@
M
M
M
M
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MW([6'O\ MPIT_-M9BBFW<QZOA<45U7++XKC.WU04E;E5&@"50
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MYMN;=6WQ;;YMOVDH80A;@K=M*-N*222HDEP227!)+DCR#Y/H
M
M
M
M
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ME*$XN,9./E]'5*+E.0(K$Y
M
M
M
M
M                ]6;"A64*776,2+85]A%D0I\";':E0IL*4TMB5$EQ7T.,
M28LEAQ2'&UI4A:%&1D9&.2U=NV+L;UF4H7H24HRBVI1DG5--<4T^*:XI\4<5
M^Q9R;,\;)A&YCW(N,HR2E&49*DHRBZIQ:;33333HRMA\@_Q,S\3.]W7U9IG[
M3%>9=MF&GH#;LFVQI)FJ1*M=?L));UM0(+R4Y5%S*A$1?2D\R?M1IM]G?4+9
MU!6MK[^NJWG\(6<R5%"[X*&0^4+G*EWYD_V3IDNJ=;'J$])E_27?WKVLLRNZ
M5\5S(T^*;N6?&4\1<7<M<V['S[?[%UP?3:@-4DTF:5$:5),TJ2HC(TF1\&1D
M?J1D8ERFFJKD0%::='S/X/T$PW0_Y5\TZ^E4:NW>JVV'IELV(%3;I<^LS76\
M;GP;*M<?42\DQ>,1\*KWG"?C-$1Q'"2V45V-W=GL!I>\/,U[:WEX>YG64X?-
ML9+\>I+]:NO]LBNF3_7(U?F1F'V']5FM=OO)VOOCSM1V8J1MW*]63AQ\.AO]
M>L+QM2?5"/ZU*D5:G:2U]L7!MKXC39YKC**?,<0OXY2:J]I)2941]//BZPZ7
M"7X4^(Z1MR(SZ&Y,9Y*FW4(6E22@5K&C:KM_4;NDZU8N8VHV94G;FJ->QKPE
M%KC&46XR5)1;33+2=O;BT/=>D6=>VYE6<S1\B/5"[:EU1?M3\8SB^$X22G"2
M<9Q4DT=T'F'M                    &&]H]>=&;K86SM;4^"9TXMHF$6-]
MCM?(O(S9(-M)0,A;9:O:XTH/@CCR&U$7V&,ET'>6Z]KS4MOZAEXD4Z]-NY)6
MV_TUNKMR_P :+,-W3V\V-O:VX;KTG SY-4Z[MF#NQ7+X;R2NPX?>33(WMH?"
MCU2S!3TO +78>I)RO<-F'4WB,MQM!K+DC>KLO:L;]WVED7B2+9HO$S(R/E)I
MW9H/J@[@::E;UBWAZC:\7.'DW?L2LN-M5]]I^'OK&[='HH[4:PW=V_=U'2+[
MK2-N[]8LJOMAD*=UT\*7X\*KV-1][%^##>U)]0_K/:^N,_BM>:FXN0Q+S KJ
M0@O(T(8CMM9=3F\?!%^=GLH]3^]Z>NX-%]5FT\JD-<T_-P[CYNVX9$%\K;LS
MI\EMOW$?=Q>A??>#U7-LZMINH6ERC>C=Q;C]R261;KR^==BO>:/9W\;7=S7Q
MNG:]?LPNX[9+6B3@BZG8)2&T&1>;4/#+&[LTFKG[J'&$.G_Z(VII/>WM;K%%
MCZQC6IOPO]>/3Y7>C"/V5)KWFC]>]-O>[;S;R]OYE^VJTEBNWEU2\5'&G<G\
MB<5+W&I.48%G6#O_ $N:X7EF(2B6EHXV48Y<8^^3BTK6EOV;:'$<\U(:49%Q
MR9),_P AC8>!J^E:K#S-+RL?)MTK6U<A<7VX2?M1J35- UW0[GE:UA9>'=K2
ME^S<M.O'A2Y&+KP?VF=3'HGD@            !R]+CU_DDPJ_':.XOYZN/&#
M2UDVUF*YYXXC06'WCY\3_P 7\@ZV5F8F#;\[-NV[-G[Z<HP7VY-([>%I^?J5
M[ZOIUB]D9#^YMPE.7^3%-_H&TF#]!^Y6PU-%C?7/9K3;_B;$K*:/] 8+R5D1
MH=;L,\?QN"MA1'R3A.>'_*,"U7NYVTT9/Z[K6"VN:M3^L27N<;"N2K[J5-I:
M'V#[R[B:_%NW-349<I7[7U6+KXJ>4[,6O?6GO-V-=_"/VFR8V)&>9/K'6<%9
M?YQ&D7-AEV1,&9^A-U^/5RZ!\B(C\C_%D<'QP1\F9:OUGU2;!P4X:38S\ZZN
M34(V;;_QKDO,7X)F[-N^B/NGJ;C<U[*TO3+#YIW)Y%Y?)"S!VG[_ *=>'/PW
M[UE\&FAL>-B5M+:&PMD2VC2I<*BC56OJ"1Z\J;DQ4'E%\I''H1M63"OR_P#(
M6HM=]5>[<RMO0<##PK;^ZN.>1<7O3^BM_;MR-_;9]#.PM/<;NZ=4U#4KJYQM
M1AB6G[G%>?=I^IO19)%J;IEU;T@<9_6VD,$IK6(37T^1V%463Y6RIHR42V<I
MRERYR".:W$DI1-R$)4I*3,ONIXTGN'N9OW=*E#6]5R[N/*M;<9^5:=?;:M*%
MM^Q5BW2OM9)':?9CM;LAQN;;T/ LY4*4O3AYU]4]E^^[EU5?%],TFTN'!4V<
M&"FS@                     -:.S7;32_4_#SRG:F1$U836GSQC":?V)V9
M9=)8X);%)4K?8),5I:B)Z9)<8A,&9$MTEJ0E6<;&[>;G[@ZE]0T"S6S%KS;\
MZQLV4_&<Z/B_N814IRXTC1-K6?<WNULOM/H_XTW5D4R)I^3C6Z2R,B2\+=MM
M?"ONKDW&W'@I33<4ZEG<;OKN/N%>J9R*4>(ZPK9RY.,:OHYCZJ>(:3\8UED4
MOQCN93D*&O\ ZR\VAI@U+*,RPE:R58;VU[2;:[;XG5A1^LZ[.%+N5.*ZW[8V
MUQ\JW7[F+;E1=<IM*E2W>/OWO+O#G]&HR^J;7M3<K.%:D_+C[)WI<'?O)?=R
M2C&K\N$%*2>CHVH:.)$_BWTQEFV>X.LK>CC2F\=U1;Q]C9G>-%XQ:N!2D\Y4
M0'75%X+DY'=I9AH9(_<6RIYPB\&7#3ICOUN;3]O=M\[&RI1>;J%MXUFV^<I3
MHIR2]EN%9N7)248\Y).1/I;V9JV[.\&F9>#&:T[2;RS,FZOFPA;J[<&_;>N]
M-M1YN+G)+IA)JYR*S2YT
M
M
M
M
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M<G[>;;?-LSW$PL/ LK'P;5JSCKE&W&,(K@E\V*2Y)+ER2.2' =D
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MHYRYW;TZ4=V]<HG<N/VNBBOAA&,$HK,XQDS0
M
M
M
M
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M5^-87;4U.$E[*I\)+E*+I*+K&2331VP>>>L
M                                        :=]H^\_7[J;6NHV%E";3
M-W8AR*C6>+&Q:YG8FMLG(KLV&3R(V.5DCR(TR[%R.TX@E>S[RT^V>R=A]J=X
M=PKZ>C6/+TM2I/)NUA9CQXJ+I6Y)?>6U)ITZNE.IIWNCWS[?]IL9K<.4KNN.
M%;>%8I/)G55BY1JE9@_"Y><(M5Z.N2Z2K]VZ^2'??:]V=C\F>>M]2O+-+&L\
M4GR"C64=+B7&U9K>DW$G9=():$J]I:&*]"D)6B*APC<5.[MUV4VCV^C#,A#Z
M[N%+CDW8JL7R?D6^,;*Y\4Y7&FT[CCP57W=WU([^[KSN:?=N?BW:3?#"L2=)
MJM5]9NTC+(?)]+4;2:3C:4DY./@;B(^'NUM;8W-A!J:B!-M;6SEQX%;65L5^
M=86$Z6ZEB+"@PHK;LF7+DO+2AMMM*EK49$1&9CBOW[.-9GD9,XV\>W%RE*34
M8QBE5RE)T227%MNB7,YL;&R,S(AB8=N=W*NS480A%RG.4G2,8QBFY2DVDDDV
MWP18%Z._#M*G*J=H=N(CD*"7M3Z324>2MJ=,(R0Y'D[$M(3Z'*]@B^\=1%7[
MZN4E)>:\78JX?]U/4E;M*YH/;N2E=XQGFM5BO!K'C)?$_P#3272N/EQE6-Q6
M!]CO1U=ONSNCNY!PL<)6M-3I*7BGESBZP7C]7@^I\/-G"DK3L44U-48[55U%
M05=?24E1#8KZJHJ8<>OK*V!%;2U&AP8,1MJ-%BL-))*$(2E*2+@B$,LG)R<W
M(GEYER=W*N2<ISFW*4I/BY2DZMMOFVZEBF'A8>G8EO T^U;L85F"A"W;BH0A
M&*HHQC%)1BEP2221R0X#L@
M
M
M
M
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M=&GP::YIKVDN(3A<@KEMJ5N2333JFGQ337!IKDSR#Y/H
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MOIWV1VBLQS<:'U_=KBU/-O175&JI*./;K*-B#54^ERN23:G<E%J*WZ&HC?H
M
M
M
M
M
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M*)2%H41*2I*DF:5)4D^2,O0R&B6FG1\&B4":DE*+3BUP9^A^'Z
M                                         !K?OOMOU[ZT5ZY6W=DT
M=#9J90_"Q&&Z=UF]HAWR)A<'$ZHI5Q](\M/C]4ZVU#0?[-Y!>HS7:/;O>.^+
MWE[<P;MZQ6DKS718C3GU79TA5<^A-S?A%FM]^]W.WO;3'=W=^I6,?*Z:QQXO
MS,F:?)QL0ZKG2^77)1MK[J:(#NR_S8;-S5N=C/6_&$ZJH7O>CJSG)45]]L"9
M'4I2$NUM;XRL8Q13K"N%D?XI(0KA;3[2B$N=C^E[0M+<,[>U_P#&&6J/R+75
M;QXOV2EPNW:/E^M1?*4)(@/W,];&Y];C<TSMOBK2L!U7UF]T7<N2]L(?%9L5
M7/\ 7Y)\87(-$*F4Y9E&<7UCE.9Y'>99DMN\<FTO\CM9MU<6#YD1>[,L;%^1
M+D*))$1>2SX21$7!$)/X&GX&E8D,#3+-K'P;:I&W;A&$(KV*,4DOL(A3JNK:
MIKF?<U36LF_EZE>E6=V].5RY-^V4YMR?V7RX'7QW#SSM>$X+F6R<FK,-P#%[
MS,,JN7B8K:''JZ3:64I9F7FLH\5MQ3<9A)^3KR_%IELC6M24D9EY^J:MIFB8
M-S4]7OVL; M*LKER2C%?9?-ODDJMO@DWP/5T30M9W)J=K1M Q;^9JMZ5(6K,
M)3G+WTBG1+G*3I&*JY-)-E@7J'\+#$<ZS.>V]@F2\7LS(NF\6M/\V;4E1*]C
M.<MK7.9/)$9+AU#J4<^)_7*+R:$/NXWJ=E/KTKMW#ICQ3S+L>/RV+,EP]T[R
MKS7E+A(L#[0^BR%ORM<[N7%*?"4=.L3X+W961!_%[[>/)+D_/:K G]Q;%,9P
MB@J\4P['Z;%L9I(J(5108_71*FHK8K?/BQ#@06F8S".3,S\4EY*,S/DS,Q$/
M/U#.U7,N:AJ5Z[D9UV75.Y<DYSD_;*4FV_MD_M+TK3-#T^UI6C8]G%TRQ'IM
MVK4(V[<(KPC"*44OD7%\7Q.?'3/0
M
M
M
M
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MW5!R55XJM5R:.U#SSU0
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M9Z;^+-G8%K%C)+S+OS[]YKQNWI5N3XU:BWT0J^B,4Z&>AB1GH
M
M
M
M
M
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M>VCJB /<7L'W.[92G>U_3YW='A_\WC5OXU/;*:BIVN3X7X6G[$U1O34;+--
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M*+]CBTFG[FB0N)EXF?CPS,&[;O8EQ5C.W)3A)>V,HMQ:]Z;.0'"=@
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MM]VOQ59VEI]NUFN-)Y-SZ3*N>WJO274D^;MV^BU7E!&S8P8V:
M
M
M
M
M
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M,DXR3]Z=&OLFV<?(Q\NS'(Q9PNX\U6,H24HR7M4DVFOD9[@XSF
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MS2ZO*@NN=.3NW95NW6O"5R<G3A6AEH8Z9:
M
M
M
M
M
M       &/]B:IUGMND7CNS\"Q//:59*),#*J*ON6XZU>)F]"7-8=>KY25((T
MNL*;=2HB,E$9$8]C1MP:YMW*6;H67D8F5]]:N2@W[I=+2DO=)-/Q1C^XMJ;9
MW=A/3MSX&)GX3^XOVH7$O?%R3<)>R46I)\4R*C='PG];<Y^KL-2Y%EVEKETE
M*8@-/KSO#$.&9K-2Z?(9K.2(-:CX+V[E#3:?V+7H1#?^V/5!O;2NFSN&SC:I
MC+G)KR+W^7;B[?V[+;\9$4]Z>B?MMKG7D;2R,S1<Q\HIO*QJ_N=V2O+[&0HI
M<HD4VX/AR[>:X.9-PZMQ;<M%']QUM_"KMFNR%,1M'E[DK&,I_!I#DM1EP4>O
M?L5J]..?4BD!MOU)]N=:Z;6I3R-,RW14OP<K=7X*[:ZU3]-<C;7M(I[P]'/=
M[;;G?T:WBZS@1JT\:XH7>E>,K%_RVY?I+4KS?A7PC7SC6^PM9VJJ/8N#9=@E
MPDUD5;E^.V^.S'";5XJ6RQ;1(BWVN?L6@E(47J1F1C=VE:WHVN8_UK1<O&R\
M;[ZS<A<C]EP;H_<^)&O7-M[AVSE?4=QX.9@9G'X,BS<LR=/%*Y&+:]ZJG[3I
M8]0\4   .UXKGF<8),_$,(S/*\-G^25_78KD5OCTSS3^Q7]343(;WDGCT/RY
M(>?J&DZ5JUOR=5QL?)L_>W;<+B^U--'JZ5KVN:%>^L:'FY>'D5^=8O7+,O\
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MM=[\KGW7"1(4UC>OY\&*E3QH2\<A.RH\QYM#/"UDF-YEZI2E?!&?BWO2IO\
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ME\MRV_D)3;.]"FM9#AD;[UFQC6JUE9PX.]-KV>?=5N$)?):O1][):M)_&_U
MT2N%/QW5-=EF2PO%2,NV4[^F]U[[9D;<R/$LVBQFIFMF7W78%?$61_E$>-T=
MZ^X^[%*SFZA/'P9?L.,O(A3Q3<7YLXOV7+DT2UV3Z;^T&Q'#(T[2K>7J<.61
MF/ZS<JN4E&:\FW)>$K5JVS>9"$-H2VVE*&T)2A"$))*$(21)2E*4D24I2DN"
M(O0B&JFVW5\6S>:2BE&*2BEP1^A^'Z
M
M
M
M
M
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M&5]4Y?3W%.\Z>^;X\38 8@;
M
M
M
M
M
M                     UD[(_\ 8)?JR?\ -E?K(_\ 8/\ D;+[/_LW^'_U
M/>&<[)_UO_\ 7OSO_P!6_KG./Z/_ %])K+N3_J'_ /S'S?\ ]<?K7*?Z'_5U
ME;_LU_SFS_\ ^3__ -9_5]_Y[^PB_;_^L?\ TO\ Z;W1-;8WS+?YPO#_ 'A\
MWQ_[/L]W25O]S?UR[^:?Q_W3\[E'_M^W]-U$2TS_ )W*_P";_P#.'_\ F?\
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M_LC_ )LU_P!E_P#ZN_\ S'_T7B(M9/\ K%SY_P ^7S_G\W\_]-]][ZDW</\
MU2U^M_K<?UO];^:OF?I/O?TM#D1PG9
M
M
M
M
<                                 #__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
